Study of drug-excipient interactions regarding solubility enhancement in diluted aqueous media and solid state transformations by Saal, Wiebke
  
 
 
 
 
Study of drug-excipient interactions regarding 
solubility enhancement in diluted aqueous media and 
solid state transformations 
 
 
 
 
 
Inauguraldissertation 
 
zur 
Erlangung der Würde eines Doktors der Philosophie 
vorgelegt der 
Philosophisch-Naturwissenschaftlichen Fakultät 
der Universität Basel 
 
 
von 
 
Wiebke Svea Saal 
aus Leverkusen, Deutschland 
 
 
 
Basel, 2018 
 
 
Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel 
edoc.unibas.ch 
 
  
 
 
 
 
 
Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät 
auf Antrag von 
 
 
 
Fakultätsverantwortlicher  Herr Prof. Dr. Georgios Imanidis 
Korreferentin    Frau Prof. Dr. Christel Bergström 
 
 
 
 
 
Basel, den 20.06.2017  
 
 
 
 
 
 
Prof. Dr. Martin Spiess 
Dekan 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The significant problems we have cannot be solved at the same 
level of thinking with which we created them. 
Albert Einstein 
 
  
Abstract 
 
Nearly all marketed dosage forms comprise pharmaceutical excipients that have 
multiple functions, for example, improvement of wettability, solubilization, or 
absorption enhancement, while they can also have further technical functions such as 
diluent, glidant, disintegrant, or preservative. The selection of appropriate excipients 
is crucial for a suitable dosage form design and therefore an important step during the 
drug development process. Excipients have traditionally been considered as 
pharmacologically inert; however, they can interact with the drugs in the dosage form. 
Such interactions can be of physicochemical nature or even biological effects may 
occur that are critical for oral drug absorption. These interactions can be especially of 
relevance when formulating poorly water-soluble drugs. Different formulations are 
needed for the various development phases, where eventually different requirements 
have to be considered. In early phases, time lines and drug amounts are very limited 
and therefore, formulation development has to be fast and compound saving but long-
term stability does not have to be given. Since the choice of excipients is such a 
crucial step, a better mechanistic understanding is targeted by pharmaceutical 
scientists to avoid a purely empirical trial-and-error approach. A thorough general 
mechanistic understanding of drug-excipients interactions is helpful for designing a 
robust formulation. 
In academic and industrial research, there is a huge interest in understanding the 
different mechanisms of drug-excipient interactions with regards to formulation 
processes or with respect to dissolution and absorption. The present work centers 
around the latter aspects and makes use of miniaturized test methods to obtain 
comparatively large experimental datasets. 
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The present thesis consists of six studies, which all focus on excipient effects on the 
solubility and solid state of poorly water-soluble drugs. Excipients effects were 
studied at low concentrations that are relevant for solution and suspension formulation 
in early phases but the effects are of equal importance for oral solid dosage forms 
upon dissolution and dilution in the gastrointestinal (GI) tract. New methods were 
introduced to study kinetic solubility and possible solid state transformation in a 
miniaturized scale to save material and to obtain multiple results in a short time 
frame. 
The first study introduces a miniaturized X-ray powder diffraction (XRPD) assay for 
quantification of polymorphic mixtures. This approach was applied to simultaneously 
study kinetic solubility and time evolution of optional solid state changes. 
Additionally, the influence of four excipient vehicles and biorelevant media on the 
solid state and the solubility were tested. Excipient effects could be differentiated into 
effects in the solid and liquid phase of the slurries as enabled by the parallel study of 
kinetic concentrations and XRPD. As a result, effects were rather specific and no 
general interaction type was found for the two excipient classes tested. 
The second study introduced image and fractal analysis into the pharmaceutical field 
of solvent-mediated phase transformation to gain an improved mechanistic 
understanding. It was possible to monitor the fractal dimension of crystallized 
compound in different media and it could be interpreted as an indicator of the cluster 
growth phase of the hydrate crystals. Additional, parallel tests based on a miniaturized 
scale, provided similar excipient trends for the solid state transformation. There were 
no general polymer or surfactant trends, and each excipient appeared to have specific 
effects on the kinetics. 
The third study focusses on surfactant effects at low concentrations by studying solid 
state and solubility of 13 model compounds in parallel. It was found that solid state 
transformations played a minor role for the extent of solubility enhancement. 
However, the surfactants showed individual effects on solid state transformations of 
some drugs, which needs to be considered for formulation development. The obtained 
dataset demonstrated high solubilization correlations among pegylated surfactants of 
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similar type. Such correlations may be used to omit individual surfactants for a 
resource-saving solubilization testing in preformulation. 
In the fourth study, we focused on a methacrylic copolymer (Eudragit EPO) which is 
already known for interacting with anionic drugs and is applied for stabilizing them in 
an amorphous state. These ionic interactions led also to a great solubility 
enhancement in aqueous environment of eight crystalline, anionic model compounds. 
With 
1
H nuclear magnetic resonance (NMR) spectroscopy, we could also detect 
hydrophobic interaction that contributed to the overall interaction additionally to the 
expected ionic interactions. An additional and important finding was the correlation 
between diffusion data measured by diffusion ordered spectroscopy (DOSY) and the 
solubility enhancement.  
The understanding of the interaction mechanism, resulted in the fifth study, where we 
investigated the solubility enhancing effect of the same polymer on six basic 
compounds. Unexpected high solubility enhancement was obtained considering that 
polymer and drugs are equally charged in the aqueous environment. DOSY-
experiments indicated that the polymer undergoes conformational changes in presence 
of the drugs which may contribute to the interaction mechanism. 
Finally, such in vitro obtained results were tested in vivo in rats in the sixth study. 
Two formulations with Eudragit EPO (EPO) were compared to conventional 
formulation approaches such as a pH-adjusted solution or suspensions. The in vitro 
obtained solubility enhancement did not translate into improved in vivo bioavailability 
in rats; however, the pharmacokinetics were significantly influenced. Delayed and 
decreased absorption of the drugs was most likely due to hydrophobic drug polymer 
interactions and co-precipitation of the compound with polymer in the gastrointestinal 
tract of the rats. Solid state analysis showed an absence of crystalline compound in the 
co-precipitate. The polymeric co-precipitation in vivo can be used for high-dose in 
vivo studies in the early phases of pharmaceutical development like toxicology or 
pharmacokinetic studies to circumvent high peak to trough plasma ratios. 
In summary, this thesis provides new analytical methods and an improved 
mechanistic understanding of drug-excipient interactions in vitro as well as in vivo. 
However, it was seen that excipient effects especially on the solid state are highly 
Abstract iv 
  
 
specific between drug and excipient, which makes it hard to formulate general rules or 
guidelines. Due to choosing the same experimental conditions, excipient effects can 
be better compared and the concomitant study of solid state and kinetic concentrations 
is key for a better understanding of molecular drug-excipient interactions in a 
dispersed system. The obtained findings can be used to guide early formulation 
development and the mechanistic insights may be help to decrease the number of 
experiments and needed amounts of compound, which is highly desirable in 
preformulation or early development. 
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Chapter 1 
Introduction 
 
1.1 Background 
The increased use of high throughput (HT) combinatorial and parallel chemical 
synthesis processes has led to an enormous library of compounds that can be used for 
lead identification in drug development. While such early screening tests target 
effective receptor binding, other physicochemical drug properties are considered 
typically at a later stage. Consequently, the compounds are often highly selective and 
potent, but essentially difficult to formulate. It is often barely possible to administer 
them in high doses as needed in toxicology studies. Also adequate clinical drug 
exposure might be difficult to achieve, which can increase further the attrition rate in 
development. 
It is estimated that approximately 40% of all lead compounds have a high molecular 
weight and are rather lipophilic.
1
 Based on their solubility and permeability, drug 
substances can be classified according to the biopharmaceutical classification system 
(BCS) (Figure 1.1).
2
 BCS class II compounds have a limited oral absorption due to 
insufficient drug solubility. Bulter and Dressman
3
 proposed a further development of 
the BCS, the so-called developability classification system (DCS), which includes a 
modified version of the solubility definition. The authors proposed estimation of a 
solubility limited absorbable dose together with effective permeability. This 
modification additionally allows a differentiation between dissolution-rate limited or 
solubility-limited class II compounds. This characteristic is especially important when 
choosing an appropriate formulation strategy for improving the oral bioavailability of 
these compounds.
4-6
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In addition to their poor water solubility, BCS class IV drugs exhibit insufficient 
membrane permeability, which is difficult to improve with formulation strategies. The 
use of permeability enhancers is limited by safety of the drug product so the best way 
to improve this property of absorption is to go back to the discovery phase to optimize 
a substance by modifying the chemical structure. 
 
 
Figure 1.1: Biopharmaceutical classification system (BCS)
2
 modified from Fahr and Liu
4
 with the 
inclusion of the developability classification system by Butler and Dressman.
3
 
Formulation strategies for oral bioavailability enhancement are either based on an 
improvement of the dissolution rate or on enhancing the solubilization of the 
compound. Unfortunately, not all formulation strategies can be applied in early 
development phases since there is only a limited amount of compounds available. In 
addition to small drug quantities, the synthesis process is not finalized at this stage 
and therefore the physical quality might not be ideal for the formulation process. The 
most common dosage forms in early phases are rather simple systems such as 
solutions, suspensions, or emulsions.
7, 8
 In case of solutions, pH adjustment and the 
use of cosolvents, cyclodextrins, and surfactants are the most commonly applied 
strategies to dissolve the drug compounds.
7
 
Based on this, pharmaceutical buffers can be used to adjust the pH of weak bases and 
acids that ionize at physiological pH between 2 and 9. As described in the Henderson-
Hasselbalch-equation (Equation 1.1), the total solubility of a compound increases 
when its ionized fraction increases. The pH that is chosen for the formulation depends 
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on drug solubility and stability. However, extreme pH values can cause 
biocompatibility issues such as tissue irritation or potential drug precipitation. 
𝑝𝐻 =  𝑝𝐾𝑎 + log
[𝐴−]
[𝐻𝐴]
                Eq. 1.1 
Cosolvents are known for their enormous capacity for solubilizing poorly water-
soluble compounds especially for neutral compounds that cannot be formulated by 
pH-adjustment.
9
 The most commonly used cosolvents are propylene glycol, 
polyethylene glycol, and glycerin.
9, 10
 However, it is important to note that drug 
precipitation can occur when cosolvent-solutions are diluted in vivo with aqueous 
media (blood or intestinal fluid). This is not only an issue for intravenously 
administered formulations but may also lead to lacking tolerability or erratic 
absorption from oral dosage forms. 
Polymers and surfactants are of particular importance as pharmaceutical excipient 
category. Micellar systems play for example an important role during the drug 
development process. They enhance drug solubilization, improve particle wettability 
and dissolution and may also hinder precipitation of drugs. Surfactants are used in 
many dosage forms, e.g. solutions, emulsions, capsules or tablets.
9, 11 
In addition to 
solutions, suspensions are broadly employed in animal studies. In these dosage forms, 
a small percentage of hydrophilic polymers and surfactants are often added to aqueous 
vehicles. Polymers are used for particle suspending and homogeneity, while 
surfactants are used for particle wetting and dispersing. The major concern of 
suspensions is the physical stability since particle aggregation, sedimentation or 
changes in particle morphology are frequent problems.
7, 8
  
All of these different formulation approaches include the use of a variety of excipients 
that are influencing mainly drug solubility. A selection of excipients was established 
on an empirical knowledge obtained over years in formulation development. More 
recently, there is particular interest in better understanding the mechanisms of drug-
excipient interactions in formulation manufacturing processes 
12-16
 but also during 
drug dissolution
17
 as well as resulting effects on drug absorption.
6, 18
 
Drug-excipient interactions regarding drug solubilization are not only of interest with 
respect to the liquid phase but by considering the solid phase, as there is a solid-liquid 
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phase equilibrium (SLE). It is desired that already in the early phases of the drug 
development process, drug solubilization is combined with an assessment of the 
residual solid drug form and results obtained are likely to affect the following 
formulation strategy. 
 
1.2 Objective 
The aims of this thesis address the challenges to formulate poorly water-soluble drugs 
with comparatively simple formulation approaches. Considering the high number of 
poorly water-soluble compounds emerging from the discovery process, special 
attention was paid to solubility enhancement. Since solubility strongly depends on the 
solid state of the drug substance, the solid state was studied in parallel. A special 
focus in the experimental sections was the performance of experiments in 
miniaturized and high-though put approaches to conduct solubility and solid state 
studies already in an early development phases when time-lines are stretched and 
compounds are limited. The thesis is subdivided into individual chapters addressing 
different kinds of drug-excipient interactions and it additionally introduces methods 
for quantitative and qualitative analysis of drug-excipient interactions.  
Background information on the formulation aspects of solubility and solid state are 
presented in the theoretical section (Chapter 2) as well as established miniaturized 
assays and reported/latest studies on drug-excipient interactions.  
Chapter 3 introduces a quantification method on a miniaturized scale for polymorphic 
mixtures. The aim of this method was to study excipients’ influence on solid state 
transformations of active compounds. 
For a more mechanistic understanding, image and fractal analyses were applied to 
solid state transformations in excipient vehicles in Chapter 4. The focus is on gaining 
an improved understanding of the excipient effects in aqueous environment on 
hydrate formation. Additionally, the excipient effects were classified according to 
their influence in the liquid and the solid phase and these effects were compared 
regarding their influence on the final drug’s solubility. 
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The primary aim of Chapter 5 is to broadly study drug solubilization by surfactants at 
a rather low concentration that should mimic dilution of an oral dosage form. 
Potential solid state changes are again checked by means of XRPD. Based on these 
results, a second aim is to correlate solubility enhancement factors among different 
surfactants. Such correlations can be used for decreasing the number of surfactant that 
need to be tested in preformulation for a more focused early solubility screening. 
The Chapters 6 to 8 emphasize the application of a known excipient for enabling 
formulations, a polyelectrolytic polymer (Eudragit EPO), in a rather simple 
formulation approach to test specific drug-excipient interactions regarding 
solubilization and optional solid state changes. Additionally, nuclear magnetic 
resonance (
1
H NMR) methods are evaluated to assess the strength of drug-excipient 
interactions. This polymer was applied to formulate not only acidic drugs but also 
basic compounds with the same charge as the polymer. It was aimed to show that 
excipient selection should not only be based on obvious ionic interactions but a more 
refined view of molecular interactions is required in the selection of solubilizing 
excipients. The rather counterintuitive interactions of Eudragit EPO with a basic and a 
neutral drug were also studied in a pharmacokinetic rat study to better assess 
biopharmaceutical consequences of these molecular interactions. 
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Chapter 2 
Theoretical section 
 
2.1 Solid state properties 
The probability that a drug can exist in different polymorphic forms is reported to be 
between 50 and 80%.
19
 The existence of different crystal forms can translate into 
changes in physicochemical properties such as solubility, melting point, chemical 
stability, or wettability (Table 2.1).
20-22
 These alterations do not only influence the 
technical processes during formulation development, but they might also result in 
bioavailability changes. Additionally, the presence of metastable or amorphous forms 
can lead to recrystallization as a stability issue. The occurrence of polymorphs often 
follows Ostwald’s rule of stages23, which states that metastable forms appear first and 
are followed by crystallization of the thermodynamically most stable form. This 
results in polymorphic mixtures of drugs, during not only the production or storage, 
but also possibly during dissolution. In order to avoid these undesired polymorphic 
changes, a proper understanding about polymorphism of a drug substance is very 
important. 
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Table 2.1: Physical properties that can differ among polymorphic forms adjusted based on Brittian et 
al.
24
 
Packing properties Molar volume and density 
Refractive index 
Hygroscopicity 
Thermodynamic properties Melting or sublimation temperature 
Enthalpy 
Heat capacity 
Thermodynamic activity 
Kinetic properties Dissolution rate 
Solubility 
Stability 
Surface properties Surface free energy 
Crystal habit 
Mechanical properties Hardness 
Tensile strength 
Compatibility 
Flowability 
 
The stability of polymorphs depends on their free energies. Under defined 
experimental conditions, only one polymorphic form has the lowest free energy. This 
polymorph is the thermodynamically stable form, whereas other polymorphs are 
thermodynamically unstable and therefore named metastable forms. A metastable 
polymorph might be desirable for formulation development as it may result in e.g. 
higher bioavailability. However, polymorphic changes can be induced during 
manufacturing and processing and are studied more in detail in the next chapter. 
In general, the solid state of drugs can be divided into three main categories, namely 
polymorphs, solvates and amorphous forms (Figure 2.1). According to McCrone’s 
definition, polymorphic forms are only represented by different crystal arrangements 
of the same chemical composition.
25
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Figure 2.1: Classification of solid state based on Hilfiker.
26
 
 
Solvates are no polymorphic forms according to this strict definition
25
 as they do not 
have the exact same chemical composition as the other polymorphic forms. Instead, 
solvates differ in their chemical composition through the inclusion of one or more 
solvent molecules per unit cell.
26
 Therefore the term pseudopolymorphism was 
introduced for solvates. Based on this, hydrates are a special example within the 
group of solvates, where the solvent associated with the molecule in the crystal is 
water. Solvates can be classified according to the ratio of drug and solvate molecules: 
stoichiometric solvates have a definite ratio, whereas for non-stoichiometric solvates 
the ratio of solvent to drug molecule may vary continuously. Another classification of 
solvates is based on analytical results and distinguishes between isolated site solvates, 
channel solvates and ion associated solvates.
27
 Approximately one third of all active 
pharmaceutical ingredients (APIs) have the ability to form hydrates.
24
 In many stages 
of the pharmaceutical development, drugs are exposed to solvents or solvent vapor, 
where solvate-formation might occur. These include precipitation, crystallization, wet 
granulation, and spray drying. 
The amorphous forms build a special category within polymorphic forms. Amorphous 
solids are defined as non-crystalline solids, as the consequence of the absence of long-
range molecular order. Amorphous materials can be prepared by several techniques 
including quench cooling, milling, spray drying or freeze-drying.
28, 29
 There is a high 
interest in amorphous pharmaceutical solids because they provide great advantages in 
terms of solubility and bioavailability due to the high energetic state.
24
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A variety of analytical methods are available to obtain qualitative and quantitative 
information about the solid state. They have been extensively described in several 
reviews and textbooks.
24, 26, 30, 31
 Table 2.2 summarizes commonly used analytical 
techniques and the unique information that are obtained by applying these methods. 
Appropriate methods have to be chosen according the particular case and the 
investigated properties. Moreover, the system (pure drug, drug-excipient mixtures, 
formulations) and the experimental set-up (aqueous environment, scale) has to be 
considered when choosing the analytical method. Usually, a combination of several 
techniques is used to achieve a comprehensive understanding of the solid state 
properties. 
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Table 2.2: Analytical techniques commonly used for solid state characterization. 
Analytical technique Information Limitation 
X-ray diffraction 
(XRPD)
32-34
 
Crystallographic properties 
like structural information and 
degree of crystallinity 
Preferred orientation effects 
No information about the 
chemical structure 
Infrared (IR) 
spectroscopy
35, 36
 
Chemical information like 
intramolecular vibrations and 
H-bonding 
Sample preparation can 
induce solid state 
transformation  
Near infrared (NIR) 
spectroscopy
35, 37
 
Chemical information from 
vibrational overtones and 
combinations of vibrations 
Low sensitivity and 
selectivity 
Chemometrics might be 
needed for analysis 
Raman spectroscopy
14, 36
 Chemical information from 
molecular vibrations and 
complementary to IR 
spectroscopy  
Local heating of the sample 
Photodegradation 
Solid state nuclear 
magnetic resonance 
spectroscopy (ss-NMR) 
Chemical information like 
nuclei and chemical 
environment within a molecule 
Long data acquisition time 
and expensive method 
Differential scanning 
calorimetry (DSC)
38, 39
 
Thermal events e.g. glass 
transition (Tg), crystallization 
(Tc) and melting temperature 
(Tm) 
Destructive method 
Nature of thermal events is 
not determined 
Overlapping thermal events 
at the same temperature 
cannot be differentiated 
Thermogravimetric 
analysis (TGA)
38
 
Transitions related to a gain or 
loss in mass, decomposition 
temperature 
Destructive method 
Unsuitable for materials that 
degrade at low temperatures 
Dynamic vapor sorption 
(DVS)
40
 
Hygroscopicity behavior Interference with water-
containing excipients 
possible 
Isothermal 
microcalorimetry (IMC) 
Heat changes in reaction e.g. 
heat of crystallization 
Large amount of sample is 
required 
Low specificity 
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Table 2.2: Continued. 
Analytical technique Information Limitation 
Microscopy, polarized light 
microscopy (PLM), 
scanning electron 
microscopy (SEM)
41-44
  
Morphology, color, crystal 
habit, topographical properties, 
crystallinity 
No quantitative information 
are available 
Careful sample preparation 
is required (SEM) 
Hyperspectral imaging 
(UV, Raman, IR, NIR)
45-49
 
Visualization of 
crystallization, morphology, 
drug dissolution behavior, 
distribution of chemical 
components 
Local heating of (dry) 
samples (Raman) 
Depending on pixel 
resolution 
 
 
2.1.1 Process-induced transformations 
Solid state transformations that occur during processing steps of the drug 
development process are important to monitor and understand, which should ensure 
an appropriate quality and stability of the final drug product. Process-induced 
transformations are caused by mechanical or thermal stress or they follow an exposure 
to solvents. Figure 2.2 represents possible phase transitions during pharmaceutical 
processing and their resulting effect on the solid state of the drug product. 
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Figure 2.2: Representation of possible process-induced phase transformations. 
 
During pharmaceutical processing, solid state changes cannot only occur in the active 
ingredients but also the solid state of excipients might be affected. Such changes in 
excipients can also have an important influence on the product quality and the final 
performance and therefore need to be considered. 
Phase transformations can be classified by their underlying mechanism as proposed 
by Zhang et al.
50
 Some solid state changes occur without passing through an 
intervening transient, liquid or vapor phase. This mechanism is strongly affected by 
the environmental factors such as temperature, pressure or relative humidity but also 
by the presence of crystalline defects, particle size and distribution, and impurities. A 
phase transition might as well occur when heating a compound above its melting 
point and subsequently cooling it back to ambient temperatures. The final solid state 
after melting is depending on the nucleation, crystal growth, and cooling rate. 
Additionally, impurities or excipients can affect the crystallization. Many processes in 
pharmaceutical development include the complete or partial dissolution of a 
compound in a solvent, usually water. Removing the solvent can induce solid state 
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transformations from a stable to a metastable phase or vice versa. The final solid form 
may also be a mixture of different solid states depending on the rate of solvent 
removal, the nucleation and crystal growth rate and the processing conditions. The 
undissolved drug may serve as seeds for crystallization of the original form but 
impurities or insoluble excipients provide surfaces for heterogeneous nucleation of 
different phases. The fourth possible mechanism is solvent-mediated phase 
transformation. It only allows transition from a metastable phase to the stable phase. 
Since the focus of this work was on solid state transformations in aqueous 
environments such as formulation vehicles for suspensions and solutions or during 
dissolution, solvent-mediated phase transformations will be discussed in more detail 
in the next chapter. 
 
2.1.2 Solvent-mediated phase transformations 
Cardew and Davey described solvent- or solution-mediated phase transformation as a 
two-step process as shown in Figure 2.3.
51, 52
 The metastable form dissolves first, 
which results in a supersaturated solution with respect to the stable form and this 
stable form subsequently crystallizes out. The crystallization step is started with a 
nucleation of the stable form followed by growth of the crystals. The nucleation step 
may occur in the bulk phase or it is primarily a surface process.  
 
Figure 2.3: Schematic representation of solvent-mediated phase transformation process. 
Solvent-mediated phase transformations can be either dissolution- or crystallization-
controlled depending on the relative kinetics of the dissolution and crystallization 
steps. The dissolution process is affected by the thermodynamic solubility of the 
metastable form, the particle size, and hydrodynamics. More details on dissolution 
rates of solids will be discussed in Chapter 2.2. Usually, the nucleation or the crystal 
growth is rate limiting and therefore any factors influencing nucleation or crystal 
growth will influence the overall transformations. Nucleation occurs when a solution 
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is supersaturated with respect to the stable phase, which is necessary for the growth of 
the more stable phase. Primary nucleation can be divided into two types, 
homogeneous and heterogeneous nucleation. Homogeneous nucleation does not occur 
very often as it requires significant supersaturation levels. Heterogeneous nucleation 
occurs when e.g. impurities or grain boundaries act as nucleation seed and lower 
therefore the free energy barrier. The primary nucleation rate J1 can be described in 
these cases by the classical nucleation theory.
53
 
𝐽1 = 𝐴′𝑆𝑒
𝐵′𝑣0
2𝛾3
(𝑘𝑇)3𝑙𝑛2𝑆
                Eq. 2.2 
Where A’ is a kinetic factor that is proportional to the number of nucleation-active 
centers, B’ is a factor of shape and homogeneity, v0 is the molecular volume of the 
crystalline phase and γ is the interfacial energy per unit area of the crystal. Moreover, 
k holds for the Boltzmann constant, T is the temperature and S the drug 
supersaturation. 
In crystal suspensions it is more likely that the suspension itself serves as 
crystallization nuclei as a result of secondary nucleation. Secondary nucleation 
describes any nucleation mechanism that requires the presence of suspended parent 
solute crystals as it is caused by interaction of existing crystals with the vessel, 
impeller or by collisions and providing thereby new seed crystals through breakage. 
The secondary nucleation J2 rate can be described by an empirical equation, taking the 
agitation rate (ω), the suspension density (ρs) and the supersaturation (σ) into 
account:
53
 
𝐽2 = 𝑘𝑁𝜔
𝑙𝜌𝑠
𝑗𝜎𝑖                         Eq. 2.3 
The secondary nucleation rate constant is described by kN and the exponents i, j, l are 
empirically determined. 
2.2 Solubility and dissolution 
In addition to a detailed solid state characterization of a drug substance, there are 
other key parameters that need to be determined during the drug discovery process. 
Physicochemical properties such as the ionization constant (pKa) or the partitioning 
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and distribution coefficient (logP, logD), are calculated or measured along with 
stability and permeability measurements. Moreover, aqueous solubility is one of the 
most important drug properties in the discovery and development process. These 
measured parameters together with initial results of in vivo exposure are used to make 
decisions on the biopharmaceutical developability of new APIs. 
In principle, thermodynamic solubility is an easy parameter to measure, since it is 
defined as the concentration reached at equilibrium between the solid drug substances 
in a liquid solvent to form a homogenous solution of the solute in the solvent.
54
 It is 
typically determined using the shake-flask technique where the pure crystalline 
compound is incubated in a saturated suspension containing the medium of interest 
for several days 
55
 In this experimental set-up, it can be tested if equilibrium has been 
reached. In addition, the solid state of the residual solid and the end pH of the medium 
should be investigated
56
 even though this is often neglected. However, depending on 
the experimental set-up, solubility measurements can define apparent, intrinsic or 
thermodynamic solubility (see Table 2.3 for definitions).
57
 
Table 2.3: Solubility definitions according to Bergström et al.
55
 
Thermodynamic solubility (S) Saturated solution in equilibrium with the 
thermodynamic stable polymorph 
Intrinsic solubility (S0) Equilibrium solubility at pH where the API is in its 
neutral form 
Apparent solubility (Sapp) Solubility measured under given assay conditions 
 
Thermodynamic solubility is often regarded as the “true” solubility of a compound.57 
However, experimental factors such as the polymorphic form at the start and end of 
the experiment, the pH, the mixing conditions or compound purity can influence the 
measured values. Therefore, solubility values should be seen rather in context of the 
experimental conditions and values may slightly differ from one experimental test 
protocol to another. 
For the oral absorption processes not only the thermodynamic solubility, but also the 
dissolution rate needs to be considered. Noyes and Whitney conducted the first 
dissolution experiments in 1897.
58
 The authors mathematically defined the 
proportional relation of the rate of dissolution and the difference between 
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instantaneous concentration C at time t and the saturation solubility Cs, known as the 
Noyes-Whitney-law (Equation 2.4), where k is a constant. 
𝑑𝐶
𝑑𝑡
= 𝑘(𝐶𝑠 − 𝐶)                         Eq. 2.4 
Later on, the Noyes-Whitney equation was modified, considering the exposed surface, 
stirring rate, temperature, structure of the surface and the type of apparatus.
59
 The 
work of Nernst and Brunner followed, which was based on the diffusion layer concept 
and Fick’s second law known as the Nernst-Brunner equation (Equation 2.5).58, 60 
This equation replaces the constant k1 (k =k1 S) that was introduced by Bruner and 
Tolloczko:
59
 
𝑑𝐶
𝑑𝑡
=
𝐷𝑆
𝑉ℎ
 (𝐶𝑆 − 𝐶)                        Eq. 2.5 
Here, D is the diffusion coefficient, h the thickness of the diffusion layer and V is the 
volume of the dissolution medium. For an overview of more recent theoretical 
developments of diffusion-controlled dissolution, Wang et al. have written an 
excellent review.
61
 
Nowadays, dissolution studies are an essential part in drug development and provide 
useful information especially for administration via the oral route. There are several 
methods known to measure the dissolution rate of a pure drug, drug-excipient 
mixtures or even complete formulations. Many of these methods aim to use only 
small amounts of compounds and were reviewed recently.
62
 Additionally, there are 
several techniques available for a real-time analysis of the dissolution behavior. They 
are usually based spectroscopic techniques such as UV, Raman or IR, but also 
potentiometric principles and a method based on the ultrasound resonator technology 
were applied to dissolution studies.
62
 
Although solubility and dissolution rate are in principal easy to determine, there is 
still the need to define and validate solubility measurement techniques to ensure the 
comparability of obtained results. Within a European project about oral 
biopharmaceutical tools (OrBiTo project), an inter-laboratory comparison of small-
scale solubility and dissolution measurements were performed.
63 
Therefore, solubility 
and dissolution experiments were performed at 12 different laboratories including 
Theoretical section 19 
  
 
industry and academia. Values from individual protocols were compared with values 
obtained by an established protocol used by all institutions. Andersson et al. found 
that establishing of standardized protocols is required for the experimental design but 
also for the data analysis to decrease the variability of obtained results.
63
 Moreover, 
the authors identified experimental factors contributing to the variability like the 
quality of the standard curve or the amount of undissolved particles in powder 
dissolution measurements. 
 
2.3 Miniaturized assays 
Although, HT approaches have been intensively used in the discovery phase for 
synthesis of new compounds and crystallization screening, the following development 
phases use barely similar HT approaches. This has resulted in some disconnect 
between the discovery and development stage. In recent years, scaled down methods 
were developed to determine various compounds’ characteristics such as to rapidly 
identify solubility-enhancing formulations.
11, 55
 These approaches allowed the 
scientists in pharmaceutical profiling to provide feedback to the discovery researchers 
for improving the “developability” of candidate molecules. 
Investigation of the physical form of a drug candidate has two major benefits. On the 
one side, the performance can be optimized by choosing a polymorphic form that has 
a high oral bioavailability or the maximum chemical stability.
64, 65
 On the other hand, 
the risk of developing a metastable form is typically avoided because this could lead 
to a conversion later on that compromises the pharmaceutical performance. Solid state 
screenings coupled with crystallization optimization are hence powerful methods for 
exploring and optimizing the polymorphic form of a drug substance and product in 
the early development process. Critical elements during the screening include the 
crystallization technique, handling procedure, detection method, data processing, and 
storage. Solid form screenings are typically used to understand the effects of 
crystallization variables on the polymorphic outcome. Hilfiker et al.
19
 combined high 
throughput screening and crystallization optimization for the example of 
carbamazepine. They showed that by designing good crystallization processes, 
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commercial advantages can be obtained. However, for this process a profound 
knowledge of the physicochemical characteristics of the drug is required. 
Screening of the solid form and determining the aqueous solubility of critical 
importance in pharmaceutical discovery and development. There are several 
approaches described that evaluate kinetic solubility.
11, 57
 Kinetic solubility 
measurements are based on a dilution of a drug solution in an organic solvent (often 
dimethyl sulfoxide) in aqueous media. When the drug reaches its solubility in the 
aqueous medium, the excess of drug precipitates and is detected by turbidity or UV 
absorption.
11
 These experiments are simple to perform in a HT format since organic 
stock solution can be provided easily. However, the residual organic solvent 
additionally to the solid state of the precipitate influences the solubility and might 
therefore lead to values that are higher compared to the equilibrium solubility. 
Traditional methods to determine the thermodynamic equilibrium are not practical for 
testing a large number of samples with low compound availability and stretched time-
lines. Therefore, thermodynamic solubility assays were developed on a smaller scale. 
They can be divided into scaled-down shake-flask and solvent-evaporation methods. 
Drug concentrations are usually measured with UV spectroscopy or high performance 
liquid chromatography (HPLC).
56, 66
 Some assays also include a final pH 
measurement and solid state determination.
56
 The detection methods applied are the 
limiting points for the use of these miniaturized assays. HPLC with a UV detector or 
UV spectroscopy are only possible for compounds which have a suitable 
chromophore. In case of the solvent-evaporation methods, polymorphic changes are 
likely to occur during the evaporation step, which can lead to substantial changes in 
the solubility values. 
Also later on in the preformulation phase, only rather limited amounts of the 
compounds are available. However, during this stage not only physicochemical 
parameters need to be determined but also suitable formulation vehicles have to be 
supplied for pharmacokinetic or toxicology studies. Screening experiments using 
excipients and entire formulation vehicles are more challenging to handle on a 
miniaturized scale due to different viscosities and even dispending of solid excipients. 
There are still several miniaturized assays described in the literature for example 
regarding compound and excipient compatibility or to identify polymers for 
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stabilizing amorphous compounds.
67-69
 Additional approaches are available in a 96-
well format to examine the tendency of APIs alone and in presence of excipients to 
supersaturate
70
 in media like buffers as well as simulated fluids.
71, 72
 
 
2.4 Excipient effects on solubility and solid state 
Regardless of the dosage form, drug characteristics, or administration route, nearly all 
drug products contain mainly excipients. The active compound represents typically 
only a small percentage of the dosage form. There is certainly much literature about 
the diverse excipient effects on quality attributes and aspects of industrial additive 
selection can be inferred from a recent article.
73
 
Since excipients are used for a wide variety of functions in drug product, also the 
effect mechanisms are diverse. A focus of this work is the influence of excipients on 
the solubility and the solid state of drugs in aqueous environment (Figure 2.4). 
Solubility is one of the most important properties in drug discovery and strongly 
dependent on the solid state of the active compound. A drug already has several 
possibilities for interaction with itself as either in the solid form or as self-association 
in solution.
74, 75
 The drug can further interact with an excipient in the liquid bulk or in 
a solid phase (Figure 2.4).  
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Figure 2.4: Schematic overview over different states, in which the active pharmaceutical ingredient 
(API) may occur upon aqueous dispersion with possible drug-excipient interactions. 
 
These different drugs states with and without excipient already provide some 
complexity. Such complexity may be further increased by different interaction motifs 
of a given drug and excipient.
76
 The idealized states depicted in Figure 2.4 come with 
kinetic processes that are expected to occur at least partially in parallel  
The kinetic aspect is especially of interest when performing in vitro tests. Upon 
aqueous dispersion in the GI tract, the release rate of both, excipients and drug is key 
for molecular interactions. Different kinetic scenarios can be imagined. For example, 
if the excipient dissolves very fast, whereas the API is dissolution limited, it might 
happen that the undissolved API remains in e.g. the stomach but the excipient is 
already transported to the small intestine. This would result in minor drug-excipient 
interactions during the absorption process since excipients and drug exhibit 
differences in spatial and temporal distribution thereby preventing molecular 
interactions that may increase drug solubilization. When administering already 
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dissolved API and excipient, as e.g. in a solution formulation, the chances are higher, 
that both excipient and API will be transported together through the GI tract. 
However, APIs and excipients might be pH-dependent soluble and therefore 
precipitate in a certain section of the GI tract. For example, dissolved acidic APIs are 
very likely to precipitate in the stomach depending on their pKa. However, such 
precipitation can be influenced by excipients regarding the precipitation rate or the 
solid state of the precipitate. 
More recently, modern methods such as real-time spectroscopy revived the interest in 
better characterization and understanding of drug-excipient interactions by 
considering the solid state.
13, 20, 77
 This interest can be motivated with respect to 
manufacturing processes or it may rather stem from a biopharmaceutical perspective. 
In many pharmaceutical processes the active compound is exposed to water or water 
vapor which increases the likelihood of hydrate appearance. Especially during wet 
milling, wet granulation or dissolution, solvent-mediated phase transformations might 
occur and may lead to substantial changes in drug substance or drug product 
characteristics. Gift et al. studied transformation kinetics in presence of different 
polymeric excipients in high-shear wet granulation
12
 and aqueous slurries.
16
 They 
showed that the addition of certain polymeric excipients can inhibit hydrate formation 
of few model compounds. Very little amounts of polymers can lead via two 
mechanisms to a decrease in hydrate formation. On the one hand, polymers adsorb 
granulation liquid and thereby reduce the amount of available water. On the other 
hand, polymers interact with the surfaces’ of particles, which leads to a smoothed 
surface and therefore also to reduced crystal growth. Wikstroem et al.
78
 came to 
similar conclusions when studying the hydrate formation of theophylline during high-
shear wet granulation. They also studied kinetics of anhydrate-to-hydrate formation of 
several model compounds and saw that not only solubility and dissolution play a role 
in solvent-mediated phase transformations but also surface properties and external 
factors such as shear force or the presence of seeds play an important role.
15
 However, 
they also showed a noticeable retardation of hydrate formation by addition of 
polymeric excipients.
78
 The mechanisms, they identified were similar to those from 
Gift et al. since they were arguing with a smoothing of the particles’ surface by 
adsorption of the polymer and therefore decreasing of possible nucleation points. 
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Christensen et al.
79
 studied not only the influence of polymeric excipients but also 
added cosolvents like ethanol. They identified high water-absorbing polymers and 
cosolvents with water-activity reducing characteristics as suitable for delaying the 
hydrate formation of their model compound, piroxicam. Ilevbare et al. published 
several results on the influence of polymers on the crystallization rate from 
supersaturated compounds.
43, 80, 81
 They identified physicochemical characteristics of 
the polymers like hydrophobicity or functional groups to influence specific drug-
excipient interactions and therefore also be responsible for the effectiveness of the 
crystallization inhibition. These structural relationships may also help to develop new 
excipients with excellent crystallization inhibition characteristics. 
Polymeric excipients are not only useful for stabilization of a metastable solid state 
but they were also studied regarding their influence in liquid-liquid phase separation. 
Jackson et al.
82
 studied the influence of three different polymers on the liquid-liquid 
phase separation and additional crystallization of danazol from supersaturated 
solutions. Liquid-liquid phase separation is observed for highly lipophilic compounds 
that are known to form aggregates in solutions. Although self-aggregation has been 
widely observed for chemically diverse compounds, the mechanism is not well 
understood yet. Liquid-liquid phase separation results in a two phase system, 
consisting of a solute-riche and a solvent-riche phase. This phenomenon is well 
known for protein solutions and organic crystallization. However, liquid-liquid phase 
separation in aqueous solutions of lipophilic drugs has only recently been studied 
more thoroughly. Ilevbare et al.
83
 tested the influence of several experimental 
conditions like temperature and ionic buffer strength on the aggregation behavior of 
ritonavir and applied well-known thermodynamic principles to predict concentrations 
at which phase separation can occur. 
There were also attempts to use miniaturized experimental set-ups to study a larger 
number of compounds in combination with various excipients. Avdeef et al.
84
 studied 
the influence of frequently used liquid excipient vehicles on the solubility 
enhancement of eight model compounds to mimic conditions that can be expected 
after dissolution and dilution of dosage forms in the gastrointestinal tract. They also 
took into account in their study that several APIs are known to aggregate with 
themselves when they are dissolved in aqueous media. For the authors, it was possible 
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to classify excipients’ effects and identify trends; however there are still mechanistic 
questions unanswered and an additional examination of solid state properties was not 
reported. However, Wyttenbach et al.
56
 studied the solubility and the solid state of 
three compounds in parallel in aqueous and non-aqueous vehicles. Although, the 
study was intended to introduce a miniaturized approach for testing these two key 
parameters in parallel, the obtained data can be used when choosing model 
compounds or excipient vehicles for further studies since the research is providing 
solubility and solid state data in common formulation vehicles as well as in 
biorelevant media. 
Not only polymeric excipients can influence solvent-mediated phase transformations 
but also surfactants can have an influence on transformation kinetics. Rodriguez-
Hornedo and Murphy studied the influence of two anionic surfactants on the hydrate 
formation of carbamazepine.
85
 Since carbamazepine anhydrate is transforming to its 
hydrate via a solvent-mediated process, the transformation kinetics is very sensitive to 
solution conditions such as pH, temperature or additives. When adding two anionic 
surfactants, an increase in the transformation rate was reported.
85
 However, this 
influence of the surfactants was highly specific and depended on the molecular 
structure, concentration, and supramolecular association. The influence of surfactants 
plays also during the dissolution in the human body a major role. During the digestion 
process, drug formulations are exposed to gastric and intestinal media, which contain 
biorelevant surfactants. Lehto et al.
17
 studied therefore the influence of simulated 
intestinal fluid on the solvent-mediated phase transformation of carbamazepine. Also 
with biorelevant media, specific drug-excipient interactions were found to occur via 
hydrogen bonding that were inhibiting crystal growth on the surface and therefore 
also inhibited the hydrate formation.
17
 To obtain relevant results for the in vivo 
performance of drug product, it is very important to choose biologically representative 
dissolution media that mimic the situation in vivo. 
Although there was important research done on excipients’ effects on solubility and 
solid state, these studies often lack a large number of model compounds and 
experimental conditions like excipient concentrations and pH values differ from one 
study to another. Pronounced difference in these conditions are especially given when 
studies are compared that were about aqueous manufacturing processes as opposed to 
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in vitro experiments that were intended to reflect biopharmaceutical performance. 
Therefore, it is hard to compare the mechanisms and specific excipients effects within 
these studies and only trends can be noticed. For an improved understanding of drug-
excipient interaction, a focus must be defined for example to mimic oral formulation 
performance. Same conditions in terms of excipient concentrations and pH should be 
maintained and it is important to study both, solubility and solid state in parallel to 
distinguish between effects in the solid phase and in the liquid phase. 
  
Kirchmeyer et al. Miniaturized X-ray powder diffraction assay (MixRay) for quantitative kinetic analysis of 
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Chapter 3 
Miniaturized X-ray powder diffraction assay 
(MixRay) for quantitative kinetic analysis of 
solvent-mediated phase transformations in 
pharmaceutics 
 
Summary 
Many pharmaceutical compounds exhibit polymorphism, which may result in solvent-
mediated phase transformations. Since the polymorphic form has an essential 
influence on physicochemical characteristics such as solubility or dissolution rate, it is 
crucial to know the exact polymorphic composition of a drug throughout 
pharmaceutical development. This study addressed the need to perform quantitative 
X-ray analysis of polymorphic mixtures on a 96-well scale (MixRay). A calibration of 
polymorphic mixtures (anhydrate and hydrate) was performed with three model 
drugs, caffeine, piroxicam, and testosterone, and linear correlations were obtained for 
all compounds. The MixRay approach for piroxicam was applied to a solubility and 
residual solid screening assay (SORESOS) to quantify the amount of hydrate and 
anhydrate corresponding to kinetic bulk concentrations. Changes in these drug 
concentrations correlated well with the kinetic changes in the residual solid. The 
influence of excipients on the solid state and kinetic concentrations of piroxicam was 
also studied. Excipients strongly affected polymorphic transformation kinetics of 
piroxicam and concentrations after 24 h depended on the excipient used. The new 
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calibration X-ray method combined with bulk concentration analysis provides a 
valuable tool for both pharmaceutical profiling and early formulation development. 
 
3.1 Introduction 
The majority of pharmaceutical compounds exhibit polymorphism. Since different 
polymorphic forms of a drug can have different bioavailability and behavior during 
processing,
86, 87
 it is important to properly characterize the solid form of the drug 
already early on. Sensitive analytical methods are required especially in case of 
polymorphic mixtures. A thorough understanding of potential solvent-mediated phase 
changes is needed for clinical candidates' selection and for in-process controls to 
avoid quality issues of the final drug product. 
An early solid state screening is nowadays typically conducted as part of the 
pharmaceutical profiling work aiming at the selection of the most suitable polymorph 
of a compound for development.
19, 31
 Here, not only qualitative information is needed 
but also a quantification of polymorphic mixtures would be desirable. 
At an early stage of development, high-throughput (HT) methods for compound 
characterization (solubility, stability) or testing drug-excipient compatibility are 
convenient because only a small amount of compound is available. HT-experiments 
provide the opportunity to test a number of different drugs and excipients, for e.g. 
solubility determination, in parallel at a miniaturized scale. Parallel testing has also 
already been reported in the field of drug discovery for the screening of polymorphic 
forms and for crystallization optimization.
31, 64
 In the field of API-excipient 
interactions and solubility measurements, some HT-approaches have previously been 
reported.
56, 57, 88
 In some of these assays, solid state analysis on a miniaturized scale 
has already been introduced but only on a qualitative level.
56
 Thus there is clearly a 
need to also quantitatively determine drug solid state changes in a HT-format 
throughout kinetic processes for example during solubility and dissolution studies.  
Today, solid state characterization of pharmaceuticals is typically performed for bulk 
powders on a much larger scale than HT-experiments. The different bulk 
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characterization methods include X-ray powder diffraction (XRPD),
33, 89
 optical and 
electron microscopy,
90
 spectroscopic methods like Raman spectroscopy,
13
 near 
infrared (NIR) spectroscopy,
13, 91
 and thermal methods such as differential scanning 
calorimetry (DSC).
92
 Among these different methods, XRPD has been used for 
quantitative solid phase analysis for almost a century.
93
 It is based on direct 
proportionality of X-ray reflection intensity and the weight fraction of the phase for 
which the scattering is characteristic. The technique was also successfully utilized for 
quantification of solid state changes of diverse active pharmaceutical compounds,
33, 89
 
the drug amounts required in these studies are usually in the 100 mg range. Single 
peaks or entire diffraction patterns of XRPD spectra can be used to establish 
correlations between phase composition and quantification. In general, quantification 
methods based on single peak measurements do require limited knowledge about the 
phases to be quantified, whereas whole pattern methods, such as the Rietveld method, 
are based on refinement of crystal structure parameters. Single peak methods are often 
more sensitive but also suffer from higher variability due to the influence of diverse 
experimental factors such as preferred orientation.
32
 Among the whole pattern 
methods there are examples that do not require prior knowledge of the crystal 
structure like the factor-based Partial Least Square (PLS) analysis
94
 and the whole 
pattern method described by Smith et al.
95
 These methods require no knowledge of 
crystal structure date since they are based on empirically-derived correlation of 
intensities from one or more diffraction regions as a function of the analyte 
concentration. 
XRPD quantitative analysis using Bragg-Brentano parafocusing configuration is 
currently most widely used.
96
 In this reflection geometry, the specimen thickness 
exceeds the penetration depth of the X-ray beam into the powder bed and the powder 
volume contributing to scattering is consistent throughout a series of samples with 
comparable density. However, reflection mode XRPD requires sample amounts in the 
100 mg range and the method is prone to effects of preferred orientation and specimen 
height. Thus, careful sample preparation, usually incl. powder milling, is a 
prerequisite for reflection mode XRPD quantification. In contrast, the orientation and 
specimen height effects are less relevant for transmission mode XRPD, and usually 
less sample is required. However, in transmission geometry the sample volume that 
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contributes to XRPD scattering usually varies considerably from one sample 
preparation to another. The addition of an internal standard to the measured sample 
can be used to normalize diffraction intensities in support of quantification a 
polymorphic mixture. However, the internal standard method is not applicable for 
polymorph screening applications. Therefore, a novel miniaturized X-ray powder 
diffraction quantification method (MixRay) is applied in the present study. 
Accordingly, the contribution of air/background scattering is quantified for each 
sample using an appropriate air/background reference pattern. Then, a least squares fit 
is performed that uses the references of the crystalline polymorphic forms and the 
air/background reference pattern to quantify the fractions in the polymorphic mixture. 
As the air/background pattern is not a “true” component of the polymorphic mixture 
the quantities of the crystalline constituents are normalized to 100%. 
In the present study, the MixRay is applied to monitor solvent-mediated phase 
changes in a 96-well based HT test. First, three known hydrate-forming drugs were 
selected, caffeine,
97
 piroxicam,
98, 99
 and testosterone.
100
 Anhydrates and hydrates of 
these drugs were used to perform HT-XRPD-calibrations on a miniaturized scale. 
Moreover, solid state transformation of the model compound piroxicam was studied 
in vehicles with different excipient and compared with drug solubility at different 
time points. The novel HT-test provides kinetic data of the changes in both the solid 
and liquid phase. The MixRay will help to better understand solvent-mediated phase 
changes in the presence of various excipients to support formulation development. 
 
3.2 Materials and Methods 
3.2.1 Materials  
Anhydrous piroxicam (PRXAH), caffeine (CAFAH), and testosterone (TESAH) were 
purchased from TCI Europe N.V. (Zwijndrecht, Belgium), Sigma-Aldrich Chemie 
GmbH (Buchs, Switzerland), and TCI Europe N.V., respectively. Piroxicam 
monohydrate (PRXMH) was prepared by stirring PRXAH in 10 ml of deionized water 
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for 72 h, followed by filtration, and drying at 25 °C /45 % relative humidity as 
described in the literature.
98
 Caffeine hydrate (CAFH) was purchased from MP 
Biomedicals LLC (Santa Ana, California, USA). Testosterone hydrate (TESMH) was 
prepared by suspending TESAH in water for 72 h, filtering, and drying for 24 h at 
room temperature. Complete transformation of piroxicam and testosterone to the 
hydrate form was confirmed by thermogravimetric analysis (TGA) and XRPD 
analysis. 
Hydroxypropylmethylcellulose (HPMC) was obtained from Harke Group (Mülheim 
a.d. Ruhr, Germany), carboxymethylcellulose sodium salt (NaCMC) from Sigma-
Aldrich Chemie GmbH, polysorbate 80 from Croda Europe Ltd. (Cowick Hall, UK) 
and sodium dodecyl sulfate (SDS) from Stepan Company (Northfield, Illinois, USA). 
Sodium chloride and sodium phosphate monobasic anhydrous were from Sigma-
Aldrich Chemie GmbH and sodium chloride from Sigma Aldrich Co. (St. Louis, 
Missouri, USA). N-methyl-2-pyrrolidone, trimethylamine and methansulfonic acid 
were obtained from Sigma-Aldrich Chemie GmbH. Hydrochloric acid (0.1 M), 
sodium hydroxide (0.1 M) and ethanol were purchased from Merck KGaA 
(Darmstadt, Germany). Heptane and acetonitrile was from Biosolve BV 
(Valkenswaard, Netherland) and SIF
®
 powder from Biorelevant (Croydon, UK). 
 
3.2.2 Thermal gravimetric analysis (TGA) 
Thermogravimetric analyses were performed with a TGA/DSC 1 STARe system from 
Mettler-Toledo AG (Greifensee, Switzerland). Samples (2–3 mg) were heated at 10 
°C/min in 40 µl aluminum pans with pierced aluminum lids (Mettler-Toledo AG) to a 
maximum temperature of 300°C. Nitrogen was used as a protective gas at a flow rate 
of 100 ml/min. TGA was used to confirm the pseudopolymorphic transformation of 
the active pharmaceutical ingredients (APIs). 
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3.2.3 X-ray powder diffractometry (XRPD) 
The polymorphic form of all materials (hydrates/anhydrates) was verified 
experimentally with XRPD using a STOE Stadi P Combi diffractometer equipped 
with primary Ge-monochromator (CuKα radiation), imagine plate position sensitive 
detector (IP-PSD), and 96-well plate sample stage. The IP-PSD allowed simultaneous 
recording of diffraction patterns on both sides of the primary beam. The software 
STOE WinXPOW was used for improving XRPD data quality by merging both 2-
theta ranges and for calculating the composition of the mixtures. Effects related to 
poor crystal orientation statistics were reduced by summing up diffracted beam 
intensities on both sides of the primary beam. Each well of the imaging plate was 
exposed to X-ray radiation for 5 min. Samples were analyzed directly in the 96-well 
filter (polycarbonate membrane) plate (in triplicate) without prior preparation or 
additional processing. 
 
3.2.4 Microscopy 
Microscopic images were obtained by using a Zeiss Axiolab (Carl Zeiss AG, Jena, 
Germany) polarizing optical microscope. Powder samples of the different 
polymorphic forms were placed onto a glass slide, dispersed in silicone oil, and 
roofed with a cover slip. Photomicrographs were taken using an AxioCam MRc 5 and 
AxioVision software (version 4.6). 
 
3.2.5 Preparation of polymorphic mixtures 
Binary mixtures of hydrate and anhydrate were prepared by mixing proportions of 
components from 0% to 100% in steps of 10%. The total amount of drug per well in a 
96-well filter plate (MultiScreen
®
HTS, Merck Millipore Ltd., Carrigtwohill, Ireland) 
was 10 mg. The powder was subsequently suspended in n-Heptane (100 μl) and 
stirred for 30 min to evaporate the heptane to achieve homogenous mixing of the 2 
polymorphic forms. Subsequently, the 96-well plate was left for 12 h at RT to 
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evaporate heptane. Residual heptane in the dried powders of random samples was 
finally determined by using TGA as described in section 3.2.1.1. 
 
3.2.6 XRPD data analysis 
Win XPow Kombi/Quant was used for quantitative analysis of X-ray diffractograms. 
This program analyzes any powder diffraction pattern as a mixture of its possible 
standard components. It is assumed that at any 2theta the intensity I(2ϴ) of the 
mixture can be expressed as 
𝐼(2𝜃) = ∑ 𝑥𝑖𝑆𝑖(2𝜃)𝑖                            Eq. 3.1 
where the xi is the mass fraction of the standard i present in the mixture and Si(2ϴ) 
holds for the observed intensities of the same amount of the pure phase at this 2theta 
angle. The xi values are determined by a linear least squares procedure and then 
rescaled to give a total of 100%. 
To account for different scattering volumes, the analyzed samples were normalized 
with the air/background scattering. Therefore, an air/background reference pattern 
recorded under identical conditions was used to account for air/background scattering 
contribution of the samples and quantified as a "component" of the mixture. 
Subsequently, the ratio of the crystalline polymorph phase was normalized by the 
"content" of the air/background "component". 
 
3.2.7 Kinetics of drug concentrations and polymorphic transformation 
3.2.7.1 Preparation of solutions 
The effect of formulations vehicles with polymers and surfactants on the solid state 
transformation kinetics were compared with biorelevant media. To keep the systems 
as simple as possible only excipient solutions with one excipient were used instead of 
excipient mixtures. Thus, pure water and biorelevant phosphate buffer (pH 6.5) were 
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selected as reference media. All solutions were adjusted to a pH of 6.5 before 
incubation to minimize the differences between the media. For each group of 
excipients, two examples were selected, one charged (NaCMC, SDS) and one neutral 
additive (HPMC, polysorbate 80).  
Phosphate buffer, pH 6.5 (hereafter named blank-buffer) was prepared by dissolving 
sodium hydroxide (0.42 g/l), sodium phosphate monobasic anhydrous (3.44 g/l), and 
sodium chloride (6.19 g/l) in deionized water followed by adjusting the pH to 6.5 
(25°C). A standard medium composition was used to mimic intestinal fluid:
101
 Fasted 
state simulated intestinal fluid (FaSSIF) was prepared using SIF
®
 instant powder 
according to the manufacturer's preparation protocol
102
 for FaSSIF solution. 
Excipient solutions were prepared by dissolving HPMC, NaCMC, SDS or polysorbate 
80 at 0.5 % (w/w) in deionized water and adjusting the pH to 6.5 with hydrochloric 
acid or sodium hydroxide at 25°C. 
 
3.2.7.2 Kinetic concentration and residual solid analysis 
Kinetic concentrations of piroxicam were determined in different excipient solutions 
by using a slightly modified SORESOS (SOlubility and REsidual SOlid Screening) 
assay.
56
 PRXAH (ca. 7 mg), TESAH (ca. 6 mg) and CAFAH (ca. 15 mg) was 
dispensed in a 96-well flat bottom plate (Corning Inc., Durham, New York, USA) 
using the so-called powder-picking-method.
103
 After adding stir bars and 150 µl 
excipient vehicle, the plate was sealed with pre-slit silicon caps. The mixtures were 
agitated by head-over-head rotation for 10, 20, 30, 45, 60, 90, 120, 180, 240, 300, 360 
and 1440 min at room temperature. The suspensions were transferred into 96-well 
filter plates (MultiScreen
®
HTS) and liquid was separated from residual solid by 
centrifugation. Filtrates of piroxicam and testosterone were diluted with N-methyl-2-
pyrrolidone and filtrates of caffeine with ethanol. Drug concentrations were 
determined using a Waters Acquity Ultra Performance Liquid Chromatographic 
(UPLC) system equipped with a 2996 Photodiode Array Detector and an Acquity 
UPLC BEH C18 column (2.1x50 mm, 1.7 μm particle size) from Waters (Milford, 
Massachusetts, USA). An isocratic flow was applied for 0.3 min at a flow rate of 0.75 
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ml/min. Subsequently, the concentration of solvent B was linearly increased to 100% 
within 0.5 min. Table 3.1 lists the composition of the mobile phase during isocratic 
flow and the wavelength of detection. Solid state analysis of residual solid was 
performed by XRPD. 
 
Table 3.1: Experimental conditions used for UPLC analysis. 
 Gradient (A:B)
a 
[%] Detection wavelength [nm] 
Caffeine 95:05 273 
Piroxicam 65:35 342 
Testosterone 60:40 244 
a
Mobile phase A: deionized water with 0.1% (v/v) triethylamine adjusted to pH 2.2 with 
methanesulfonic acid Mobile phase B: acetonitrile. 
 
 
3.3 Results and Discussion 
3.3.1 Characterization of raw materials 
The X-ray diffractograms of anhydrous polymorphs and hydrates of caffeine and 
piroxicam are shown in Figure 3.1. The diffractograms agreed well with published 
data.
97-99
 For TESMH, there was no reference pattern available in the literature. 
Therefore a reference powder pattern was calculated by the program mercury
104
 based 
on a single crystal cif-file from the Cambridge Structural Database (CSD). The 
obtained diffraction pattern was compared with experimental data and good 
agreement with the calculated reference was evidenced. Figure 3.1 shows 
diffractograms of the model compounds and indicates that the hydrates can be well 
differentiated by both unique peaks and intensities. 
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Figure 3.1: X-ray diffractograms of anhydrous polymorphs and hydrates of caffeine (CAFAH/CAFH), 
piroxicam (PRXAH/PRXMH), and testosterone (TESAH/TESMH). 
Results of TGA measurements of anhydrous and hydrated raw materials are listed in 
Table 3.2. The stoichiometry that was inferred from thermal analysis agreed well with 
those reported in the literature.
98, 100, 105
 Thus, piroxicam and testosterone were shown 
to form the expected 1:1 molecular monohydrates, whereas caffeine hydrate was 
different due to the specific channel structure and has therefore been previously 
described as a 4/5 hydrate.
105
 
 
Table 3.2: Thermoanalytical results. 
 𝒏𝒉𝒆𝒑𝒕𝒂𝒏𝒆
𝒏𝒅𝒓𝒖𝒈
 a 𝒏𝒘𝒂𝒕𝒆𝒓
𝒏𝒅𝒓𝒖𝒈
 b
 
Caffeine anhydrous 0.00  
Caffeine hydrate  0.80 
Piroxicam anhydrous 0.00  
Piroxicam hydrate  0.98 
Testosterone anhydrous 0.07  
Testosterone hydrate  0.95 
a 
nheptane/ndrug is the molar ratio of heptane and drug after supending in heptane and drying of the 
samples, 
b
 nwater/ndrug is the molar ratio of water and drug in hydrate forms 
 
According to the thermal analysis, there was no residual heptane in caffeine and 
piroxicam (Table 3.2). Only in TESAH a small amount of residual heptane (heptane: 
drug molar ratio 0.07) could be detected; however, this does not seem to affect XRPD 
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analysis since no difference was detected between the diffractograms of TESAH and 
TESAH suspended in heptane (data not shown). 
 
3.3.2 XRPD calibration 
XRPD patterns from binary mixtures were analyzed with Win XPow Kombi/Quant by 
considering the pure anhydrous, pure hydrated drug, and additionally the background 
as standard components. Validation of mixtures was carried out in the 5-35° 2ϴ 
range. Calculated compositions of the different binary mixtures were plotted against 
weight fractions (not shown). For all compounds this resulted in linear correlation; 
however the respective correlation coefficients differed (R
2
 (CAF) = 0.9375, R
2
 
(PRX) = 0.9734, R
2
 (TES) = 0.9284). 
Likely sources of variation are differences in scattering intensities or particle sizes and 
shapes; the latter is known to cause errors in quantitative analysis using XRPD.
33
 
Thus, the lower correlation coefficient for caffeine mixtures might be caused by the 
caffeine hydrate that has long, needle-like crystals
13
 as shown in Figure 3.2b. 
 
 
Figure 3.2: Microscopic images of crystals of CAFAH (a), CAFH (b), PRXAH (c), PRXMH (d), 
TESAH (e), and TESMH (f). 
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Given the miniaturized nature of the MixRay, the obtained regression models were 
considered in all cases as sufficiently good. It was beyond the scope of this study to 
further optimize the HT-method and to determine parameters such as the limit of 
quantification or detection; further method optimization and validation would then be 
part of later stage development. The intended use of the miniaturized calibration is the 
early screening phase in combination with other assays such as SORESOS 
56
. Here 
many different compounds are tested with various excipients and it is primarily 
important to gather much information on a short time scale. For a faster and less 
work-intensive preparation process compared to the method described in section 
3.2.5, the polymorphic mixtures were prepared by mixing different volumes of 
suspensions of pure PRXAH and PRXMH in heptane (100 mg/ml), followed by 
heptane evaporation. Calibration measurements resulted here also in a linear 
regression (data not shown). 
 
3.3.3 Piroxicam in excipient-solutions and biorelevant medium  
3.3.3.1 Kinetic concentrations and qualitative analysis of residual solids - 
Screening test 
The kinetic SORESOS assay
56
 was used to determine kinetic concentrations of 
PRXAH in four different excipient-vehicles, FaSSIF, blank-buffer pH 6.5, and pure 
water as a reference. In parallel, solid state properties of the residual solid was 
qualitatively analyzed with XRPD. The time-dependent concentration curves of 
PRXAH and the corresponding composition of solids are shown in Figure 3.3. 
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Figure 3.3: Solid state (bars at the upper section) and concentrations (curves in the lower section) of 
piroxicam in excipients-vehicles (0.5%, pH 6.5) and water. Time points of solid state and 
concentrations are the same in the upper and lower part of the figure. 
 
To use the assay as a “quick test”, i.e., for qualitative determination of occurrence and 
classification of the kinetics of drug phase transformations (fast vs slow), we only 
distinguished between the different polymorphic forms or mixtures thereof. As 
expected, the initial drug concentration decreased in the media where PRXMH was 
formed because the PRXMH solubility is lower compared to PRXAH.
56, 90
 The 
appearance/disappearance of hydrate/anhydrate (Figure 3.3) can here only be roughly 
related to the measured kinetic drug concentrations in the bulk phase of the different 
excipient media. However, these “screening test” results can be analyzed further to 
gain more in depth kinetic knowledge as described in section 3.3.3.2. 
 
3.3.3.2 Kinetic concentrations and quantitative analysis of residual solids - 
MixRay assay 
For a more detailed analysis of polymorphic transformations, the established MixRay 
calibration curve for piroxicam was used to quantitate anhydrate to hydrate 
conversion in the residual solids. In a previous paper, similar excipient effects were 
observed,
90
 but solid state was determined only after 24 h at the end of the solubility 
experiments, which makes a profound difference to the present work. It is from a 
Miniaturized X-ray powder diffraction assay (MixRay) for quantitative kinetic analysis of solvent-mediated phase 
transformations in pharmaceutics 40 
  
 
 
biopharmaceutical perspective relevant to learn about more detailed kinetic changes 
as they are likely to impact in vivo drug absorption.  
 
 
Figure 3.4: Concentrations (empty circles) and solid state (filled circles) of piroxicam in (a) water, (b) 
FaSSIF, and (c) blank-buffer. 
 
In water, solid state transformation to PRXMH started instantaneously once PRXAH 
was added PRXAH could be detected up 200 min and conversion to PRXMH was 
completed after 6 h. Among the vehicles tested, PRX-solubility was lowest in water 
after 24 h (Figure 3.4).  
In the biorelevant FaSSIF medium, PRXMH formation was completely inhibited 
(Figure 3.4). In contrast, PRXMH transformation in blank-buffer (FaSSIF without 
phospholipids and bile salts) was fast and after 10 min already 30% hydrate was 
formed. Transformation was more rapid than in pure water and completed after only 2 
h at RT. The faster transformation of PRXMH in blank-buffer compared to water may 
be attributed to the ion composition and/or pH of the blank-buffer medium. Bulk drug 
concentrations correlated well with the solid state analysis. Kinetic drug 
concentrations in FaSSIF remained high at 0.3 mg/ml over 24 h, whereas the high 
initial concentration in blank-buffer decreased rapidly when PRXAH was completely 
transformed into PRXMH. Similar results have been reported for carbamazepine 
where sodium taurocholate and lecithin were also shown to inhibit hydrate 
formation;
17
 in the latter study the observed increased piroxicam concentration in 
FaSSIF compared to blank-buffer in the bulk was attributed to drug solubilization in 
micelles. 
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Figure 3.5: Concentrations (empty circles) and solid state (filled circles) of piroxicam in (a) water, (b) 
HPMC (0.5%), and (c) NaCMC (0.5%). 
 
Polymer-solutions had different effects on piroxicam pseudopolymorphic 
transformation. HPMC completely inhibited PRXMH formation. In contrast, NaCMC 
only delayed PRXMH formation compared to water alone (Figure 3.5c). Solid state 
transformation kinetics in NaCMC can be divided into two phases, an initial slow one 
where only 10% of the PRXAH was transformed to PRXMH within 1.5 h followed by 
a fast conversion of remaining PRXAH to PRXMH within the next 3 h. Compared to 
water, piroxicam kinetic concentrations were slightly increased in HPMC solutions 
and remained almost constant for 24 h. In contrast, drug concentration rapidly 
decreased in NaCMC-solution when hydrate was formed and even after 24 h, 
equilibrium solubility was presumably not yet reached. 
The difference between the two tested polymers may be related to different charges. 
Polymers typically inhibit polymorphic transformations by adsorption onto particles' 
surfaces.
70
 At the test pH of 6.5, HPMC is neutral and NaCMC and piroxicam are 
negatively charged. Thus, in case of NaCMC, repulsion between piroxicam and 
NaCMC molecules may have reduced polymer adsorption to the surface of piroxicam 
particles and hence PRXAH to PRXMH conversion may be more pronounced than 
with HPMC. Kinetic concentrations of piroxicam in HPMC and NaCMC after 24 h 
were both higher than in water. This may result from an incomplete transformation to 
PRXMH or an increase in drug solubility by the polymers.  
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The two surfactants used, SDS and polysorbate 80, also affected piroxicam hydrate 
formation differently (Figures 6b and c). SDS slightly accelerated PRXMH formation 
compared to water (30 min), whereas polysorbate 80 delayed PRXMH formation for 
up to 20 h. An influence on the kinetic concentrations was not noticed although about 
10% hydrate was detected after 24 h. Probably the better soluble species (PRXAH) 
was dominating bulk concentrations, which might be a more general case as long as a 
sufficient amount of the more soluble form is present. Moreover, pseudopolymorphic 
transformation kinetics are strongly influenced by a variety of factors, such as pH 
differences, contaminations or ionic strength of the media, and it is therefore quite 
common that repeated results may vary from well to well.
56
 These variations between 
the polymorphic compositions in the single wells seem to not influence the solubility 
significantly, since in Figures 6a and c, the curves of the solid state transformation 
vary whereas the solubility curves are almost identical. 
 
 
Figure 3.6: Concentrations (empty circles) and solid state (filled circles) of piroxicam in (a) water, (b) 
polysorbate 80 (0.5%), and (c) SDS (0.5%). 
Transformation of piroxicam in polysorbate 80-solution was not completed after 24 h 
and drug concentration remained almost constant over 24 h (Figure 3.6b). In contrast, 
piroxicam concentrations in SDS-solution decreased from 0.27 mg/ml to 0.075 mg/ml 
after hydrate transformation was completed.  
Noteworthy is that for all excipient solutions, the pH was rather stable (± 0.5) around 
the initial value.
90
 The only exception was polysorbate 80, where the pH dropped 
from 6.5 to 4.27 (±0.39). 
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For those systems where hydrate formation was completely inhibited (like FaSSIF 
and HPMC-solution) no additional information was obtained from the more detailed 
quantitative results (MixRay) of solid state transformation. Here the "screening test" 
without calibration would obviously provide sufficient information on the given 
pseudopolymorphic transformation. 
 
3.4 Conclusions 
This study presents a miniaturized, high throughput X-ray method (MixRay) that was 
developed for quantification of different polymorphic forms in mixtures. The 
introduction of the correction of X-ray pattern with measured background pattern 
allowed the detection of much smaller quantities of polymorphic forms in binary 
mixtures than in previous studies. 
33, 89
 The method allows the determination of both 
solid state transformations and kinetic concentrations in parallel in a single assay. A 
simplified version of the assay may analyze a phase transformation also without 
polymorphic quantification, which provides as a kind of “screening test”. Both, the 
MixRay and the simpler kinetic assay can support pharmaceutical profiling of a 
clinical candidate and solvent-mediated phase transformations can be studied to 
screen excipients as part of formulation development. The new promising assay may 
in the future also be used to study kinetic changes of amorphous compounds or of 
metastable polymorphs.  
  
Kirchmeyer et al. Influence of excipients on solvent-mediated hydrate formation of piroxicam studied by dynamic 
imaging and fractal analysis. Crystal Growth & Design, 2015, 15, 5002-5010. 
 
 
Chapter 4 
Influence of excipients on solvent-mediated 
hydrate formation of piroxicam studied by 
dynamic imaging and fractal analysis 
 
Summary 
Hydrate formation of pharmaceutical compounds can affect critical drug properties 
such as solubility and dissolution. There is early on in development a need for a 
deeper understanding of how excipients influence mechanistically hydrate formation. 
The influence of excipients and of biorelevant medium on the kinetics of hydrate 
formation of piroxicam was studied with the aim to describe the kinetic changes of 
both the bulk suspension and the drug compact surface. Kinetic experiments were 
based on a miniaturized method using x-ray diffraction for solid state analysis and 
ultra-high pressure liquid chromatography for drug concentration determination in 
bulk solution. Surface changes on drug compacts were monitored by dynamic image 
analysis of microscopic pictures and subsequent determination of a fractal dimension 
using box counting. Surface analysis correlated well with bulk monitoring of the 
piroxicam hydrate formation. Individual excipients exhibited highly specific effects 
on the kinetics of hydrate formation but at equilibrium, the finally obtained fractal 
dimensions reached the same value of 1.85. The cluster structure of hydrate particles 
and therefore the recrystallization process were hardly affected by excipients; in 
contrast excipients strongly affected the kinetics of hydrate formation which is of 
pharmaceutical relevance.  
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4.1 Introduction 
More than a third of pharmaceutical compounds are known to form hydrates.
86
 
Different types of hydrates exist, ranging from crystal structures with isolated hydrate 
sites (lattice hydrates) to channel-type structures (channel hydrates) and finally to 
hydrate forms, where the water is primarily associated with ions (ion associated 
hydrates).
27
 Since the crystal structure of a hydrate can be quite different from its 
anhydrous form, several important solid state properties of drugs can be affected by 
hydrate formation such as for example solubility and dissolution rate.
106
 Hydrates 
often have lower solubility than their corresponding anhydrous form. Uncontrolled 
hydrate formation may result in impaired or erratic oral absorption, which can result 
in reduced drug absorption.
107
 This is a prime concern during pharmaceutical 
development of novel drug candidates and it is important to identify hydrate 
formation or any other crystal structure changes (salt formation, polymorphic 
changes) early on as part of a pharmaceutical solid state screening. 
For polymorphic or pseudopolymorphic changes it is important to evaluate the rate of 
conversion under defined conditions. Comparatively rapid conversion kinetics can 
lead to solvent-mediated solid phase transformations already during pharmaceutical 
processing. An example was recently reported by Wikstroem et al. who studied 
various factors influencing the anhydrate-to-hydrate transformations in aqueous 
medium
15
 with emphasis on the process of high-shear wet granulation.
78
 The authors 
found that external parameters like seeding and agitation conditions influence the 
hydrate formation. Excipients also had strong effects on hydrate formation and could 
even prevent their formation during high-shear wet granulation.  
Hydrate formation may even be fast enough to occur in the gastrointestinal tract after 
oral drug administration. For example, Letho et al.
17
 studied carbamazepine anhydrate 
to hydrate conversion in simulated intestinal fluids with Raman spectroscopy in a 
channel flow cell. They observed that transition kinetics was greatly influenced by 
medium composition; for example hydrogen bonding between carbamazepine and the 
bile salt sodium taurocholate inhibited hydrate formation. Other studies focussed on 
aqueous slurries to identify excipient effects on the kinetics of hydrate formation.
16, 22, 
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107, 108
 In these studies, no general effect of excipients was found but drug-excipient 
interactions were rather specific. Excipients may interfere via several mechanisms 
with hydrate formation. The classical Cardew and Davey model
109
 described solvent-
mediated phase transformations as a multi-step process and additives may affect the 
kinetics of anhydrate dissolution and/or subsequent nucleation and growth steps of a 
hydrate. Due to this complexity, additional data are needed to gain more insight into 
excipient effects on anhydrate-to-hydrate conversions. This could then be the basis for 
a more rational excipient selection for the formulation development of hydrate 
forming drugs. 
This work focuses on piroxicam (PRX). PRX has two pKa values (2.3 (acid), 5.3 
(base)) and its different solid state forms have been studied previously.
98, 99, 110
 
Piroxicam anhydrate (PRXAH) has a substantially different crystal lattice compared 
to the hydrate. The crystal structure of the anhydrate of PRX is based on the neutral 
molecule, whereas the piroxicam monohydrate (PRXMH) contains the zwitterionic 
molecule (Figure 4.1).
111
 Interestingly, the anhydrous form is colorless, whereas 
PRXMH has a bright yellow appearance.
98, 112
 
 
 
Figure 4.1: Anhydrate-to-hydrate transformation of piroxicam. Adapted from Sheth et al.
98 
 
A recent paper emphasized particularly the effect of sodium dodecyl sulfate on 
solvent-mediated phase changes of piroxicam.
22
 In this study, 1% SDS (w/w) in a 
slurry inhibited conversion of PRXAH to PRXMH. However, more data of such 
excipient effects are needed for practical formulation development and to ultimately 
gain better mechanistic understanding.  
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The current work addresses the need for more data by analysing effects of additional 
excipients and simulated intestinal medium on the kinetics of hydrate formation.  
Image analysis was used in line with recent advancements in characterizing poorly 
water-soluble drugs.
49
 A particular new idea was to apply fractal analysis to dynamic 
surface imaging. Concepts of fractal geometry describe the heterogeneous nature of a 
structure or process. This is different from other models that describe homogenous 
structures and systems. Such models based on homogeneity assumption have been 
proposed to describe solvent-mediated phase transformations.
109, 113, 114
 It is likely that 
a consideration of structural heterogeneity and fractal geometry could lead to further 
insights into the pseudopolymorphic changes. Since the pioneer article by Kopelman 
in “Science”,115 other applications of fractal geometry have been reported in chemical 
and pharmaceutical sciences,
116, 117
 e.g. a recent study demonstrated fractal-like drug 
dissolution kinetics in biorelevant media.
118
 The present study introduces a fractal 
analysis of the solid surface to the field of solvent-mediated phase transformations. 
Fractal dimensions are determined during the PRXAH to PRXMH transition in 
presence of different additives to better understand the underlying physicochemical 
process. 
 
4.2 Materials and Methods 
4.2.1 Materials  
Piroxicam was from Sigma Aldrich (Buchs, Switzerland). Sodium chloride, sodium 
hydroxide pellets and sodium phosphate monobasic anhydrous were from Fluka 
Analytical Ltd. (Buchs, Switzerland). SIF
®
 powder was obtained from Biorelevant 
(Croydon, UK). Hydrochloric acid (1 M) and sodium hydroxide solution (1 M) were 
from Scharlau (Barcelona, Spain) and paraffin was purchased from Hänseler AG 
(Herisau, Switzerland). 
Hydroxypropylmethylcellulose (HPMC) was obtained from Harke Group (Mülheim 
a.d. Ruhr, Germany), carboxymethylcellulose sodium salt (NaCMC) from Sigma-
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Aldrich (Buchs, Switzerland), Polysorbate 80 (P80) from Croda Europe Ltd. (Cowick 
Hall, UK), and sodium dodecyl sulfate (SDS) from Stepan Company (Northfield, 
USA). 
 
4.2.2 Preparation of solutions 
Phosphate buffer, pH 6.5 (hereafter named blank-buffer) was prepared by dissolving 
sodium hydroxide (0.42 g/l), sodium phosphate monobasic anhydrous (3.44 g/l), and 
sodium chloride (6.19 g/l) in deionized water and adjusting the pH to 6.5 (25°C). A 
standard medium composition was used to mimic intestinal fluid
101
: Fasted state 
simulated intestinal fluid (FaSSIF) was prepared using SIF
®
 instant powder according 
to the manufacturer's preparation protocol
102
 FaSSIF solution. 
Excipient solutions were prepared by dissolving HPMC, NaCMC, SDS or P80 (0.5 % 
(w/w)) in deionized water, adjusted to a pH 6.5 by hydrochloric acid or sodium 
hydroxide, and the final pH was verified again at 25°C. 
 
4.2.3 Preparation of piroxicam monohydrate 
For preparation of piroxicam monohydrate (PRXMH), 1 g piroxicam anhydrate was 
added to 10 ml deionized water and stirred for 72 h at room temperature. After 
filtration and drying at 25°C, 45% relative humidity, the PRXMH was obtained as 
previously described in the literature.
98
 
 
4.2.4 Differential scanning calorimetry (DSC) 
A differential scanning calorimeter DSC 8500 from Perkin Elmer Ltd. 
(Schwerzenbach, Switzerland) was used to characterize the thermal properties of the 
drug and its corresponding hydrate. Samples of PRXAH and PRXMH (average 
weight: 2 mg) were placed in hermetically sealed aluminum pans (50 μl) and heated at 
5°C min
-1
 from 20°C to 220°C under a nitrogen purge (20 ml/min). Melting 
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temperature and heat of fusion of piroxicam samples were determined from the peak 
onset and the area under the peak using the Pyris Analysis software (V. 11.0.0.0449) 
from Perkin Elmer (Schwerzenbach, Switzerland). All measurements were conducted 
in triplicates. 
 
4.2.5 X-ray powder diffraction (XRPD) 
Crystal structures of all materials (hydrate/anhydrous forms) were verified by XRPD 
using a STOE Stadi P Combi diffractometer with primary Ge-monochromator (CuKα 
radiation), imagine plate position sensitive detector (IP-PSD), and 96-well plate 
sample stage. The IP-PSD allowed simultaneous recording of diffraction pattern both 
sides of the primary beam. The software STOE WinXPOW was used for improving 
XRPD data quality by merging both 2-theta ranges. Effects related to poor crystal 
orientation statistics were reduced by summing up diffracted beam intensities both 
side of primary beam. The imaging plate was exposed for 10 min to X-ray radiation 
for each well. Samples were analyzed directly in a 96-well filter plate without prior 
preparation and additional processing and the measurements were conducted in 
triplicate. 
 
4.2.6 Raman spectroscopy 
Raman spectra were recorded with a 785-nm excitation laser in the backscattering 
mode using a Raman RXN1 analyzer (Kaiser Optical systems Inc., Ann Arbor, USA). 
The system was equipped with a charge-coupled device (CCD) camera. A laser power 
of 400 mW was given and background Rayleigh scattering was removed by a 
holographic filter during acquisition of the spectra. Raman spectra were recorded with 
a single fiber probe (spot size 0.007 mm
2
) of powder samples obtained from slurries 
as well as powdered raw materials. A single spectrum of the powder was acquired in 
the backscattering mode using a 30 sec acquisition time. Finally, three scans were 
averaged to generate a single spectrum. The baseline was corrected and intensities 
were normalized by setting the maximum peak to unity. Data acquisition, spectral pre-
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processing, and the subsequent analysis were based on the iC Raman (V. 3.0) 
software from Mettler-Toledo AutoChem Inc. (Columbia, USA). 
4.2.7 Solubility and residual solid analysis 
Kinetic solubility of piroxicam in different excipient solutions was determined by 
using a slightly modified 96-well solubility assay (SORESOS).
56
 PRXAH (ca. 7 mg) 
was dispensed using the powder-picking-method
103
 in a 96-well flat bottom plate 
(Corning Inc., Durham, USA). After adding stirring bars and excipient vehicles (150 
µl) the plate was sealed with pre-slit silicon caps. Filling steps were performed at 
different time points over a period of 24 h so that the incubation times were variable 
(10 min, 30 min, 60 min, 120 min, 240 min, 360 min and 1440 min) and a time 
depending kinetic was obtained. The mixtures were agitated by head-over-head 
rotation at room temperature. After mixing, the suspension was transferred into 96-
well filter plates and liquid was separated from residual solid by centrifugation. 
Filtrates were collected, diluted with N-methyl-2-pyrrolidone and drug content in 
filtrates was determined using a Waters Acquity Ultra Performance Liquid 
Chromatographic (UPLC) system equipped with a 2996 Photodiode Array Detector 
and an Acquity UPLC BEH C18 column (2.1x50 mm, 1.7 μm particle size) from 
Waters (Milford, USA). Mobile phase A and B consisted of 0.1% (v/v) triethylamine 
in deionized water adjusted to pH 2.2 with methanesulfonic acid and acetonitrile. An 
isocratic flow of 65:35% (v/v) (A:B) was applied for 0.3 min at a flow rate of 0.75 
ml/min. Subsequently, the concentration of solvent B was linearly increased from 
35% to 100% B within 0.5 min. The wavelength of detection was at 342 nm. Solid 
state analysis of residual solid was performed by XRPD with an exposure time of 5 
min per well. Moreover, the pH of the samples was measured in a slightly larger scale 
(500 μl) after 24 h using the experimental setup of the other kinetic measurements. 
 
4.2.8 Microscopy 
For microscopy studies, samples were prepared with a diameter of 7 mm by 
compacting 110 mg of PRXAH using a Korsch XP0 tablet press (Korsch AG, Berlin, 
Influence of excipients on solvent-mediated hydrate formation of piroxicam studied by dynamic imaging and 
fractal analysis 51 
  
 
 
Germany). Compact strength was measured and a comparable value targeted to 
achieve a standardized degree of particle consolidation (data not shown). To assure 
that no hydrate seeds were present on the compact surface, the samples were dried for 
24 h at 100 °C at a reduced pressure (75 mbar) as previously described.
119
 The 
compacts were embedded in paraffin leaving one of the surfaces uncovered. 
Compacts were placed in a crystallization dish under the Olympus microscope SZX10 
(Olympus Corporation, Tokyo, Japan) and were covered with the medium (30 ml). 
Images were recorded every 0.5 hour over a period of 24 hours at room temperature. 
The microscope was equipped with a CCD chip camera UC30 from Olympus 
(Olympus Corporation, Tokyo, Japan) and a VisiLED ringlight (Lightning and 
Imaging SCHOTT North America Inc., Southbridge, USA). Picture acquisition was 
conducted with the Olympus Stream (V. 1.8.5) from Olympus Corporation (Tokyo, 
Japan). 
 
4.2.9 Data analysis 
4.2.9.1 Image and fractal analysis 
The acquired images were converted to black-and-white (binary) pictures by using the 
image processing software GIMP (V. 2.8.10).
120
 For each image the contrast was 
increased and a conversion to grey-scale was performed. For creation of the final 
binary images a threshold value from 180 was used (where 0 and 255 resulted in an 
entirely white and black image). The final pictures had a size of 2080 x 1544 pixels.  
A standard box-counting method was used for fractal analysis. The pre-processed 
binary images were used with white pixels as background. All image calculations 
were based on the integrated fractal analyzing module Fraclac
121
 of ImageJ
122
, which 
employed a maximum box size of 45% relative to the whole image size. 
For box counting, an image is covered by a series of grids with decreasing caliber. 
The number (N) of these calibers (boxes) containing any part of the structure is 
counted for each box size (ε). The principle of box counting is depicted in Figure 4.2. 
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The obtained counts are related to the caliber with the negative fractal dimension (D) 
as exponent, Equation 4.1. 
𝑁(𝜀) ∝ 𝜀−𝐷             Eq. 4.1 
 
 
Figure 4.2: Principle of box-counting method: The object is covered by a series of grids with 
decreasing caliber. For each box size the amount of boxes that cover any part of the structure is 
counted. 
 
For fractal objects a double-logarithmic plot yields a straight line, and D can be 
determined as the absolute value of the slope: 
ln 𝑁(𝜀) =  −𝐷 ln 𝜀 + 𝑐               Eq. 4.2 
The constant c describes the ordinate intercept
123
 and a typical plot of double-
logarithmic plot of box counting is shown in Figure 4.3. The bias caused by the 
circular surface of the tablet was taken into account for the fractal analyses. 
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Figure 4.3: Example of a double logarithmic plot of number of boxes (N) against box size (Ɛ) for 
calculating the fractal dimension, D. 
4.2.9.2 Statistical analysis 
The STATGRAPHICS Centurion XVI ed. Professional (V. 16.2.04) software from 
Statpoint Technologies Inc. (Warrenton, USA) was used for statistical processing. 
Analysis of variance (ANOVA) was used to estimate the repeatability and 
reproducibility of the measurement system in terms of the fractal dimension in the 
plateau. Mean values of fractal dimension (D) in the plateau were compared for three 
different excipients. Included in the ANOVA a F-test was performed to identify any 
significant differences among the means. 
 
4.3 Results 
4.3.1 Initial characterization of piroxicam 
According to the thermal analysis, Raman spectroscopy and XRPD results, the 
purchased PRX was the form I described by Vrečer et al.99 and by Sheth et al.110 The 
same methods were used for characterization of prepared hydrate samples and results 
agreed well with published data.
22, 77, 98, 119
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4.3.2 Solubility and residual solid analysis of piroxicam in excipient-
solutions 
The solubility of PRX was determined in four different excipient-vehicles, FaSSIF 
and blank-buffer pH 6.5 (Table 4.1). As a reference, the solubility of PRX was 
analyzed in pure water (Milli-Q-water). In addition to the kinetic solubility, residual 
solid drug was analyzed by XRPD. The diffractograms indicated that after 24 h (at 
room temperature) PRXAH was not converted in all media to PRXMH. The 
monohydrate was clearly detected in water, blank-buffer, NaCMC-, and SDS-
solutions but not in HPMC-, P80-solutions, and FaSSIF. 
 
Table 4.1: Kinetic solubility of piroxicam (PRX) in different vehicles and identified crystal forms of 
the residual solids after an incubation time of 24 h as determined by XRPD. 
 Solubility 
[μg/ml]a 
Residual 
solids 
pH after 24 h
a 
Water  
(initial measurement as reference)  
37.0 (0.0)
b
 PRXAH
c
 5.29 (0.25)
c 
Water  9.3 (1.5) PRXMH 5.93 (0.73) 
Blank-buffer pH 6.5 75.7 (2.5) PRXMH 6.50 (0.01) 
FaSSIF 307.3 (18.3) PRXAH 6.39 (0.02) 
0.5 % NaCMC in water (w/w) 37.3 (2.5) PRXMH 6.19 (0.05) 
0.5 % HPMC in water (w/w) 73.7 (2.1) PRXAH 5.72 (0.06) 
0.5 % SDS in water (w/w) 70.3 (3.2) PRXMH 5.92 (0.18) 
0.5 % P80 in water (w/w) 66.7 (1.2) PRXAH 4.27 (0.39) 
a
All measurements were performed at 25±3°C (24 h except for the reference in water), expressed as 
mean (standard deviation), n=3. 
b 
Kinetic (non-equilibrium) solubility after 30 min. 
c
Incubation time was 30 min instead of 24 h and the solid state of PRX was verfied with XRPD. 
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Figure 4.4: Kinetic solubility of PRX in (a) water, 0.5% SDS- and P80-solution, (b) water, 0.5% 
NaCMC- and HPMC-solution, (c) water, blank-buffer and FaSSIF over 24 h. 
 
The kinetic solubility results of piroxicam are shown in Figure 4.4. During the first 
hour almost no difference in solubility was observed between water and P80 (Figure 
4.4a). Afterwards, concentration decreased in water but not in P80. SDS substantially 
increased the initial drug concentration; however concentration dropped after 4 h. The 
final concentration in SDS-solution was still markedly higher than in P80-solution or 
water. 
In NaCMC-solutions, PRX concentrations decreased continuously over 24 h. In the 
presence of HPMC, drug concentrations remained nearly constant over 24 h, being 
higher than in water. High drug concentrations were initially observed in both FaSSIF 
and its blank-buffer. However, in blank-buffer concentration dropped rapidly within 
the first 3 h, while it remained high in FaSSIF over 24 h. In all media, where PRXMH 
was formed, initial concentrations decayed. This decrease in solubility is caused by a 
lower solubility of PRXMH compared to the anhydrous form. 
Kinetic solubility results were further evaluated in terms of a supersaturation ratio 
(Table 4.2). This data presentation better marks the time course of PRXAH to 
PRXMH conversion than only showing kinetic concentrations (Figure 4.4). The 
supersaturation ratio was calculated as apparent value by dividing any drug 
concentration at a given time by its solubility after 24 h. This period was not for all 
systems long enough to reach equilibrium (=complete formation of PRXMH). 
Therefore, the solubility in these systems was determined after 72 h and the last two 
consecutive time points were checked for absence of relevant differences to verify 
that equilibrium has been reached.  
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Table 4.2: Apparent supersaturation ratios of piroxicam (PRX) in different vehicles at various time 
points. 
 
Supersaturation
a 
  10 min 30 min 60 min 120 min 240 min 360 min 
Water  
4.61 
(1.33) 
4.70 
(1.17) 
5.57 
(2.96) 
5.04 
(1.61) 
2.43 
(0.33) 
1.48 
(0.19) 
Blank-buffer  
3.68 
(0.37) 
3.72 
(0.21) 
3.52 
(0.27) 
2.00 
(0.30) 
1.05 
(0.04) 
1.03 
(0.13) 
FaSSIF
 b
  
3.80 
(0.17) 
3.83 
(0.16) 
3.87 
(0.21) 
4.06 
(0.31) 
4.05 
(0.29) 
4.03 
(0.24) 
0.5 % NaCMC in water (w/w)
b 4.25 
(0.16) 
4.21 
(0.52) 
3.98 
(0.50) 
3.96 
(0.35) 
3.49 
(0.20) 
2.89 
(0.13) 
0.5 % HPMC in water (w/w)
 b
 
1.33 
(0.67) 
1.55 
(0.79) 
1.37 
(0.55) 
1.50 
(0.59) 
1.36 
(0.26) 
1.35 
(0.32) 
0.5 % SDS in water (w/w) 
3.60 
(0.24) 
3.52 
(0.24) 
3.41 
(0.18) 
3.16 
(0.12) 
1.09 
(0.05) 
0.99 
(0.03) 
0.5 % P80 in water (w/w)
 b
 
3.56 
(0.97) 
3.64 
(1.05) 
3.49 
(0.96) 
3.38 
(0.95) 
3.28 
(0.93) 
3.23 
(0.90) 
a
Ratios calculated from the concentration divided by the corresponding 24 h solubility with standard 
deviations according error propagation (Gauss). 
b
Supersaturation values were calculated by using the solubility of PRXMH in the vehicles after 72 h 
instead of the solubility after 24 h. 
 
Conversion to the monohydrate within 360 min occurred in water, blank-buffer, and 
in the excipient solutions of NaCMC and SDS. In all systems, the observed 
supersaturation values were always below 6. Maximum supersaturation was reached 
in water after one hour. In blank-buffer and SDS the maximum was achieved earlier, 
after 30 min and 10 min, respectively. In both systems supersaturation was negligible 
after 4 h (value close to unity). In NaCMC-solution, drug supersaturation reached its 
maximum of 4.25 already after 10 min and decreased only gradually to about 3 after 6 
h. 
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4.3.3 Dynamic microscopic imaging and fractal dimensions 
Changes of the bulk were measured in suspensions using the described XRPD 
analysis of the slurries (see Chapter 4.2.5). All experiments in the different media 
were also investigated in the microscopic studies as a function of time. The 
experimental details can be inferred from the method description. The yellow colored 
crystals indicated hydrate formation which is well described in the literature.
8, 12, 13
 
Moreover, we conducted experiments (DSC, Raman spectroscopy and XRPD) to 
prove that the appearance of yellow crystals means indeed crystallization of the 
hydrate. The images of the compacts' surfaces were converted into binary images and 
the pixels were counted to determine clusters and their extents on the compact 
surface. In our study yellow color was converted into black, so black pixels were 
counted for quantification of hydrate formation. 
 In unbuffered water, PRXAH converted to PRXMH on the surface of the compact 
(Figure 4.5). Most pronounced changes were detected between 3 h and 17 h, 
variability between measured samples was high. 
 
 
Figure 4.5: Solid state transformation of piroxicam in water monitored by microscopic imaging. 
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In the presence of the excipients P80 and HPMC complete inhibition of the 
conversion was observed (Figures 4.6b and 4.6d).This is in line with the XRPD 
results obtained in bulk suspension experiments (Figure 4.4). NaCMC almost 
completely inhibited PRXAH transformation to PRXMH and only a small amount of 
hydrate (1% of the surface) could be detected in the microscopic study (Figure 4.6c). 
In the presence of the surfactant SDS (0.5% (w/w)), the surface of the samples was 
almost completely covered with hydrate after 17 h (Figure 4.6a). The kinetics of the 
conversion to the monohydrate was similar to water but seemed to be delayed and less 
variable by the additive. 
 
 
Figure 4.6: Solid state transformation (by microscopic imaging) of piroxicam in (a) SDS-solution 
0.5%, (b) P80-solution 0.5%, (c) NaCMC-solution 0.5%, and (d) HPMC-solution 0.5%. All solutions 
were adjusted to pH 6.5. 
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Figure 4.7: Solid state transformation of piroxicam in blank-buffer pH 6.5 and FaSSIF, pH 6.5 
(microscopic image analysis). 
 
In blank-buffer pH 6.5, transformation of PRXAH to PRXMH was accelerated 
compared to water (Figure 4.7). In contrast, FaSSIF did not reveal any transformation 
to the monohydrate. This result might be attributed to the presence of bile salt and 
phospholipid in FaSSIF, which is the only difference to blank-buffer. The observed 
spots of PRXMH on the surface of samples covered with blank-buffer and with water 
differed (Figure 4.8). In blank-buffer initially only a few spots of PRXMH formed 
close to the compact’s periphery which then grew to cover a wider surface area 
(Figure 4.8b). In contrast, PRXMH in water initially displayed a higher number of 
PRXMH nucleation surface spots distributed over the whole surface followed by a 
growth phase of these dispersed clusters (Figure 4.8a).  
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Figure 4.8: Tablet surface in (a) water and (b) blank-buffer at different time points (black: hydrate, 
white anhydrate). 
 
The analysis from the box-counting method in media in which an almost complete 
conversion to PRXMH has been reached is shown in Figure 4.9. This data evaluation 
confirmed the aforementioned kinetic trends. Thus, SDS appeared to delay hydrate 
formation compared to water, whereas blank-buffer clearly accelerated the process. In 
water and blank-buffer a considerable variability in conversion was observed at the 
beginning but results were very reproducible when most of the surface was covered 
with hydrate. A fractal dimension of less than unity was expected for nucleation and 
initial formation of clusters. Interestingly, maximal surface coverage in all samples 
resulted in the same fractal dimension of 1.85. 
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Figure 4.9: Fractal surface dimension of PRXMH obtained by microscopy (box counting method) in 
water, blank-buffer pH 6.5 and 0.5 % (w/w) SDS-solution. 
 
This fractal dimension was essentially lower than the Euclidean dimension of two 
because the surface coverage of PRXMH was not complete. Remarkable was that the 
value appeared to be the same for all samples studied. 
 
Table 4.3: Fractal surface dimension of piroxicam (PRX) in different vehicles after plateau was 
reached. 
Media Fractal dimension (D)                                   
in plateau 
Milli-Q-Water 1.853 
1.854 
1.852 
Blank-buffer pH 6.5 1.841 
1.853 
1.854 
0.5 % SDS in water (w/w) 1.852 
1.852 
1.851 
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The ANOVA-analysis confirmed that there was no significant difference between the 
mean fractal dimensions of media at the 95 % confidence interval. 
 
4.4 Discussion 
The effect of excipients on the kinetics of hydrate formation of PRX was studied. A 
96-well assay was used to determine both solubility by UPLC and residual solid state 
changes in suspension by XRPD (SORESOS).
56
 Obtained results were compared to 
surface imaging analysis of API compacts using fractal geometry. These two 
approaches differ in their experimental set-up for the study of conversion kinetics: in 
SORESOS, the conversion kinetics of bulk phases is analyzed whereas in dynamic 
imaging experiments the focus is on the surface analysis of the compacts. The two 
approaches further differ in stirring conditions and hence in hydrodynamics. Together, 
both approaches were expected to gain complementary information and to give more 
insight into anhydrate-to-hydrate transformation of PRX. 
Solvent-mediated polymorphic and pseudopolymorphic transformation can be divided 
in several steps. The classical Cardew and Davey model assumes that an initial 
dissolution step of the anhydrate is typically followed by heterogeneous nucleation on 
for example grain boundaries or impurities followed by a growth phase of the 
nuclei.
109
 The authors pointed out that Poisson statistics may be applied for the 
probability of r nuclei per crystal in a monodisperse powder. Based on a random 
nucleation process and introduction of a growth step, the overall conversion kinetics 
was mathematically modeled.
109
 
For heterogenous nucleation, the classical nucleation theory
53
 can be considered in 
case of anhydrate-to-hydrate transformation:
78
 
𝐽1 = 𝐴
′𝑆 𝑒
−
𝐵′𝜈0
2𝛾3 
(𝑘𝑇)3𝑙𝑛2𝑆                                                                                                            Eq 4.3 
Where J1 holds for a primary nucleation rate, A’ is a kinetic factor that is proportional 
to the number of nucleation-active centers and takes much lower values for 
heterogeneous compared to homogenous nucleation.
124
 B’ is a factor of shape and 
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homogeneity, ν0 is the molecular volume of the crystalline phase, and γ is the 
interfacial energy per unit area of the crystal. Moreover, k holds for the Boltzmann 
constant, T is the temperature, and S is the drug supersaturation. There are different 
ways to formulate this classical nucleation rate equation and regarding heterogeneous 
nucleation, the contact angle of the crystallizing phase on the solid may be considered 
as part of B’. Heterogeneous nucleation occurs in general on so-called foreign 
particles like impurities but for anhydrate-to-hydrate transformations, it is primarily 
the surfaces of the anhydrate that exist in abundance.  
For hydrate formation in suspensions, it is possible that depending on the 
hydrodynamics, a secondary nucleation rate J2 becomes important.
78
 This rate is in 
theory depending on the density of the crystal suspension and on the agitation rate.
78
 
It is therefore theoretically expected that different kinetics can occur with the same 
excipient vehicle when different experimental setups are compared. Considering our 
experiments, stirred suspensions were studied as well the corresponding monolithic 
solid samples in liquid. Moreover, the solid concentration and hence the density of the 
crystal suspensions, differ between the experiments. The bulk analysis employed a 
solid concentration of about 5% (w/w), whereas for surface analysis the solid 
concentration was 0.4% (w/w). While the suspension was stirred, the surface analysis 
was carried out without a stirring device. These different hydrodynamic effects may 
explain for example the different transformation kinetics of the NaCMC system in 
both experimental setups (Figures 4.4b and 4.6c). 
To go beyond the level of general data interpretations with classical nucleation theory 
is often difficult because parameters like the kinetic prefactor in Equation 4.3 or 
interfacial energy of the nuclei are not well experimentally accessible. Moreover, 
there are various simplifications in the classical nucleation theory. These 
simplifications have been discussed in several textbook and reviews and the present 
work focuses on the neglected aspect of fractal geometry. Fini et al. were pioneers to 
use fractal geometry for studying hydrates of diclofenac sodium.
125, 126
 The current 
study followed a novel approach in the anhydrate-to-hydrate transition by monitoring 
the changes in fractal dimension of PRXMH clusters. The initial values were below 
unity indicating that nucleation started from preferred surface points. Such sites could 
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have been grain boundaries or edges to the sample holder as it was for example 
observed with the blank-buffer medium (Figure 4.8b). Regardless of this initial 
nucleation, the fractal dimension reached a final value of 1.85. This fractal dimension 
was hence lower than the Euclidean embedding two dimensional space. 
Macroscopically, the surface of the samples appeared to be covered with PRXMH 
after conversion, however there were still some pixels in the binary images that did 
not hold for the hydrate. This may either arise from a highly rugged surface due to 
deposition of PRXMH crystals, while leaving some pixels blank in the projection 
area. Alternatively, some crystal surface sites may indeed not have been converted to 
hydrates. It was remarkable that all samples finally reached a value of 1.85 (Table 
4.3). This dimension described a resulting PRXMH cluster structure which was likely 
dominated by the growth process. It is known from phenomena of diffusion-limited 
aggregation and growth that a fractal dimension of about 1.7 can result in two-
dimensional systems or around 1.7-1.8 in three dimensions.
127
 For a reaction-limited 
process in two dimensions, a much lower value of 1.53 was reported.
127
 The observed 
fractal dimension in the current study indicates that drug diffusion to the growing 
nuclei may have been the limiting step during the growth phase of the PRXMH 
clusters. It would be interesting to see whether other excipients/drugs also show in 
solvent-mediated phase transformations a fractal dimension close to the value 
reported for the reaction-limited process. The nature of the fractal dimension was 
hence of interest to better understand the mechanisms of hydrate crystallization. 
A central emphasis of this work was to study the influence of excipients on 
conversion kinetics to PRXMH. The excipients' concentration of 0.5% (w/w) was 
arbitrarily selected and holds for a comparatively high additive concentration 
regarding the dispersion of typical oral dosage forms in gastrointestinal fluids. 
Without excipients, unbuffered water displayed rather variable transformation rates, 
which can be due to differences in pH, impurities, or ionic strength. The presence of 
excipients generally reduced variability and greatly influenced the conversion 
kinetics. In HPMC- and P80-solutions, the formation of PRXMH was completely 
inhibited (Figures 4.4a and 4.6b/d). Antinucleant influences of HPMC on aqueous 
formulation of piroxicam as well as an inhibition of the pseudopolymorphic 
transformation were also shown by Pellett et al.
128
 in a former study. HPMC was also 
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found in another study to hinder the nucleation and the growth of carbamazepine 
hydrate.
16
 This is probably caused by HPMC adsorption onto the surface of particles. 
These findings are in good agreement with our results where HPMC inhibited the 
solid state transformation in both assays. Chen et al.
129
 found that P80 exhibited 
opposing effects depending on the concentration used. Below the CMC (<0.5 mg/ml), 
P80 reduced the surface tension, increased nucleation, and caused the transformation 
to a less soluble polymorphic form. Above the CMC the authors reported that P80 
hindered the polymorphic transformation and suggested increased viscosity and 
adsorption onto the surface of the particles as possible mechanisms. In the present 
study, P80 concentration was also above the CMC and the inhibitory effect on 
PRXMH formation observed in our experiments are in line with their results. 
In our studies, solid state transformation of PRXAH to PRXMH differed only slightly 
between SDS and water. In water, on average, the nucleation started 2 h earlier than in 
presence of SDS. Paaver et al.
22
 monitored the solid state transformation of PRX in 
aqueous slurries using Raman spectrosopy in combination with a partial least square 
(PLS) regression model. They also found that SDS delayed the onset of the solid state 
transformation of PRX and claimed that this is caused by an inhibition of nucleation.
22
 
In contrast, another study reported that SDS promoted the crystallization of 
carbamazepine dihydrate during dissolution due to a facilitation of surface-mediated 
nucleation.
85
 
The polymer NaCMC inhibited solid state transformation of PRX less than HPMC. A 
potential reason could be that NaCMC hinders nucleation less than HPMC. Polymers 
have a general tendency to adsorb onto particle surfaces.
70
 They can thus mask 
preferred sites on the solid surface for nucleation such as grain boundaries of 
PRXAH. Moreover, adsorbed polymer layer would change the interfacial boundary 
layer between the crystal and the solution. This can generally hinder diffusion 
processes that were previously discussed to be rate limiting for the solvent-mediated 
phase transformation.
70, 112
 In contrast to HPMC, NaCMC is negatively charged at pH 
6.5 and also over 98% of the PRX molecules are expected to be negatively charged at 
this pH.
130
 This may result in a repulsion between the two molecules, less polymer 
onto the solid surface, and hence less kinetic inhibition compared to HPMC. 
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In blank-buffer the solid state transformation was faster than in water and after 10 h 
compact surface was completely covered with hydrate crystals. Differences in ion 
composition and/or the pH of the medium could be potential reasons. Interestingly, 
FaSSIF medium that contained additionally sodium taurocholate and lecithin, showed 
a complete inhibition of the monohydrate transformation over 24 h. The biorelevant 
surface active components were evidently dominating the kinetics. Lehto et al.
17
 also 
found for the solvent-mediated conversation of carbamazepine anhydrate to dihydrate 
an inhibitory effect of FaSSIF on the amount of dihydrate formed. They tested FaSSIF 
in comparison to a simple buffer solution and found that hydrate formation of 
carbamazepine was slowed down caused by interaction between carbamazepine and 
sodium taurocholate. The authors explained their findings by a crystal growth 
inhibition of carbamazepine dihydrate. In addition, Lehto et al.
17
 also emphasized that 
high carbamazepine solubilization in the micelles of the medium may have 
contributed to the reduced conversion. Solubilization of PRX in micelles alone may 
not explain the observed inhibition of PRXMH conversion in our study. The solubility 
not only in FaSSIF, blank-buffer, and SDS was initially about ten times higher than in 
in water, however hydrate formation and concomitant decrease in solubility was only 
observed in blank-buffer and SDS but not in FaSSIF. 
The influence of excipients on the solid state transformation generally showed similar 
trends in both microscopic studies and the 96-well assay. This was remarkable 
considering the huge differences in hydrodynamics (unstirred vs. stirred) and the 
differences in the presentation of samples (compact vs. slurry). These differences 
affected the magnitude of individual excipient effects but general trends for an 
excipient ranking were similarly reflected by both experimental set-ups. The parallel 
assay had certainly has the advantage of a higher experimental throughput and drug 
solubility can be determined in the different media. Such solubility data enable 
calculation of apparent drug supersaturation as a function of time and thus allow 
direct monitoring of the driving forces of hydrate crystallization. 
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4.5 Conclusions 
In this study two different approaches were used to determine the solid state 
transformation of piroxicam. In the miniaturized assay, bulk suspensions were studied 
and in dynamic imaging the surface of compacts was analyzed. The latter combined 
with fractal analysis was of high interest from a mechanistic viewpoint. It was 
possible to monitor the fractal dimension of crystallized PRXMH in different media. 
A final value of 1.85 was found in all samples and was interpreted as an indicator of 
the cluster growth phase. Accordingly, drug diffusion to the clusters of PRXMH on 
the surface and cluster-cluster growth were assumed to dominate the kinetics of the 
solvent-mediated phase transformation. The fractal dimension appeared to be 
unaffected by the presence of excipients and it could be universal, which needs to be 
confirmed with other drugs. The parallel tests based on SORESOS provided similar 
excipient trends for the anhydrate-to-hydrate conversion of PRX. There were no 
general polymer or surfactant trends and each excipient appeared to have specific 
effects on the kinetics of PRXMH formation. All excipients increased the different 
aqueous concentrations of PRX compared to pure water but in case of SDS, NaCMC, 
and blank-buffer bulk concentrations then decreased due to the formation of PRXMH. 
Knowledge of excipient effects on solvent-mediated phase transformations are of 
critical importance in pharmaceutical development. It can be applied to liquid dosage 
forms such as for example suspensions that are often used in preclinical formulations 
for animal studies. Other applications are development processes that use aqueous 
solvents for manufacturing of solid dosage forms such as for example wet 
granulation. Finally, this knowledge can be of considerable relevance for formulated 
anhydrous drug if they rapidly convert to hydrates in the gastro-intestinal tract after 
oral administration and hence may have lower or more variable oral bioavailability. 
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Chapter 5 
The quest for exceptional drug solubilization in 
diluted surfactant solutions and consideration of 
residual solid state 
 
Summary 
Solubility screening in different surfactant solutions is an important part of 
pharmaceutical profiling. A particular interest is in low surfactant concentrations that 
mimic the dilution of an oral dosage form. Despite of intensive previous research on 
solubilization in micelles, there is only limited data available at low surfactant 
concentrations and generally missing is a physical state analysis of the residual solid. 
The present work therefore studied 13 model drugs in six different oral surfactant 
solutions (0.5%, w/w) by concomitant x-ray diffraction (XRPD) analysis to consider 
effects on solvent-mediated phase transformations. A particular aspect was potential 
occurrence of exceptionally high drug solubilization. As a result, general 
solubilization correlations were observed especially between surfactants that share 
chemical similarity. Exceptional solubility enhancement of several hundred-fold was 
evidenced in case of sodium dodecyl sulfate solutions with dipyridamole and 
progesterone. Furthermore, carbamazepine and testosterone showed surfactant-type 
dependent hydrate formation. The present results are of practical relevance for an 
optimization of surfactant screenings in preformulation and early development and 
provide a basis for mechanistic modeling of surfactant effects on solubilization and 
solid state modifications.  
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5.1 Introduction 
A central task of pharmaceutical profiling is to screen solubility of drug candidates in 
various solvents and excipient solutions that should include different surfactants. 
These surfactant solutions are typically used for preclinical formulations or they may 
serve as intermediate bulk solutions for preparation of a final dosage form that should 
enable oral delivery of poorly soluble compound.
6, 131
 While most of these colloidal 
test solutions contain several percent of surfactant, it is further of interest to extend 
the solubility screening to diluted surfactant solutions. Such rather low surfactant 
concentrations of about one percent and less are for example relevant with respect to 
concentrations in the gastro-intestinal (GI) tract. A recent review article discussed the 
various effects of surfactants in oral formulations from a biopharmaceutical 
perspective.
132
 Key is here to which extent surfactants can solubilize drugs at rather 
low surfactant concentration. Although the science of drug solubilization in micelles 
has a long tradition,
133, 134
 it is currently not possible to reliably predict solubilization 
of new compounds. There are trends known for given surfactant types, for example 
that an increase of polysorbate alkyl chain from C12 to C18 provided increasing 
solubilization capacity for barbiturates.
135
 Similar effects of varying hydrophobic 
chain length were also observed with another surfactant series of polyoxyethylene 
stearates.
136
 As for the solubilized compound, there were further trends observed for 
example that the partition coefficient of steroid hormones into polyoxyethylene lauryl 
ether micelles was correlated with the partition coefficient between an aqueous 
solution and octanol (logP).
137
 There are certainly more studies in the literature that 
report solubilization trends of a specific drugs with a specific classes of surfactants, 
which leaves the practical question unanswered if such findings can be generalized. 
It has also been tried to quantitatively predict surfactant solubilization based on 
measured predictors such as the surface pressure at the critical micelle concentration 
(CMC) and a reference value of surface tension reduction.
138
 However, this 
interesting approach is still limited by a focus on aromatic hydrocarbons and there are 
experimental input data required. More recently there have been thermodynamic 
modeling approaches reported in the literature, which appears to be very 
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promising,
139, 140
 but there is still a long way to go before such in silico methods are 
implemented in the practice of drug profiling. 
A first step towards any future theoretical approach is to have sufficient experimental 
data for model validation. However, reliable and comparable solubilization data of 
drugs are hard to obtain at low surfactant concentrations. It is further desirable to 
check the residual solid in solubility experiments 
56
 to account for potential solid 
phase changes. In general, data of solid state analysis are not available in 
solubilization studies of surfactants systems. However, this can be a relevant 
experimental point since a recent study demonstrated that kinetics of a 
pseudopolymorphic transition (i.e. hydrate formation of piroxicam) was influenced by 
the presence of 0.5% (w/w) sodium dodecyl sulfate (SDS) or polysorbate 80 (P80), 
respectively.
141
  
The outlined need for solubilization data of diluted surfactant solutions in conjunction 
with characterization of the residual solid state provided the aim of the current 
research. A particular objective was to find correlations between different surfactants 
used and to look for outliers with exceptional drug solubilization. Finally, some 
guidance for pharmaceutical profiling should be given based on the obtained findings. 
 
5.2 Materials and Methods 
5.2.1 Materials  
In total, 13 compounds were chosen as model compounds for studying the solubility 
and solid state changes in surfactant solutions at low concentrations. Acetylsalicylic 
acid (ASP), carbamazepine (CBZ), diflunisal (DFL), dipyridamole (DPL), estradiol 
(ESL), flurbiprofen (FLU), haloperidol (HPL), naproxen (NPX), pindolol (PDL), 
progesterone (PGN), dioctyl sulfosuccinate (DOSS) and cremophor EL (CEL, 
synonymous name is Kolliphor EL) were obtained from Sigma Aldrich (St. Louis, 
USA). Furosemide (FRS) was purchased from Molekula GmbH (München, 
Germany), while ibuprofen (IBU) was from Satwik Drugs Ltd. (Bidar, India). 
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Testosterone (TES) was from TCI Europe N.V. (Zwijndrecht, Belgium), hydrochloric 
acid (0.1 M), and sodium hydroxide solution (0.1 M) were supplied by Merck KGaA 
(Darmstadt, Germany). Polysorbate 80 (P80) was from Croda Europe Ltd. (Cowick, 
United Kingdom), while sodium dodecyl sulfate (SDS) was from Stepan Company 
(Northfield, USA), solutol (SOLU, synonymous name is Kolliphor HS 15) was from 
BASF SE (Ludwigshafen, Germany) and sucrose monolaurate (SUCM) was obtained 
from Selectchemie AG (Zürich, Switzerland). 
 
5.2.2 Sample preparation 
Surfactant solutions were prepared by dissolving P80, solutol, cremophor EL, sucrose 
monolaurate, SDS, and DOSS (0.5% (w/w)) in deionized water and adjusting the pH 
of the solutions to pH 6.0 with hydrochloric acid or sodium hydroxide solution at 
25°C. All solutions were visually inspected for absence of residual particles. 
 
5.2.3 Solubility and residual solid analysis 
Solubility of compounds in surfactant solutions was determined using a slightly 
modified 96-well SORESOS assay, which measures both equilibrium solubility and 
solid form of the residual solid.
56
 In brief, APIs were dispensed using the powder-
picking-method by Alsenz 
103
 in 96-well flat bottom plates (Corning Inc., Durham, 
USA), stirring bars and excipient vehicles (150 µL) were added. The plate was sealed 
with pre-slit silicon caps and the mixtures were agitated by head-over-head rotation 
for 24 h at room temperature. After equilibration, the suspensions were carefully 
transferred into 96-well filter plates and liquid was separated from residual solid by 
centrifugation. Collected filtrates were diluted with N-methyl-2-pyrrolidone and drug 
content was determined using a Waters Acquity Ultra Performance Liquid 
Chromatographic (UPLC) system equipped with a 2996 Photodiode Array Detector 
and an Acquity UPLC BEH C18 column (2.1x50 mm, 1.7 μm particle size) from 
Waters (Milford, USA). Table 5.1 summarizes the experimental conditions (solvents, 
composition of mobile phase, detection wave length) used for the drugs. An isocratic 
The quest for exceptional drug solubilization in diluted surfactant solutions and consideration of residual solid 
state 72 
  
 
 
flow of a mixture of solvent A and solvent B was applied for 0.3 min at a flow rate of 
0.75 ml/min. Subsequently, the concentration of solvent B was linearly increased to 
100% within 0.5 min. Solid state analysis of residual solid was performed by X-ray 
powder diffraction (XRPD) as described before.
56, 90
 Samples were analyzed directly 
in the 96-well filter plate with an exposure time of 5 min per well. 
 
Table 5.1: Experimental conditions used for UPLC analysis. 
Compound Composition (A:B)
a 
[%] 
Detection wavelength [nm] 
Acetylsalicylic acid (ASP) 80:20 276 
Carbamazepine (CBZ) 70:30 285 
Diflunisal (DFL) 50:50 314 
Dipyridamole (DPL) 81:20 284 
Estradiol (ESL) 60:40 280 
Flurbiprofen (FLU) 50:50 255 
Furosemide (FRS) 75:25 274 
Haloperidol (HPL) 70:30 244 
Ibuprofen (IBU) 50:50 232 
Naproxen (NPX) 55:45 272 
Pindolol (PDL) 90:10 264 
Progesterone (PGN) 40:60 243 
Testosterone (TES) 60:40 244 
a
Mobile phase A: deionized water with 0.1% (v/v) triethylamine adjusted to pH 2.2 with 
methanesulfonic acid, mobile phase B: acetonitrile. 
 
5.2.4 Correlation and regression analysis 
The program STATGRAPHICS Centurion XVI ed. Professional (V. 16.1.15) from 
Statpoint Technologies Inc. (Warrenton, USA) was used for statistical correlation as 
well as regression analysis. 
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5.3 Results and discussion 
5.3.1 Drug solubilization screening at low surfactant concentration and 
analysis of residual solid 
In preformulation, solubility screening in surfactant solutions typically includes 
several percent of surfactant in order to use it directly as a potential vehicle in 
preclinical formulation or as an intermediate drug product solution. In this work, a 
concentration of 0.5% (w/w) surfactant at pH 6.0 was used which may represent the 
surfactant concentration of a dissolved orally administered dosage form in the GI 
tract. A constant mass concentration was selected as it represents a diluted 
formulation. However, this practical approach comes with slightly varying molar 
concentrations. The chosen mass concentration was generally higher than the critical 
micelle concentrations (CMC) of the different surfactants that were reported in the 
literature.
142-147
 The extent of drug solubilization will certainly depend on their 
physicochemical properties (Table 5.2) as well as on physicochemical properties of 
the surfactants (Table 5.3). The 13 compounds comprised acids, bases as well as 
neutral compounds at the given reference pH. 
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Table 5.2: Molecular weight (Mw), ionization constant (pKa) and distribution coefficient (logD) at pH 
6.0 for the different model compounds. 
Compound Mw [g/mol] pKa
a 
LogD
b
 (pH 6.0) 
ASP 180.2 3.7 (a)* -1.3 
CBZ 236.3 - 2.8 
DFL 250.2 2.7 (a)* 0.8 
DPL 504.6 6.2 (b) 1.8 
ESL 272.4 - 3.7 
FLU 244.3 4.2 (a)* 2.4 
FRS 330.7 3.5 (a) 0.0 
HPL 375.9 8.4 (b)* 1.6 
IBU 206.3 4.4 (a)* 2.7 
NPX 230.3 4.4 (a)* 1.2 
PDL 248.3 9.2 (b)* -1.4 
PGN 314.5 - 4.1 
TES 288.4 - 3.4 
a
Measured pKa-values via photometric titration. 
b
Values calculated by the Marvin program suite (V. 16.5.30) (ChemAxon Ltd., Cambridge, USA). 
*Calculates pKa-values by the MoKa-software (V. 2.6.6) (Molecular Discovery, Hertfortshire, UK). 
 
Table 5.3: Molecular weight (Mw), hydrophilic-lipophilic balance (HLB), and critical micelle 
concentration (CMC) of surfactants. 
Compound Mw* [g/mol] HLB CMC [mM] 
Polysorbate 80
145, 148
 1310 15 0.01 
Solutol
142
 345 14-16 0.37 
Cremophor EL
143
 2500* 12-14 0.20 
Sucrose monolaurate
144
 525 13
+
 0.34 
SDS
146, 149
 288 40 7.80 
DOSS
147, 150
 445 11 2.92 
*mean molecular weight of pegylated surfactants based on description of excipients’ composition. 
+
Calculated with Molecular Modeling Pro, V.6.2.6 (Norgwyn Montgomery Software Inc., North 
Wales, USA). 
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The lipophilicity as expressed by the calculated distribution coefficient (logD at pH 
6.0) exhibited a broad range of values from -1.4 (PDL) to 4.1 (PGN). More lipophilic 
compounds are more likely to partition into micellar cores, whereas hydrophilic 
compounds are either predominantly in the bulk phase or interact with the hydrophilic 
head groups (Figure 5.1). It was shown in a study of electron resonance spectroscopy 
that not only lipophilicity was decisive for drug location in micelles but also acid/base 
properties play a role.
151
 The study concluded that the tested positively charged β-
blockers were primarily located on the surface of SDS and bile salt micelles whereas 
neutral lipophilic benzodiazepines were in the deeper interior of the micelles. Such a 
location in the core of micelles can be further differentiated from drugs that are rather 
accommodated in the palisade region of micelles (Figure 5.1). Amphiphilic 
compounds appear to prefer this location and a recent study with amlodipine 
hydrochloride and a nonionic surfactant evidenced formation of mixed micelles.
152
 
 
 
Figure 5.1: Different possible locations and mechanisms of drug solubilization in presence of 
surfactant micelles (example of sodium dodecyl sulfate). One or several mechanisms are likely to 
dominate depending on the physical compound properties. 
 
Table 5.4 lists the solubility data for the various compounds and surfactants whereas 
the solubility enhancement factors are shown in Table 5.5. The comparatively 
hydrophilic compounds ASP and PDL did not show a pronounced solubilization in 
the micellar systems, except for a slight enhancement with the charged surfactants 
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SDS and DOSS. As expected, the more lipophilic steroid drugs showed a clear 
solubilization in ionic surfactants compared to pure water. SDS increased the 
solubility of PGN and of DPL almost 200- and 400-times, respectively, compared to 
water. These results are exceptionally high compared to the other solubilization 
results. These highest values have in common with other rather high SE results that 
aqueous drug solubility was in these cases comparatively low. The magnitude of 
achieved solubilization in such individual cases suggests that it is worthwhile in 
preformulation to screen for the best drug solubilizer by comparing various surfactant 
types. 
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Figure 5.2: Solubility of carbamazepine, haloperidol, naproxen, and testosterone in 0.5% (w/w) 
surfactant solutions at room temperature after 24 h incubation time. 
 
Figure 5.2 depicts a typical comparison of the different surfactants for selected drugs. 
The solubilization by SDS was here very pronounced compared to DOSS or the other 
non-ionic surfactants. Similar solubilization pattern was found for the majority of 
tested compounds despite of their logD values and charges. However, care is needed 
with any generalization for non-ionic surfactant because even though NPX showed 
also best solubilization in SDS as well, a previous work showed also excellent 
solubilization in non-ionic surfactants of the type Brij.
154
 The comparative 
solubilization pattern among surfactants was also found to vary, as in the case of DFL 
and FLU. Even though these acidic drugs differ in their logD values, a similar pattern 
of preferred solubilization in pegylated non-ionic surfactants was evidenced for these 
fluorinated aryl acetic acid derivatives (Figure 5.3). 
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Figure 5.3: Solubility of diflunisal and flurbiprofen in 0.5% (w/w) surfactant solutions at room 
temperature after 24 h incubation time. 
 
In contrast to most other studies, micellar solubilization at low surfactant 
concentration was conducted in parallel to the characterization of the residual solid 
state. Solvent-mediated phase changes were only observed for CBZ and TES (Table 
5.6), although also for FLU and DFL hydrate formation is reported in the literature.
155, 
156
 Only sucrose monolaurate promoted hydrate formation of CBZ, in all other 
surfactants and in pure water, the anhydrate remained unchanged. In case of TES, 
hydrates were formed in water, ionic surfactants and non-pegylated non-ionic 
surfactants. 
 
Table 5.6: Solid state change of CBZ and TES in residual solids after incubation for 24 h in 0.5% 
(w/w) surfactant solutions at room temperature. 
  Solid state characterized by XRPD analysis 
Compound Polysorbate 
80 
Solutol Cremophor 
EL 
Sucrose 
monolaurate 
SDS DOSS Water 
CBZ AH AH AH H AH AH AH 
TES AH AH AH H H H H 
Other 
compounds* 
AH AH AH AH AH AH AH 
*for an overview of the other tested compounds, see Table 5.1; AH: anhydrous form of compound, H: 
hydrated form of compound 
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Adsorption of a specific surfactant onto particle surfaces plays an important role in a 
potential stabilization of anhydrates. Such surfactant effects have recently been 
studied with piroxicam
90
 where imaging showed that the kinetic hydrate 
transformation was suppressed by 0.5% (w/w) of polysorbate 80. This is in line with 
the present findings of pegylated surfactants. It can be argued that solubility values 
with anhydrate as residual solid are not representing true thermodynamic solubility 
but rather a metastable equilibrium for those compounds where hydrate formation is 
known. However, from a practical perspective, a pseudo-equilibrium for a certain 
time might be of interest since formulations are often prepared immediately before 
administration and not stored for a longer time. For the calculation of SE factors 
(Table 5.5), solubility values after 24 h incubation time were used without adjusting 
solubility values from pseudo-equilibria. Although, this calculation is for hydrate-
forming compounds not in line with the thermodynamic understanding of SE, it is a 
practically oriented approach, which is biopharmaceutically meaningful and can be 
applied for solubility screening. However, present findings underline that proper solid 
state characterization is an absolute requirement at the end of solubility experiments. 
 
5.3.2 Correlation and regression analysis of solubility enhancement 
Similar patterns of drug solubilization among surfactants can be further studied by a 
correlation analysis. We used for this purpose the logarithmic SE, i.e. the surfactant-
mediated solubilization divided by the solubility in pure water (Table 5.5). This 
normalization is helpful for a comparison among compounds with greatly varying 
aqueous solubilities. Figure 5.4 shows the results of a Pearson product moment 
correlation, which is a measure of the linear correlation between the log(SE) values in 
two surfactants. The correlation coefficients as well as p-values are listed in Table 5.7. 
All correlations between surfactants reached the level of statistical significance but 
the quality of the correlation differed considerably. Some values were deviating from 
linearity as the overview of Figure 5.4 displays. 
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Figure 5.4: Box-and scatter plots of the different solubility enhancements (SE) in 0.5% (w/w) 
surfactant solutions over water. Surfactants are polysorbate 80 (P80), solutol HS (SOL), cremophor EL 
(CEL), sucrose monolaurate (SUCM), sodium dodecyl sulfate (SDS), and dioctyl sulfosuccinate 
(DOSS). Box plots from the lower to upper quartiles are shown for log(SE) of each surfactant with the 
median lines (and cross for the means). Correlation between any log(SE) values for a pair of surfactants 
is displayed by individual scatter plots. 
 
Exceptional solubility enhancement was shown for the different steroid compounds as 
well as for FLU and DPL (Table 5.5). Such high values were expected for the 
compounds with rather high logD value and in case of DPL is notable, that its pKa 
value is close to the pH 6.0 of the solutions. It can be expected that slight 
perturbations would affect partitioning into the micelles. A quantitative measure for 
such partitioning can be inferred from log(SE) values as it has been reported 
previously in the literature.
157
 It was hence of interest to compare log(SE) with the 
distribution coefficient logD. As a result, these correlations were limited for the 
different surfactants and notable was mainly SDS that reached r of 0.638 (p=0.014). It 
was expected that a single molecular property would not provide high correlation due 
to the complex physicochemistry of partitioning.
158
 We therefore focussed primarily 
on correlations between different surfactants rather than attampting further predicitons 
based on molecular drug properties. 
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Table 5.7: Correlation coefficients for the different 0.5% (w/w) surfactant solutions. 
 Log(SE) P80 Log(SE) 
SOLU 
Log(SE) 
CEL 
Log(SE) 
SUCM 
Log(SE) 
SDS 
Log(SE) 
DOSS 
Log(SE) P80  0.9912  
(p= 0.0000) 
0.9903  
(p= 0.0000) 
0.8414  
(p= 0.0002) 
0.6341  
(p= 0.0149) 
0.7525  
(p= 0.0019) 
Log(SE) SOLU   0.9972  
(p= 0.0000) 
0.8682  
(p= 0.0001) 
0.6646  
(p= 0.0095) 
0.7368  
(p= 0.0026) 
Log(SE) CEL    0.8660  
(p= 0.0001) 
0.6599  
(p= 0.0102) 
0.7174  
(p= 0.0039) 
Log(SE) SUCM     0.9108  
(p= 0.0000) 
0.8422  
(p= 0.0002) 
Log(SE) SDS      0.8373  
(p=0.0002) 
Log(SE) DOSS       
 
 
Correlations were very high among pegylated surfactants, which form a good basis 
for regression. The surfactant solutol and cremophor EL are very similar since 
ricinoleic acid and hydroxystearic acid provide similar lipophilic surfactant tails. 
Figure 5.5a shows the regression line with R
2
 of 0.994.  
SOLU Log(SE)*0.989297 + 0.0251297 = CEL Log(SE)                                      Eq. 
5.1 
Equation 5.1 describes a relationship that is close to the identity line. Fairly good 
model can also be formulated for the other relationships among pegylated surfactants 
as suggested by the r-values.  
An example is shown by Figure 5.5b where solubility enhancement in cremophor EL 
correlates well with the values obtained in polysorbate 80 solutions (R
2
 = 0.981): 
P80 Log(SE)*0.966479 + 0.0117639- = CEL Log(SE)                                       Eq. 5.2 
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Figure 5.5: Regression analysis of solubility enhancement (SE) in 0.5% surfactant solutions over water 
in case of (a) cremophor EL versus log(SE) of solutol and (b) cremophor EL versus log(SE) of 
polysorbate 80. 
The high correlations and adequate regression models allow predicting drug 
solubilization in one pegylated surfactant solution from another based on the results of 
our study. Thus, it seems to be justified to experimentally determine only one or two 
pegylated surfactant(s) to save resources in preformulation screening. Later in 
pharmaceutical development, the initially predicted values can be experimentally 
grounded when there is a special interest is for a given surfactant. Such an interest 
may, for example, origin from preformulation of lipid-based formulation if a 
particular surfactant is attractive because of its phase behavior.
159
 Moreover, 
solubilization may in vivo differ due to the presence of bile salts and phospholipids as 
well as by potential enzymatic hydrolysis of a given surfactant.
160
 There are also 
additional technical aspects that may lead to final excipient selection so that SE values 
provide only one aspect albeit their biopharmaceutical importance for poorly soluble 
compounds.
73
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The correlation analysis (Figure 5.4 and Table 5.7) indicates poorer correlations 
between sucrose monolaurate and anionic surfactants. A potential reason could be the 
comparatively short tail and sucrose head group which make sucrose monolaurate 
rather unique in the present study of surfactants. Interestingly, although SDS and 
DOSS share the negatively charged head group, their correlation is rather limited 
regarding log(SE) values. A potential reason could be the branched hydrophobic tail 
group of DOSS which may in many cases be less effective in drug solubilization 
compared to SDS. Therefore, a predictive regression model for DOSS and SDS was 
not possible. The current lack of a predictive model for the log(SE) may suggest that 
both anionic surfactants should be part of an early screening of surfactant 
solubilization. This inclusion of DOSS is also meaningful because apart from 
solubilization there is further surfactant performance in drug wettability and 
dispersion stabilization. 
The current dataset shows that remarkable solubility enhancement can be achieved 
even at rather low surfactant concentrations, which may mimic a realistic range upon 
dilution of an oral dosage form. 
 
5.4 Conclusions 
A surfactant screening has to consider different excipient properties like, for example, 
tolerability, pharmaceutical quality, and especially its technical and biopharmaceutical 
performance. For the latter excipient performance, drug solubilization is of crucial 
importance. We therefore studied drug solubility enhancement at low surfactant 
concentrations that provide a model for diluted oral dosage forms. A broad screening 
of drug solubilization was conducted by consideration of optional solvent-mediated 
phase transformations. Findings suggest that especially charged surfactants like SDS 
may bear promise to achieve a solubility increase of several hundred-fold compared to 
water. High solubilization correlations were identified among pegylated surfactants of 
similar type. These correlations may be used to omit individual surfactants for a 
resource-saving solubilization testing in preformulation. Our results further stress the 
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importance of solid state characterization of residual drug since surfactants may affect 
solvent-mediated phase transformations. Current findings may serve as basis to guide 
a surfactant screening in preformulation and data may in the future become part of a 
bigger database. Solubility values are also needed to estimate drug supersaturation 
upon aqueous formulation dispersion. The values will find additional use for in silico 
models of drug solubilization as well as more complex physiologically-based 
pharmacokinetic modeling. 
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Chapter 6 
A systematic study of molecular interactions of 
anionic drugs with a dimethylaminoethyl 
methacrylate copolymer regarding solubility 
enhancement 
 
Summary 
The methacrylate-copolymer Eudragit EPO (EPO) has raised interest in solubility 
enhancement of anionic drugs. Effects on aqueous drug solubility at rather low 
polymer concentrations are barely known despite of their importance upon dissolution 
and dilution of oral dosage forms. We provide evidence for substantial enhancement 
(factor 4-230) of aqueous solubility of poorly water-soluble anionic drugs induced by 
low (0.1-5% (w/w)) concentration of EPO for a panel of seven acidic crystalline 
drugs. Diffusion data (determined by 
1
H nuclear magnetic resonance spectroscopy) 
indicate that the solubility increasing effect monitored by quantitative ultra-pressure 
liquid chromatography was caused primarily by molecular API polymer interactions 
in the bulk liquid phase. Residual solid API remained unaltered as tested by X-ray 
powder diffraction. The solubility enhancement (SE) revealed a significant rank 
correlation (rSpearman= -0.83) with rDiffAPI, where SE and rDiffAPI are defined ratios of 
solubility and diffusion coefficient in the presence and absence of EPO. SE decreased 
in the order of indomethacin, mefenamic acid, warfarin, piroxicam, furosemide, 
bezafibrate, and tolbutamide. The solubilizing effect was attributed to both ionic and 
hydrophobic interactions between drugs and EPO. The excellent solubilizing 
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properties of EPO are highly promising for pharmaceutical development and the 
dataset provides first steps towards an understanding of drug-excipient interaction 
mechanisms. 
 
6.1 Introduction 
An increasing number of new active pharmaceutical compounds (APIs) exhibit low 
water solubility which may lead to poor oral bioavailability.
1
 Various approaches 
have been reported to increase drug solubility for these candidates. Formulations were 
designed to promote intestinal solubility like micro- and nanosuspensions,
161
 
cyclodextrin complexes,
162-164
 and lipid-based formulations.
165, 166
 Formulations can 
also target primarily a transient increase of bulk concentrations by drug 
supersaturation, which thereby enhances absorptive flux. Supersaturated states can be 
obtained in vivo by pH change when the dissolved compound is transported from the 
acid stomach into the small intestine or by a loss of solubilization capacity of a 
formulation as upon dilution, dispersion or digestion in the gastrointestinal tract.
167
 
Supersaturation is only beneficial if drug crystallization is slower than drug 
absorption.
70
 The most common supersaturating formulations are amorphous solid 
dispersions that are used to enhance the bioavailability of compounds belonging to 
biopharmaceutical classification system (BCS) class II or IV.
167, 168
  
This work focusses on the copolymer EPO that belongs to the family of methacrylic 
acid copolymers. EPO is composed of dimethylaminoethyl methacrylate, butyl 
methacrylate, and methyl methacrylate at molar ratios of 2:1:1 and is positively 
charged at pH< 8 in aqueous media. Figure 6.1 displays the molecular structure of this 
copolymer. EPO has been widely used as pharmaceutical excipient for taste masking, 
moisture protection, enteric film-coating, and sustained release drug delivery.
169
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Figure 6.1: Simplified monomer structure of EPO (details are given in the text). 
 
EPO was more recently used to prepare solid dispersions, especially with anionic 
drugs
170-172
, and outstanding results were obtained in terms of solubility and 
bioavailability enhancement.
170
 Priemel et al. also reported in situ amorphization with 
EPO and indomethacin
173
 and recently in situ amorphization with naproxen and 
ibuprofen was evidenced.
174
 
Different studies attempted to gain insights into the molecular interactions of the 
copolymer EPO with anionic drugs. Kojima et al. and Higashi et al. used for example 
nuclear magnetic resonance (NMR) spectroscopy to better understand the molecular 
basis of solubility enhancement (SE) of solid dispersions and of supersaturated 
solutions using EPO and mefenamic acid.
170, 171
 These important pioneer studies 
showed that EPO acts not only as a carrier in solid dispersions but also affects drug 
solubilization and supersaturation of acidic drugs. Formulations with EPO therefore 
seem to become a research field in its own right. However so far, only few 
compounds, exclusively in amorphous state, were studied. Moreover, data for rather 
low polymer concentrations are rare, for example concentrations that would result 
from dilution of oral dosage forms in the gastrointestinal tract. Another aspect is that 
combinations of EPO and acidic drugs were primarily studied in the context of solid 
dispersions.
170
 The molecular interactions of the polymer and acidic drugs seem to be 
also promising for other formulation types but such data are currently lacking.  
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We therefore studied the influence of EPO in solution on the solubility and solid state 
of seven poorly water-soluble, acidic, chemically diverse drugs. Our final aim was to 
better mechanistically understand how the molecular interactions of acidic drugs and 
EPO would result in specific SE. 
 
6.2 Materials and Methods 
6.2.1 Materials  
Indomethacin (IMC), mefenamic acid (MFA), tolbutamide (TLB) and warfarin 
(WFN) were obtained from Sigma Aldrich (St. Louis, USA), while bezafibrate (BZF) 
and piroxicam (PRX) were from TCI Europe N.V. (Zwijndrecht, Belgium). 
Furosemide (FRS) was purchased from Molekula GmbH (München, Germany) and 
amino alkyl metacrylate copolymer E, Eudragit EPO, (EPO) was obtained from 
Evonik (Darmstadt, Germany). Chemical structures of all model compounds are 
shown in Figure 6.2. Hydrochloric acid (0.1 M) and sodium hydroxide solution (0.1 
M) were supplied by Merck KGaA (Darmstadt, Germany). 
 
Figure 6.2: Chemical structure of model drugs. 
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Table 6.1: List of model drugs and selected physicochemical properties. 
Compound Mw [g/mol] pKa
a 
LogD
b
 (pH 6.0) 
Bezafibrate (BZF) 361.8 3.2 1.8 
Furosemide (FRS) 330.7 3.5 0.0 
Indomethacin (IMC) 357.8 4.5 1.4 
Mefenamic acid (MFA) 241.3 4.2 3.3 
Piroxicam (PRX) 331.4 2.3 -0.4 
Tolbutamide (TLB) 270.4 5.1 1.4 
Warfarin (WFN) 308.3 5.0 2.2 
a
Measured pKa-values via photometric titration. 
b
Values calculated by the Marvin program suite (V. 16.5.30) (ChemAxon Ltd., USA). 
 
6.2.2 Sample preparation 
Polymer solutions were prepared by dissolving EPO (0.1%, 0.5%, 1%, 2%, 3%, 4%, 
5% (w/w)) in deionized water and adjusting the pH of the solutions to pH 6.0 with 
hydrochloric acid or sodium hydroxide at 25°C. All solutions were visually inspected 
for absence of residual particles. 
 
6.2.3 Viscosity measurements 
Apparent viscosity was measured with a cone-plate-rheometer (Physica MCR 301, 
Anton Paar GmbH, Graz, Austria) by applying a shear rate of 1000 min
-1
 for 2 min. 
 
6.2.4 Solubility and residual solid analysis 
Solubility of compounds in EPO-solutions was determined using a slightly modified 
96-well SORESOS
56
 assay, which measures both equilibrium solubility and solid 
form of the residual solid. In brief, APIs were dispensed using the powder-picking-
method
103
 in 96-well flat bottom plates (Corning Inc., Durham, USA) and stirring bars 
and excipient vehicles (150 µL) were added. The plate was then sealed with pre-slit 
silicon caps and the mixtures were agitated by head-over-head rotation for 24 h, 48 h 
and one week at room temperature. After equilibration, the suspensions were carefully 
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transferred into 96-well filter plates and liquid was separated from residual solid by 
centrifugation. Collected filtrates were diluted with N-methyl-2-pyrrolidone and drug 
content was determined using a Waters Acquity Ultra Performance Liquid 
Chromatographic (UPLC) system equipped with a 2996 Photodiode Array Detector 
and an Acquity UPLC BEH C18 column (2.1x50 mm, 1.7 μm particle size) from 
Waters (Milford, USA). Table 6.2 summarizes the experimental conditions (solvents, 
composition of mobile phase, detection wave length) used for the drugs. An isocratic 
flow of a mixture of solvent A and solvent B was applied for 0.3 min at a flow rate of 
0.75 ml/min. Subsequently, the concentration of solvent B was linearly increased to 
100% within 0.5 min. Solid state analysis of residual solid was performed by X-ray 
powder diffraction (XRPD) using a STOE Stadi P Combi diffractometer with a 
primary Ge-monochromator (Cu Kα radiation), imaging plate position sensitive 
detector (IP-PSD), and a 96-well sample stage. The IP-PSD allowed simultaneous 
recording of the diffraction pattern on both sides of the primary beam which were 
summed up by the software STOE WinXPOW to reduce effects related to poor crystal 
orientation statistics. Samples were analyzed directly in the 96-well filter plate with 
an exposure time of 5 min per well. 
 
Table 6.2: Experimental conditions used for UPLC analysis. 
Compound Composition 
(A:B)
a 
[%] 
Detection 
wavelength [nm] 
BZF 50:50 254 
FRS 75:25 274 
IMC 50:50 318 
MFA 40:60 352 
PRX 65:35 342 
TLB 60:40 265 
WFN 50:50 283 
a
Mobile phase A: deionized water with 0.1% (v/v) triethylamine adjusted to pH 2.2 with 
methanesulfonic acid, mobile phase B: acetonitrile. 
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6.2.5
 1
H NMR spectroscopy 
Solutions for NMR analyses were prepared by incubating APIs for 24 h in a 0.5% 
(w/w) EPO-solution in deuterium oxide (D2O) at pH 6.0. Samples were then 
centrifuged and supernatants (550 µl) were transferred to short disposable 5 mm 
NMR tubes. 
All NMR measurements were performed with a Bruker 600 MHz Avance II 
spectrometer equipped with a cryogenic QCI probe head at a temperature of 300 K. 
Spectrometer operation and data processing was done by Topsin 2.1 software (Bruker, 
Fällanden, Switzerland). For all samples matching/tuning of the probe head and the 
90° pulse were determined fully automated. Pseudo 2D 
1
H diffusion ordered 
spectroscopy with bipolar gradient pulse pairs and 2 spoil gradients
175
 was measured 
for all samples with presaturation of residual water. Data points (32k) were acquired 
over 18 ppm sweep-width. The interscan delay was set to 1.5 s and the SMSQ10.100 
shaped bipolar gradient was ramped from 2.65 to 50.35 gauss/cm in 16 equidistant 
steps. A diffusion time of 300 ms was used. Spectra were processed with a lb = 1 
exponential filtering.  
Diffusion coefficient D was fitted by use of the T1/T2 relaxation module implemented 
within the Topsin 2.1 (Bruker, Switzerland). For most molecules at least one API and 
excipient related NMR signal was identified by visual inspection. 
 
6.2.6 Statistical analysis and molecular modeling 
The program STATGRAPHICS Centurion XVI ed. Professional (V. 16.1.15) from 
Statpoint Technologies Inc. (Warrenton, USA) was used for statistical rank 
correlation (Spearman) testing. 
For graphical representation of the mefenamic acid interaction with EPO, both ionized 
molecules were assigned to an AMBER force field using the software Chemsite 
(V. 10.4., Norgwyn Montgomery Software Inc., Northwales, USA). The starting 
configuration was based on docking the anionic model drug to positively charged 
nitrogen of the polymer that was modeled as residue of 10 monomers. Following 
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energy minimization, the molecular dynamics simulation was running for 10 ns while 
using an implicit Born solvation model (with a relative permittivity of 78.4) at a 
temperature of 300 K. 
 
6.3 Results 
6.3.1 Viscosity 
The apparent viscosity was measured under shear (Table 6.3) for all solutions of EPO. 
A slight increase in viscosity with polymer concentration was observed, however all 
solutions had a rather low viscosity. These EPO-solutions were used to determine 
drug solubility after 24 h and 48 h. Most drugs reached equilibrium solubility within 
24 h, some compounds (MFA, FRS, TLB) showed differences between the selected 
time points especially at higher polymer concentration. For those compounds 
solubility was additionally determined after one week to prove that equilibrium was 
reached. Finally, 48 h was selected as incubation time for all solubility experiments 
(shown in Table 6.4 and Figures 6.3 and 6.4) because all systems have reached 
equilibrium after this time. 
 
Table 6.3: Apparent viscosity of EPO-solutions (25°C, 1000s
-1
). 
Concentration of 
EPO [%, (w/w)] 
Viscosity [mPas]  
(standard deviation, n=3) 
0.1 1.1 (0.01) 
0.5 1.1 (0.01) 
1.0 1.2 (0.01) 
2.0 1.5 (0.02) 
3.0 1.9 (0.05) 
4.0 2.1 (0.01) 
5.0 2.3 (0.00) 
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6.3.2 Solubility and residual solid analysis 
All test solutions were adjusted to pH 6.0 and following equilibration, the residual 
solid was analyzed by means of XRPD. Compared to water, all model compounds 
displayed an enormous SE in the different EPO-solutions (Figures 6.3-6.4 and Table 
6.4) with SE factors of approximately 4-230 fold. 
 
Table 6.4: Drug solubility and pH in water after incubation for 48 h. 
Compound 
Solubility in water 
(standard deviation, n=3) 
[mg/ml] 
pH in water (standard 
deviation, n=3) 
BZF 0.016 (0.003) 4.6 (0.1) 
FRS 0.024 (0.007) 4.4 (0.0) 
IMC 0.007 (0.003) 5.0 (0.2) 
MFA* < 0.001 6.1 (0.1) 
PRX 0.008 (0.001) 5.4 (0.1) 
TLB 0.083 (0.007) 5.0 (0.1) 
WFN 0.005 (0.001) 5.4 (0.2) 
*Aqueous solubility was below the limit of detection. 
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Figure 6.3: Solubility of BZF, IMC, PRX, and WFN in EPO-solutions after 48 h equilibration at room 
temperature. 
 
BZF, IMC, PRX and WFN (Figure 6.3) reached maximum solubility at 2% EPO 
(w/w) and their solubility increased with the polymer concentration. Above 2% EPO, 
solubility decreased again and finally reached a kind of plateau. In contrast, FRS and 
MFA (Figure 6.4) showed a constant increase of solubility with polymer 
concentration up to 5% EPO. TLB (Figure 6.4) was the only tested compound that 
reached a kind of plateau at 2% EPO where the solubility did not decrease at higher 
EPO concentrations. 
 
The residual solid analysis confirmed that none of the tested compounds changed its 
polymorphic form. Therefore, it is likely that the SE resulted from drug-EPO 
interactions in the bulk phase and not from stabilization of a metastable polymorphic 
form.  
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Figure 6.4: Solubility of FRS, MFA, and TLB in EPO-solutions after 48 h equilibration at room 
temperature. 
 
To address potential pH effects on drug solubility, the pH was measured after 48 h for 
all substances in EPO (0.5%, 2%, and 5%) (Table 6.5). For most compounds the pH 
dropped about 0.5 units. Maximum changes were observed in FRS suspensions where 
the pH dropped to pH 3.6 in 2% EPO and to pH 4.1 in 0.5% and 5% EPO. 
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Table 6.5: pH of drug suspensions in EPO after 48 h at room temperature. 
Compound pH in EPO 0.5% after 
48 h (standard deviation, 
n=3) 
pH in EPO 2% after 
48 h (standard 
deviation, n=3) 
pH in EPO 5% after 48 h 
(standard deviation, n=3) 
BZF 4.5 (0.0) 4.6 (0.3) 4.7 (0.0) 
FRS 4.1 (0.0) 3.6 (0.0) 4.1 (0.1) 
IMC  4.8 (0.0) 4.4 (0.1) 4.9 (0.1) 
MFA  5.6 (0.1) 5.2 (0.0) 5.4 (0.0) 
PRX 5.4 (0.0) 5.5 (0.1) 5.6 (0.1) 
TLB 5.2 (0.1) 5.4 (0.1) 5.6 (0.0) 
WFN  5.4 (0.1) 5.4 (0.1) 5.7 (0.1) 
 
As a trend, the pH was slightly higher in 5% EPO compared to the pH in 0.5% and 
2% EPO. The dimethylaminoethyl groups in EPO have a rather high pKa value 
(8.4)
176
 and thus concentration-dependent interactions with the dissolving acidic drugs 
are likely to affect equilibrium pH. 
 
6.3.3
 1
H NMR spectroscopy 
1
H NMR measurements were performed to evaluate the interactions between EPO and 
the compounds in solution. Peaks originating from protons of aromatic ring systems 
(present in all API molecules investigated) were observed between 7.00 and 8.25 ppm 
in D2O for PRX and 6.75 to 8.00 ppm for WFN. 
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Figure 6.5: Solution-state 
1
H NMR spectra of WFN and PRX in presence of EPO and in D2O alone. 
 
The NMR signals of WFN and PRX in D2O were very sharp (see Figure 6.5), 
indicating that API-molecules were dispersed in D2O without substantial aggregation. 
This was also observed for the other compounds (spectra not shown). All drugs had in 
common that API-related signals displayed changes in line-width and/or chemical 
shift in presence of EPO as shown for two examples, WFN and PRX, in Figure 6.5. 
Peaks derived from compounds could be still clearly observed although the peaks’ 
shapes were comparatively much broader. 
1H NMR was further used to measure the diffusion coefficient of the APIs in D2O 
with and without 0.5% EPO and results are displayed in Table 6.6. 
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Table 6.6: Diffusion coefficient of APIs in D2O with and without EPO. 
Compound Diffusion coefficient 
in D2O × 10
10
 [m
2
/s] 
Diffusion coefficient in 
EPO 0.5% × 10
10
 [m
2
/s] 
BZF 4.65 0.56 
FRS 4.73 0.36 
IMC  5.25 0.34 
MFA  5.50 0.34 
PRX 5.43 0.63 
TLB 5.40 1.32 
WFN  7.00 0.48 
EPO 0.38 - 
 
As expected, the much larger polymer EPO showed a lower diffusion coefficient  
(10 to 15-fold) than the APIs alone and therefore moves slower. The EPO diffusion 
coefficient was practically unaffected by the different drugs (in the range 5.3·10
-11
 to 
3.7·10
-11
 m
2
/s). By contrast, the diffusion coefficient of the APIs decreased 
substantially in the presence of EPO down to or even slightly below the diffusion 
coefficient of EPO. 
 
6.4 Discussion 
It is a reasonable assumption that the ionic interaction between the deprotonated drug 
and protonated amino alkyl group of EPO provides important contribution to the 
whole interaction. As an example of such a likely molecular association of drug and 
excipient, the potential EPO-MFA interaction is depicted in Figure 6.6. 
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Figure 6.6: Graphical representation of the interaction of ionized molecules and ionized EPO using 
mefenamic acid as model (light gray). 
 
MFA was selected as an example since its interaction with EPO has been investigated 
before in studies addressing supersaturation.
171
 Figure 6.6 shows that apart from 
association of the ionic groups, additional interactions e.g. between side chain methyl 
groups and the aromatic ring, are likely in case of MFA. Especially, the amino group 
may increase the polarization of the methyl C-H group and thereby favor interaction 
with an aromatic ring. Similarly, hydrophobic interactions between the dangling EPO 
side chains and aromatic drug moieties may further strengthen overall association. 
Higashi et al. studied the interaction mechanism of MFA with EPO by high resolution 
magic-angle spinning NMR and also divided the molecular interactions into ionic and 
hydrophobic interactions.
171
 They also identified peaks that indicate interactions 
between the amino alkyl group of EPO and the aromatic systems of MFA.
171
 In line 
with these results, Figure 6.6 shows that interactions with at least three spatial 
contacts could be viewed as a kind of molecular recognition in the case of MFA and 
EPO. Thus, EPO might form a kind of a polymeric pocket for MFA and additional 
interactions are conceivable that further shield MFA from the aqueous environment. 
Based on the example of MFA, we assume that such specific interaction motifs may 
also occur with other acidic drugs. In summary, these motifs are the interaction of 
acidic and positively charged amino alkyl group, the interaction of methyl amino 
group and aromatic rings, and additional hydrophobic interactions. Even though all 
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tested compounds can in principle show such interaction motifs, the molecular 
structures are quite diverse and these structural differences are very likely to influence 
the specific strength of molecular association between polymer and compound. MFA 
has a carboxylic acid group whereas other compounds, like PRX, TLB, and WFN, 
have alternative acidic groups (enolate or sulfonamide). When looking at Table 6.6, it 
is quite remarkable that the diffusion coefficient of TLB decreases the least in 
presence of polymer. Comparing all the structures, TLB is the only compound that 
has only one aromatic ring. All other compounds have at least two aromatic rings. 
Thus the number of aromatic rings could be important for the polymer-drug 
interaction, for example in case of MFA, the interaction of the methyl amino group 
and of the aromatic ring. Such interaction motifs also require that an aromatic ring is 
spatially arranged close to the amino alkyl side chain of EPO. Therefore molecular 
flexibility and hence rotatable bonds adjacent to aromatic systems are also very likely 
associated with a strong polymer-drug interaction and in turn also with a good SE. 
FRS and WFN showed excellent SE and these drugs are also flexible regarding their 
spatial arrangement of their aromatic groups. 
 
Theoretically, a certain initial conformation of the polymer might be optimal for drug 
solubilization. However, at the same time, the presence of API molecules may also 
influence conformation of the polymer. It is therefore expected that due to these 
complex molecular interactions, no simple relationship can be established between the 
polymer concentration and drug solubility. Concentration dependent solubility data 
were indeed in agreement with this view since there was no general solubilization 
pattern evidenced for the different compounds (Figures 6.3-6.4). Nonetheless, it is 
remarkable that most acidic drugs show a solubility maximum at 2% EPO. Drug 
solubility was measured in a broad concentration range of EPO and solubility could 
be affected by both the initial conformational structure of the polymer in solution and 
by the conformation induced by its interaction with the drug. 
For most compounds we observed a maximum of SE within the range of polymer 
concentration investigated. For those which do not show this maximum the curvature 
of the solubility increase proposed a maximum (or plateau) outside the range of 
polymer concentration investigated. Eventually, these compounds will show beyond 
A systematic study of molecular interactions of anionic drugs with a dimethylaminoethyl methacrylate copolymer 
regarding solubility enhancement 103 
  
 
 
the tested range also a maximum for SE at a certain polymer concentration. These 
observed maxima can be explained by steric hindrance of the interactions between 
EPO and the APIs occurring at high polymer loads. In addition conformational 
changes of the polymer at high concentration may lead to limited accessibility of the 
polymeric cavities that enable strong drug association. 
The molecular interactions discussed and exemplarily shown in Figure 6.6 were in 
agreement with our 
1
H NMR results. Notable was for example that all drugs revealed 
changes in the aromatic regions, where a change in line-width and/or chemical shift 
for peaks originated from protons of aromatic rings in presence of EPO. These results 
are in line with former results, where similar line broadening was observed for MFA 
due to strong interaction with EPO.
171
 Besides spectral information, drug diffusion 
coefficients of the compounds in presence and absence of EPO were used to monitor 
the strength of the API polymer interactions in solution. 
 
 
Figure 6.7: SE in presence of polymer (0.5% (w/w)) plotted against the rDiffAPI defined as the 
diffusion coefficient of drug with polymer divided by the value of pure drug in D2O. 
 
A relative diffusion coefficient (rDiffAPI) was considered that holds for the observed 
value of drug in the presence of polymer normalized by the diffusion coefficient of 
drug alone (in D2O). When rDiffAPI is plotted against the relative SE of the drug (drug 
solubility in polymer solution normalized by the pure aqueous solubility) there 
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appears to be a non-linear relationship. A Spearman rank correlation provided a 
coefficient of rSpearman = -0.83 that supported the view of a significant relationship (p= 
0.04). Thus, a decrease of diffusion coefficient ratio correlates well with an observed 
excipient SE (Figure 6.7). It is expected that APIs diffusion will be increasingly 
reduced by stronger interaction with EPO and therefore, a relative diffusion 
coefficient might be used as marker for the strength of drug-excipient interaction in 
the bulk phase. The approach seems promising because no additional effects of the 
drug solid state were evidenced in presence of polymer. Based on the identified 
correlation, it might be in the future possible to formulate an empirical power law that 
describes SE as a function of rDiffAPI but this should be based on an even larger 
dataset than presented in the current study. 
The non-linear nature of the relationship is likely due to a complex solid-liquid 
equilibrium where drug in the bulk phase can be either interacting or non-interacting 
with polymer. It is possible that presence of drug may induce conformational change 
of the polymer, thereby influencing its binding. On top of such multiphase 
consideration, one may also have to account for fractal physics of drug dissolution 
and diffusion.
118, 177, 178
 Such further theoretical research is beyond the scope of the 
present article. The observed empirical correlation has in any case a great practical 
relevance because it suggests how the strength of the molecular interaction, expressed 
by rDiffAPI, may translate into SE. It is here interesting that a moderate change in the 
strength of molecular interaction can exert a huge effect on solubilization. 
 
 
Figure 6.8: Plot of logP, melting point (Tm), and pKa versus solubility enhancement (SE). 
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Further possible correlations were studied between characteristics of the compounds 
(used for general solubility prediction)
179
 like logP, melting point, or pKa of the APIs 
and the solubility enhancement by EPO (data shown in Figure 6.8). As a result, the 
present dataset did not point to a comparatively simple relationship of such a 
molecular parameter with SE, which was probably due to the complex nature of ionic 
and relevant hydrophobic interactions of drug and polymer. 
 
6.5 Conclusion 
In former studies it was shown that EPO is a very potent polymer for stabilizing 
amorphous acidic compounds, which can increase oral bioavailability.
170, 171
 We 
studied the influence of EPO in solution on seven crystalline acidic drugs and could 
show that the observed huge SE was enabled by specific molecular interactions of 
drug and polymer. Thus, EPO seems to be a very well suitable polymer to formulate 
anionic drugs in both solid dispersions and in less complex formulations such as 
solutions or suspensions. The exceptional drug solubilization by EPO may even 
replace solid dispersions in many cases. This is attractive because simple formulations 
that are easy to produce and stable upon storage are clearly preferred particularly for 
early stage development. An important finding was also that a ratio of diffusion 
coefficients of an API measured by NMR in presence and absence of EPO correlated 
well with the obtained excipient solubility enhancement. The findings suggested that 
small changes in the strength of molecular interaction between APIs and EPO may 
substantially affect drug solubility in the presence of EPO. Based on the comparison 
of the acidic drugs, a better molecular understanding was achieved for the association 
of drug and polymer to target maximum solubility. Such findings of molecular 
pharmaceutics are of practical relevance and it is particularly the early development 
phase that benefits from such knowledge to formulate poorly soluble drugs, while 
coping with challenges of limited compound availability and stretched timelines. The 
results are also interesting for oral solid dosage forms in the later stage of 
pharmaceutical development where EPO could be used as well for SE.
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Chapter 7 
Unexpected solubility enhancement of drug 
bases in presence of a dimethylaminoethyl 
methacrylate copolymer 
 
Summary 
The methacrylate-copolymer Eudragit
®
 EPO (EPO) has previously shown to greatly 
enhance solubilization of acidic drugs via ionic interactions and by multiple 
hydrophobic contacts with polymeric side chains. The latter type of interaction could 
also play a role for solubilization of other compounds than acids. The aim of this 
study was therefore to investigate the solubility of six poorly soluble bases in 
presence and absence of EPO by quantitative ultra-pressure liquid chromatography 
with concomitant X-ray powder diffraction (XRPD) analysis of the solid state. For a 
better mechanistic understanding, spectra and diffusion data were obtained by 
1
H 
nuclear magnetic resonance (NMR) spectroscopy. Unexpected high solubility 
enhancement (up to 360-fold) was evidenced in presence of EPO despite of the fact 
that bases and polymer were both carrying positive charges. This exceptional and 
unexpected solubilization was not due to a change in the crystalline solid state. NMR 
spectra and measured diffusion coefficients indicated both strong drug-polymer 
interactions in the bulk solution and diffusion data suggested conformational changes 
of the polymer in solution. Such conformational changes may have increased the 
accessibility and extent of hydrophobic contacts thereby leading to increased overall 
molecular interactions. These initially surprising solubilization results demonstrate 
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that excipient selection should not be based solely on simple considerations of, for 
example, opposite charges of drug and excipient, but it requires a more refined 
molecular view. Different solution NMR techniques are here especially promising 
tools to gain such mechanistic insights. 
 
7.1 Introduction 
Poorly water soluble drug candidates are becoming more prevalent in pharmaceutical 
discovery and development.
1, 180
 These candidates can be formulated for oral 
administration by several strategies including the reduction of the particle size, 
formulation of the drug in solution, amorphous systems or lipid formulations.
165, 181-183
 
While such formulation techniques are used in preclinical formulation supply, there 
are certainly limitations of any sophisticated formulation approaches because of 
limited compound availability and stretched timelines.
7
 Formulation strategies that are 
widely used in the early phase are solubilization by pH-adjustment, the use of 
cosolvents, cyclodextrins or surfactants, formulation as suspensions, emulsions, or 
solid dispersions.
7
 Lee et al. reported that in Pfizer 85% out of more than 300 
compounds submitted for discovery and pre-clinical injectable formulation 
development were formulated by pH adjustment, cosolvent addition, or a combination 
of the two approaches.
184
 More complicated and metastable formulations such as solid 
dispersions are often not the first choice at an early development stage, for example, 
in preclinical formulation supply. However, much can be learned from the literature 
on solid dispersions regarding drug-polymer interactions that can be harnessed more 
broadly in different formulation approaches.
167, 185, 186
 
 
The current work focusses on Eudragit
®
 EPO that was introduced as pharmaceutical 
polymer for taste masking, moisture protection, enteric film-coating, and sustained 
release drug delivery
169
 but more recently, it was used for solubility enhancement of 
poorly soluble acidic drugs by stabilizing them in an amorphous state.
170-174
 EPO 
belongs to the family of methacrylic acid copolymers and is composed of 
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dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate with a 
molar ratio of 2:1:1. It is positively charged at pH < 8 in aqueous media and the 
chemical structure is displayed in Figure 7.1. 
 
 
Figure 7.1: Simplified monomer structure of EPO (details are given in the text). 
 
When using EPO as a carrier for amorphous compounds, outstanding results were 
obtained in terms of solubility and bioavailability enhancement. 
170, 172
 EPO was not 
only very potent in stabilizing compounds in an amorphous state but excellent 
solubilization was recently demonstrated with a range of acidic drugs. 
187
 Of great 
importance is here the ionic interaction between the deprotonated acid and protonated 
amine moieties of the polymer. 
171, 187
 Moreover, further relevant hydrophobic 
interactions were evidenced between the polymeric side chains and active 
pharmaceutical ingredients (APIs). The latter drugs may contain aromatic residues or 
other lipophilic groups for which such hydrophobic excipient interactions were shown 
to play a role in solubilization.
187
  
Only very few non-acidic compounds have so far been formulated with EPO
188, 189
 
and to the best of our knowledge, there are no data available using only EPO for 
solubility enhancement of basic APIs. The latter approach seems at first to be less 
promising based on the same type of positive charge that is obtained at pH values < 8. 
However, the gained knowledge of hydrophobic side chain interactions led to the 
hypothesis that potentially also drug bases may profit from a solubility enhancement 
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in presence of the copolymer despite of its dimethylaminoethyl groups. We therefore 
studied the influence of EPO in solution on the solubility and solid state of six poorly 
water-soluble, basic drugs with chemically diverse characteristics. 
 
7.2 Materials and Methods 
7.2.1 Materials  
Pimozide (PMZ) and tamoxifen (TMX) were obtained by Sigma Aldrich (Buchs, 
Switzerland), while carvedilol (CVD) was from AK Scientific, Inc. (Union City, 
USA). Cinnarizine (CNZ) was purchased from Alfa Aesar (Karlsruhe, Germany), 
mefloquine (MFQ) was obtained from F. Hoffmann-La Roche Ltd (Basel, 
Switzerland) and terfenadine (TFD) was from Carbosynth Ltd (Compton, UK). The 
chemical structures of all model compounds are shown in Figure 7.2 and their 
physicochemical properties are listed in Table 7.1. Aminoalkyl metacrylate 
copolymer E, Eudragit EPO, (EPO) was obtained by Evonik (Darmstadt, Germany). 
Hydrochloric acid (0.1 M) and sodium hydroxide solution (0.1 M) were from Merck 
KGaA (Darmstadt, Germany). 
 
 
Figure 7.2: Chemical structure of model drug bases and abbreviations used (from left to right in the 
order of carvedilol, cinnarizine, mefloquine, pimozide, tamoxifen, and terfenadine). 
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Table 7.1: Molecular weight (Mw), ionization constant (pKa) and distribution coefficient (logD) at pH 
6.0 for the different model compounds. 
Compound Mw [g/mol] pKa
a 
LogD
b
 (pH 6.0) 
Carvedilol (CVD) 406.5 8.1 0.8 
Cinnarizine (CNZ) 368.5 7.8 3.8 
Mefloquine (MFQ) 378.1 9.2 1.1 
Pimozide (PMZ) 461.2 8.6 3.5 
Tamoxifen (TMX) 371.2 9.7 3.7 
Terfenadine (TFD) 471.7 9.1 3.6 
a
Measured pKa-values via photometric titration (Roche internal data). 
b
Values calculated by Marvin Suite (V. 16.5.30, ChemAxon, Douglas Drake, USA). 
7.2.2 Sample preparation 
Polymer solutions were prepared by dissolving EPO (0.1%, 0.5%, 1%, 2%, 3%, 4%, 
5% (w/w)) in deionized water and adjusting all solutions to pH 6.0 by hydrochloric 
acid and sodium hydroxide at 25°C. Solutions were checked carefully for absence of 
particles. 
 
7.2.3 Solubility and residual solid analysis 
Solubility of compounds in EPO-solutions was determined by using a 96-well assay 
that was introduced to measure equilibrium solubility in parallel to a solid state 
analysis of the residual solid (SORESOS)
56
 as described before.
90
 In brief, APIs were 
dispensed using the powder-picking-method
103
 in a 96-well flat bottom plate (Corning 
Inc., Durham, USA). After addition of stir bars and polymer solutions (150 µl), 
mixtures were agitated by head-over-head rotation for 48 h at room temperature. After 
mixing, the suspensions were carefully transferred into 96-well filter plates and the 
liquid and solid phase were separated by centrifugation. Filtrates were collected, 
diluted with N-methyl-2-pyrrolidone and drug content in filtrates was determined 
using a Waters Acquity Ultra Performance Liquid Chromatographic (UPLC) system 
equipped with a 2996 Photodiode Array Detector and an Acquity UPLC BEH C18 
column (2.1x50 mm, 1.7 μm particle size) from Waters (Milford, USA). An isocratic 
flow (composition of the mobile phase is listed in Table 7.2) was applied for 0.3 min 
at a flow rate of 0.75 mL/min. Subsequently, the concentration of solvent B was 
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linearly increased to 100% within 0.5 min. Solid state analysis of residual solid was 
performed by X-ray powder diffraction (XRPD) using a STOE Stadi P Combi 
diffractometer with a primary Ge-monochromator (Cu Kα radiation), imaging plate 
position sensitive detector (IP-PSD), and a 96-well sample stage as described 
before.
56
 The IP-PSD allowed simultaneous recording of the diffraction pattern on 
both sides of the primary beam, which were summed up by the software STOE 
WinXPOW to reduce effects related to poor crystal orientation statistics. Samples 
were analyzed directly in the 96-well filter plate with an exposure time of 5 min per 
well. 
 
Table 7.2: UPLC analytic. 
 Gradient (A:B)
a 
[%] 
Detection 
wavelength [nm] 
CVD 80:20 331 
CNZ 90:10 230 
MFQ 90:10 222 
PMZ 90:10 214 
TMX 90:10 223 
TFD 70:30 260 
a
Mobile phase A: deionized water with 0.1% (v/v) triethylamine adjusted to pH 2.2 with 
methanesulfonic acid Mobile phase B: acetonitrile 
 
7.2.4
 1
H NMR spectroscopy 
Solutions for NMR analyses were prepared by suspending APIs for 24 h in a 0.5% 
(w/w) EPO-solution in deuterium oxide (D2O) at pH 6.0. Samples were then 
centrifuged and supernatants (550 µl) were transferred to short disposable 5 mm 
NMR tubes. 
All NMR measurements were performed with a Bruker 600 MHz Avance II 
spectrometer equipped with a cryogenic QCI probe head at a temperature of 300 K. 
Spectrometer operation and data processing was done by Topsin 2.1 software (Bruker, 
Fällanden, Switzerland). For all samples matching/tuning of the probe head and the 
90° pulse were determined fully automated. Pseudo 2D 
1
H diffusion ordered 
spectroscopy (DOSY) with bipolar gradient pulse pairs and 2 spoil gradients
175
 was 
measured for all samples with presaturation of residual water. Data points (32 k) were 
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acquired over 18 ppm sweep-width and the interscan delay was set to 1.5 s. 
SMSQ10.100 shaped bipolar gradient was ramped from 2.65 to 50.35 gauss/cm in 16 
equidistant steps. Spectra were processed with a lb = 1 exponential filtering and a 
diffusion time of 300 ms was used. 
Diffusion coefficient D was fitted by use of the T1/T2 relaxation module implemented 
within the Topsin 2.1 software (Bruker, Switzerland). For most molecules at least one 
API and excipient related NMR signal was identified by visual inspection. 
 
7.3 Results  
7.3.1 Solubility and residual solid analysis 
All excipient solutions were adjusted to pH 6.0 before incubation and following 
equilibration, the residual solid was analyzed by means of XRPD. Compared to water, 
all model compounds displayed a good solubility enhancement (SE) in the different 
EPO-solutions (Fig. 7.3-7.4 and Table 7.5). In addition to the measured aqueous 
solubilities of the model compounds, adjusted solubility values for pH 6.0 are 
displayed in Table 7.3. This extrapolation method was based on the Henderson-
Hasselbalch equation and it is generally reliable when the experimental solubility 
value is within one pH unit difference.
190
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Table 7.3: Drug solubility and pH of drug suspensions in water after 24 h incubation time. Aqueous 
solubilities were adjusted for a pH 6.0. 
Compound 
Solubility in water 
(standard deviation, n=3) 
[mg/ml] 
pH in water (standard 
deviation, n=3) 
Adjusted solubility at 
pH 6.0 [mg/ml] 
CVD 0.005 (0.002) 7.2 (0.3) 0.071 
CNZ 0.001 (0.001) 6.1 (0.3) 0.001 
MFQ 0.063 (0.001) 7.6 (0.1) 2.448 
PMZ 0.002 (0.001) 6.8 (0.2) 0.013 
TMX 0.008 (0.004) 6.9 (0.0) 0.064 
TFD 0.002 (0.001) 6.8 (0.2) 0.013 
 
Table 7.4: pH of drug suspensions in the presence of 0.5%, 2% and 5% EPO after 48 h at room 
temperature. 
Compound pH in EPO 0.5% after 48 
h (standard deviation, 
n=3) 
pH in EPO 2% after 48 h 
(standard deviation, n=3) 
pH in EPO 5% after 48 h 
(standard deviation, n=3) 
CVD 5.9 (0.0) 5.8 (0.1) 6.0 (0.0) 
CNZ 5.7 (0.1) 6.0 (0.0) 5.9 (0.0) 
MFQ 6.3 (0.1) 6.3 (0.0) 6.4 (0.0) 
PMZ 5.8 (0.1) 6.0 (0.0) 6.0 (0.0) 
TMX 5.9 (0.1) 5.9 (0.0) 6.0 (0.0) 
TFD 5.8 (0.0) 6.1 (0.0) 6.0 (0.0) 
 
pH values were also measured after 48 h for all basic compounds in EPO (0.5%, 2%, 
and 5%) (Table 7.4). The pH did not change for most compounds, only MFQ caused a 
pH increase to values of 6.3 and 6.4. Such a pH shift was expected given the 
dissolution of a basic compound. MFQ reached with 12 mg/ml at an EPO 
concentration of 5% the highest total solubility, which thereby caused the pH shift. 
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Figure 7.3: Solubility of CVD, CNZ, and TFD in EPO-solutions after 48 h at room temperature. 
 
CVD, CNZ, and TFD (Figure 7.3) solubility reached a plateau at 2% EPO (w/w). In 
contrast, MFQ, PMZ, and TMX (Figure 7.4) showed an increase of solubility with 
polymer concentration up to 5% EPO.  
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Figure 7.4: Solubility of PMZ, TMX, and MFQ in EPO-solutions after 48 h at room temperature. 
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Table 7.5: Adjusted solubility enhancement (SE) factors of model compounds in EPO-solutions (0.1-
5%) compared to solubility in water (pH 6.0). SE factors were calculated by dividing the solubility of a 
compound in polymer solutions by the adjusted solubility in water at a pH 6.0. Non-adjusted values are 
displayed in brackets. 
Compound SE in EPO 
0.1% 0.5% 1.0% 2.0% 3.0% 4.0% 5.0 
CVD 1.7  
(24.3) 
6.7 
(94.9) 
6.9  
(97.9) 
10.7 
(152.3) 
11.1 
(157.4) 
10.6 
(150.9) 
11.7 
(165.9) 
CNZ 2.7  
(2.7) 
10.3  
(10.3) 
15.3  
(15.3) 
29.3 
(29.3) 
37.3 
(37.3) 
39.0 
(39.0) 
37.0 
(37.0) 
MFQ 0.2  
(7.2) 
1.0  
(37.3) 
1.5  
(58.3) 
2.4 
(92.8) 
3.6 
(141.5) 
4.4 
(172.5) 
4.8 
(186.2) 
PMZ 2.0  
(12.8) 
5.4  
(35.3) 
5.0  
(32.3) 
6.9 
(45.0) 
8.5 
(55.2) 
9.3 
(60.2) 
9.8 
(63.8) 
TMX 1.2  
(10.0) 
3.1  
(25.0) 
5.5  
(43.6) 
13.2 
(105.8) 
23.4 
(187.6) 
31.7 
(253.8) 
45.0 
(359.9) 
TFD 2.5  
(16.0) 
6.6  
(43.2) 
8.3  
(54.0) 
11.7 
(76.2) 
15.3 
(99.3) 
14.6 
(94.8) 
14.0 
(91.2) 
 
 
The true solubility enhancement by the drug-polymer interaction was calculated by 
comparing the aqueous solubility with the solubility in presence of the excipient at the 
same pH. Since the dissolution process of acidic or basic compounds influences the 
pH of unbuffered water, it was not possible to measure both solubilities at the same 
pH. Therefore, aqueous solubility values were adjusted for constant pH 6.0 according 
to the Henderson-Hasselbalch equation to calculate true solubility enhancement 
factors (Table 7.5). Also the non-adjusted values are practically relevant but obtained 
solubility enhancement is then a confounded effect of molecular excipient interactions 
as well as pH shift. Another solubility factor could have been a changed solid state 
during drug dissolution. However, the residual solid analysis confirmed that none of 
the tested compounds exhibited a solvent-mediated phase transformation. Thus, initial 
polymorphic forms remained the same during the course of the experiments. 
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7.3.2
 1
H NMR spectroscopy 
1
H NMR spectra were analyzed to evaluate the interactions between EPO and the 
different compounds in solution. Peaks originating from protons of aromatic ring 
systems (present in all API molecules investigated) were observed between 5.50 and 
8.50 ppm in D2O for all APIs. 
The NMR signals of all APIs in D2O were very sharp (see Figure 7.5), indicating that 
API-molecules were dispersed in D2O without substantial aggregation. All drugs had 
in common that API-related signals displayed changes in line-width in presence of 
EPO as shown for the two examples in Figure 7.5. Peaks derived from compounds 
could be still clearly observed although the peaks’ shapes were comparatively much 
broader. Such line broadening suggests a form of aggregation and hence restricted 
molecular tumbling. 
 
 
Figure 7.5: Solution-state 
1
H NMR spectra of MFQ and TMX in the presence of EPO and in D2O 
alone. 
 
 
DOSY
 1
H NMR was used to determine the diffusion coefficients of the APIs in D2O 
with and without 0.5% EPO. Results are displayed in Table 7.6. The diffusion 
coefficient of EPO in presence of the APIs was also measured. 
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Table 7.6: Drug diffusion coefficient in D2O with and without EPO as well as polymer diffusion 
coefficient in presence of the different APIs. 
Compound Drug diffusion 
coefficient in D2O x 
10
10
 [m
2
/s] 
Drug diffusion 
coefficient in EPO 
0.5% x 10
10
 [m
2
/s] 
Diffusion coefficient of EPO 
with API 0.5% x 10
10
 [m
2
/s] 
DAPI(D2O) DAPI(EPO) DEPO(API) 
CVD 4.60 3.53 0.43 
CNZ 4.46 3.04 0.41 
MFQ 4.65 2.62 1.03 
PMZ 4.02 2.91 0.40 
TMX 4.43 0.58 0.44 
TFD 3.56 2.28 0.53 
EPO* 0.38   
* Reference value of pure EPO in aqueous solution. 
As expected, the much larger polymer EPO showed a lower diffusion coefficient in 
pure D2O (10 to 15-fold) than the APIs alone. The diffusion coefficient of the APIs 
decreased in presence of EPO. This reduction was for most drugs rather moderate, 
whereas a relatively higher reduction in diffusion coefficient was observed with MFQ 
and most was the change for TMX. Interestingly, the diffusion coefficient of EPO 
increased in the presence of APIs. 
 
7.4 Discussion 
Previous research on the methacrylate-copolymer EPO was primarily motivated by 
investigating the ionic drug interactions of acids with the protonated amino alkyl 
group of EPO. 
187, 188
 Based on NMR data in solution, it was shown that additional 
hydrophobic molecular interactions with the polymer side chains were providing a 
notable contribution to overall molecular polymer-API association.
171, 187
 These 
findings led to the present hypothesis that not only acids may benefit form 
solubilization by EPO. Accordingly, the present work focused on solubilization of 
basic APIs by EPO even though it may seem at first counterintuitive since both bases 
and EPO exhibit positive charges at pH values < 8. 
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Concentration dependent solubility data demonstrated that EPO had a beneficial effect 
on drug solubility of the basic model drugs. While the present hypothesis was aiming 
at some solubility enhancement in presence of the polymer, it was rather unexpected 
and highly remarkable to what extent the bases were showing increased solubilization. 
No general solubilization pattern was evidenced for the different compounds in the 
studied concentration range (Figures 7.3 and 7.4), but it is notable that half of the 
tested basic drugs showed a plateau regarding solubility enhancement starting at 2% 
EPO. Since for none of the model compounds polymorphic transformation was 
detected, the observed solubilization was therefore attributed to drug-EPO interactions 
in the liquid phase and not to a stabilization of a metastable polymorphic drug form. 
Due to the complexity of the API-polymer-interactions shown already for acidic 
drugs, 
187
 the interactions were studied more in detail by means of solution NMR 
spectroscopy. The NMR spectra of the APIs together with EPO displayed a change in 
peak width for the aromatic region indicating their interaction with the polymer. 
 
Interesting were also the DOSY NMR findings. The diffusion coefficients of the APIs 
decreased to some extent in presence of the polymer (Table 7.6) and this change was 
most pronounced for TMX followed by MFQ. Although TMX, for example, reached 
high drug solubilization, there was no clear general correlation noted of SE with a 
change in drug diffusion coefficient. Changes in drug diffusion coefficient can be here 
primarily attributed to drug binding. Such binding could be readily quantified if the 
polymer itself keeps its value of the diffusion coefficient in presence of drug. 
However, this was interestingly not the case and EPO appeared to undergo itself 
diffusional changes because of the APIs (Table 7.6). Such a clear effect of altered 
EPO diffusion was not evidenced in a previous study of tested acidic compounds.
187
 
In the present study, the diffusion coefficient of the macromolecule was evidently 
diffusing faster in the presence of basic drugs compared to pure water. Faster 
movement of the polymer must be associated with conformational changes of the 
swollen macromolecule in solution. The conformation of polyelectrolytes like EPO 
depends greatly on its concentration in solution. In dilute solutions, the intra-chain 
interactions usually dominate over the inter-chain ones. 
191
 Thus, one can effectively 
consider a single polyelectrolyte chain with counterions surrounding it, whereas in 
more concentrated solutions, polyelectrolytes chains start to overlap. The 
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conformation of polyelectrolytes, e.g. EPO in solution is generally highly influenced 
by the presence and location of counterions.
191, 192
 The insertion of additional 
positively charged drugs in this complex system of EPO chains and counterions is 
likely to cause structural changes. Since the polyelectrolyte conformation is controlled 
by the fraction of ionized groups, additional positive charges of the basic APIs that 
are attached via hydrophobic interactions to the polymer backbone may lead to 
weakening of electrostatic interactions and can promote conformational change like 
shrinkage of the polyelectrolyte chains.
191
 When the majority of counterions condense 
to the polymer backbone, polyelectrolyte can even take conformations like spheres 
that are rather typical for neutral polymers. When the polymer chain shrinks or even 
forms spherical globules, it would move faster in solution, which is in line with our 
experimental NMR diffusion results. 
 
The change in the polymeric conformation may help also to explain the observed 
solubilization pattern. The positively charged APIs are likely associated with the 
polymer by hydrophobic interactions between the aromatic systems of the compounds 
and the side chains of the polymer. However, there will be also a non-bound fraction 
of drugs. This fraction can interact with the free counterions in solution and influences 
the balance between polymer and counterions. Accordingly, complex drug-excipient 
interactions as evidenced by the NMR results were obviously forming the basis of the 
surprisingly high drug solubilization enhancement in EPO solutions. 
 
7.5 Conclusions 
EPO was earlier shown to be a potent solubilizer for acidic drugs in different 
formulation approaches. The present study now provides evidence for six positively 
charged (basic) compounds whose solubility was enhanced by the polymer EPO. 
Although some hydrophobic interactions were expected to occur, the high extent of 
solubility enhancement was surprising given the same positive charge type of 
aminoalkyl groups that abundantly exist in EPO. Results of 
1
H-NMR spectroscopy in 
solution showed that molecular interactions between hydrophobic drug moieties, such 
as aromatic rings, interact with the polymer. Additionally, conformational changes of 
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the polymer were suggested by DOSY NMR data and such changes may further point 
to the hydrophobic interactions with the basic drugs. These findings broaden the 
application area of EPO, especially for simple formulations like suspensions and 
solutions that can be used in early phases of the drug development process. 
Additionally, important insights were gained into the mechanisms of drug-EPO 
interactions. Our results indicate that beyond obvious charge-driven interactions 
between APIs and excipients additional (hydrophobic) interactions may play a role 
and should be considered in excipient selection. 
. 
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Chapter 8 
Interactions of dimethylaminoethyl 
methacrylate copolymer with non-acidic drugs 
demonstrated high solubilization in vitro and 
pronounced sustained release in vivo 
Summary 
 Recent work demonstrated remarkable solubilization effects of methacrylate-
copolymer Eudragit EPO (EPO) not only with acidic drugs but interestingly also with 
poorly soluble basic compounds. The current work studied EPO-mediated 
solubilization effects first in vitro using felodipine (FLP) and tamoxifen (TMX) as 
model compounds. EPO-containing solutions were subsequently compared in a rat 
pharmacokinetic study against reference solutions and suspensions. Surprisingly, 
solution formulations with EPO did not result in an increased relative oral 
bioavailability. Exposure was reduced for both drugs and plasma-profiles of the EPO 
solutions showed a delayed and lower maximum plasma concentration compared to 
the reference formulations. This sustained in vivo release was likely due to combined 
effects of strong drug-polymer interactions and pH-dependent precipitation of the 
polymer in the rat intestine. Remarkable was that in vitro drug-polymer coprecipitates 
did not reveal crystalline drug by polarized light microscopy. Thus, such a 
formulation approach provides a rather simple opportunity to modify drug release in 
vivo. However, this may be rather an approach for preclinical formulations, if high 
peak-to-trough ratios of plasma levels are problematic regarding adverse effects 
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related to Cmax or if plasma concentrations drop too fast below required 
pharmacological concentrations. 
8.1 Introduction 
Several enabling formulation techniques have been developed for oral delivery of 
poorly water-soluble drugs. 
4, 193
 They are either based on methods increasing 
dissolution rate and/or solubility of drug candidates. Such methods include particle 
size reduction, crystal modification, self-emulsifying systems, polymeric and lipid 
nanoparticles, solid dispersions or the use of cosolvents. 
6, 7, 9
 All of these approaches 
have specific advantages and limitations. For example, particle size reduction can lead 
to formulation issues regarding powder flow, electrostatic forces, or wettability; and 
crystal modifications may not be feasible with all compounds. 
64, 161
 Formulations 
based on lipid delivery or on solid dispersion technology are often rather sophisticated 
and therefore are mainly of interest for later stage pharmaceutical development and 
for the market, whereas simpler approaches are used for an early formulation phase. 
131, 167
 The early formulation supply typically comes with additional needs such as 
simplicity, speed, and possible dosing via gavage. This aim for simplicity is often in 
contrast to the complex biopharmaceutical task to adequately deliver poorly soluble 
drugs. In this context, the use of functional copolymers in solutions offers much 
potential; however it still requires a proper understanding of drug-polymer 
interactions in vitro and in vivo. 
Eudragit EPO (EPO) was introduced originally as pharmaceutical excipient for taste 
masking and moisture protection. 
169
 It belongs to the family of methacrylic acid 
copolymers and the aminoalkyl chain has a pKa value of 8. The chemical structure of 
EPO is displayed in Figure 8.1. 
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Figure 8.1: Chemical structure of the model drugs felodipine (FLP), tamoxifen (TMX) and Eudragit 
EPO (EPO). 
 
EPO has further been used for solubility improvement of poorly soluble acidic drugs 
in solid dispersions and outstanding bioavailability enhancement was evidenced. 
170-
172
 More recently, EPO was applied as a solubilizer to simple solution formulations of 
acidic drugs. The relevant molecular mechanisms leading to a significant solubility 
enhancement were analogous to those of solid dispersions. 
187
 Drug solubilization was 
promoted by both ionic interactions with deprotonated anionic drugs and hydrophobic 
interactions between aromatic moieties of pharmaceutical compounds and backbone 
and alkyl-side chains of the polymer. 
171, 187
 Since the solubility enhancement is not 
exclusively caused by ionic interactions, EPO was also shown to be a potent 
solubilizer also for basic compounds. 
187, 194
 While the solubility enhancement in vitro 
is rather impressive, it remains to be shown how such polymeric drug solutions would 
perform in vivo. 
The present work used felodipine (FLP) and tamoxifen (TMX) formulated as EPO 
solutions as typical examples of poorly soluble compounds. FLP (pKa 4.4 (basic), see 
Table 8.1) is protonated at pH < 4 and can be therefore charged in the stomach, 
whereas it is mostly unionized in the small intestine. Thus, variations in pH may 
barely influence its solubility at least in the small intestine. On the other hand, TMX 
is a more basic compound (pKa 9.7) and it keeps the protonated form as it passes from 
the stomach to the intestinal tract. The structures of both compounds are displayed in 
Figure 1. FLP is a dihydropyridine calcium channel blocker widely used as a potent 
anti-hypertensive drug 
195
 whereas TMX is an oral nonsteroidal antiestrogen that has 
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been considered as a gold standard in the treatment and prevention of all stages of 
estrogen-receptor-positive breast cancer. 
196, 197
 However, due to their poor solubility, 
the oral bioavailability is < 30% and is for TMX additionally reduced by enzymatic 
degradation.
196
 
 
Table 8.1: Molecular weight (Mw), ionization constant (pKa), distribution coefficient (logD) at pH 6.0 
and solubility in fasted state simulated gastric (FaSSGF) and intestinal (FaSSIF) fluid for the different 
model compounds. 
Compound Mw 
[g/mol] 
pKa
a 
LogD
b
  
(pH 6.0) 
Solubility [mg/ml] at 37°C in  
FaSSGF FaSSIF 
Felodipine (FLP) 384.3 4.4 (basic) 3.4 na
c
 0.026 ± 0.001 
Tamoxifen (TMX) 371.2 9.7 (basic) 3.7 0.035 ± 0.000 0.230 ± 0.005 
a
Measured pKa-values via photometric titration (Roche internal data). 
b
Values calculated by Marvin Suite (V. 16.5.30, ChemAxon, Douglas Drake, USA). 
c
na: Value not available, concentration below limit of detection. 
Both model compounds were first evaluated for their solubility enhancement in 
presence of different EPO concentrations in vitro. Second, drug-EPO solutions were 
compared to solutions with cosolvents or pH adjusted solutions, and conventional 
suspensions in rats to study the influence of EPO on the pharmacokinetics of the 
drugs in vivo at preclinical doses. 
 
8.2 Materials and Methods 
8.2.1 Materials  
Tamoxifen (TMX) and acetic acid were from Sigma Aldrich (Buchs, Switzerland) and 
felodipine (FLP) from Melrob-Eurolabs (Congleton, UK). The ionization constant 
(pKa) was measured by photometric titration whereas values for the distribution 
coefficient (logD) were calculated by the molecular modeling suite Marvin 16.5.30 
(ChemAxon Inc., Douglas Drake, US). Aminoalkyl metacrylate copolymer E, 
Eudragit EPO, (EPO) was obtained from Evonik (Darmstadt, Germany), 
methylcellulose (MC) was supplied by Colorcon Inc. (Harleysville, USA) and 
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polyethylene glycol 400 (PEG 400) was from Clariant SE (Muttenz, Switzerland). 
Hydrochloric acid (0.1 M) and sodium hydroxide solution (0.1 M) were purchased 
from Merck KGaA (Darmstadt, Germany). The SIF
®
 powder was purchased from 
Biorelevant (Croydon, UK) and used to produce original fasted-state simulated 
intestinal fluid (FaSSIF, pH 6.5) and original fasted-state simulated gastric fluid 
(FaSSGF, pH 1.6). Although these media were developed to mimic the human 
situation 
101
 the classical compositions serve here as an initial experimental model for 
in vivo solubilization in rodents. 
8.2.2 Sample preparation 
Polymer solutions were prepared by dissolving EPO (3% and 5% (w/w)) or MC 
(0.5% (w/w)) in deionized water that was acidified and subsequently adjusting to pH 
6.0 with hydrochloric acid or sodium hydroxide at 25°C. Solutions were filtered and 
checked carefully for absence of particles. The dosing solutions employed in the in 
vitro tests and in the in vivo study are specified in Table 8.2. 
Final formulations were prepared by weighing the required amount of FLP or TMX 
into a glass bottle, addition of vehicle and stirring for 48 h at room temperature 
protected from light. TMX dissolved in acetic acid (40 mM) resulted in a final pH of 
3.5. The dosing solutions were analyzed by LC-MS/MS using a Waters Acquity 
UPLC system equipped with an Acquity UPLC BEH phenyl column (2.1x30 mm, 1.7 
μm particle size) from Waters (Milford, USA) and a PE Sciex API400 mass 
spectrometer (AB Sciex Pte. Ltd, Concord, Canada) in a positive ion mode. The 
analytes were detected by multiple reactions monitoring (MRM). Measured drug 
concentrations were used for pharmacokinetic calculations. Formulations for groups 
1, 2, 4, and 5 were administered as clear solutions, whereas formulations for groups 3 
and 6 were fine suspensions. 
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Table 8.2: Composition and concentrations of dosing solutions. 
Compound Group Vehicle Nominal dosing 
concentration [mg/ml] 
Felodipine 
1 EPO solution 5% (w/w) pH 6.0 0.4 
2 PEG 400 + water (chaser) 4 
3 MC solution 0.5% (w/w) pH 6.0 0.4 
Tamoxifen 
4 EPO solution 3% (w/w) pH 6.0 1 
5 Acetic acid (40 mM) 1 
6 MC solution 0.5% (w/w) pH 6.0 1 
 
Final formulations were prepared by weighing the required amount of test article into 
a glass bottle, adding the vehicle and stirring for 48 h at room temperature protected 
from light. The dissolution of TMX in acetic acid (40 mM) resulted in a pH of 3.5. 
The dosing solutions were analyzed by LC-MS/MS using a Waters Acquity UPLC 
system equipped with an Acquity UPLC BEH phenyl column (2.1x30 mm, 1.7 μm 
particle size) from Waters (Milford, USA) and a PE Sciex API400 mass spectrometer 
(AB Sciex Pte. Ltd, Concord, Canada) in a positive ion mode. The analytes were 
detected by multiple reactions monitoring (MRM). The measured dosing solution 
concentration was used for pharmacokinetic calculations. Formulations for groups 1, 
2, 4, and 5 were administered as clear solutions, whereas formulations for groups 3 
and 6 were fine suspensions. 
 
8.2.3 Solubility and residual solid analysis 
EPO-solutions for solubility measurements were prepared as described in the section 
above and adjusted to pH 6.0 with hydrochloric acid or sodium hydroxide at 25°C. 
Solubility of compounds in EPO-solutions was determined using a slightly modified 
96-well SOlubility and REsidual SOlid Screening (SORESOS) assay 
56
 as described 
before. 
90
 In brief, APIs were dispensed using the powder-picking-method 
103
 in a 96-
well flat bottom plate (Corning Inc., Durham, USA). After adding stirring bars and 
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excipient solutions (150 µl), the plate was sealed with pre-slit silicon caps and the 
mixtures were agitated by head-over-head rotation for 48 h at room temperature. After 
mixing, the suspensions were carefully transferred into 96-well filter plates and liquid 
was separated from residual solid by centrifugation. Filtrates were collected, diluted 
with N-methyl-2-pyrrolidone and drug content in filtrates was determined using a 
Waters Acquity Ultra Performance Liquid Chromatographic (UPLC) system equipped 
with a 2996 Photodiode Array Detector and an Acquity UPLC BEH C18 column 
(2.1x50 mm, 1.7 μm particle size) from Waters (Milford, USA). The mobile phase 
consists of a mixture of deionized water with 0.1% (v/v) trimethylamine which was 
adjusted to pH 2.2 (mobile phase A) and pure acetonitrile (mobile phase B). An 
isocratic flow with a gradient of 40:60% (A:B) for FLP and a gradient of 90:10% 
(A:B) for TMX was applied for 0.3 min at a flow rate of 0.75 ml/min. Subsequently, 
the concentration of solvent B was linearly increased to 100% within 0.5 min. The 
substances were detected at wavelengths of 238 nm (FLP) and 223 nm (TMX). Solid 
state analysis of the residual solid was performed by X-ray powder diffraction 
(XRPD) using a STOE Stadi P Combi diffractometer as described before. 
56
 Samples 
were analyzed directly in the 96-well filter plate with an exposure time of 5 min per 
well. 
 
8.2.4 Precipitation of polymer in presence and absence of APIs 
EPO exhibits pH-dependent solubility with highest values at pH< 5.0. Above pH 6.0, 
the polymer does not dissolve but only swells. The precipitation behavior of polymer 
solutions (3% and 5%) with and without APIs was studied in pH range 6.0 to 9.0 by 
adjusting the pH in intervals of 0.5 units. After magnetic stirring for 30 min, solutions 
and precipitates were visually inspected. The solid state of precipitates was analyzed 
by XRPD as described above and polarized light images of the precipitates were taken 
using a Zeiss Axiolab microscope (Carl Zeiss AG, Jena, Germany). 
Drug concentration in the supernatant was quantified by UPLC after dilution with N-
methyl-2-pyrrolidon as described above. Drug concentration in the precipitated phase 
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was calculated based on nominal total amounts and measured drug concentrations in 
the supernatant. 
 
8.2.5 Dynamic image analysis 
The particle size and shape of the precipitate of formulations 2 (PEG solution with 
FLP) and 3 (MC-suspension with FLP) in biorelevant media were assessed by 
dynamic image analysis with an XPT-C particle analyzer (PS-Prozesstechnik GmbH, 
Basel, Switzerland) with a peristaltic pump (Ismatec SA, Glattbrugg, Switzerland) 
that transported the samples through a measuring cell equipped with a Flea 2, 
1392 × 1032 pixel CCD camera to analyze the size of precipitated samples (n=1000). 
Formulations were suspended in biorelevant media in 1:1 (v/v) ratio (FaSSGF) and 
1:3.3 (v/v) ratio (FaSSIF). The number of crystals was detected in each sample by 
analyzing the pictures using the XenParTec software (Version 5.1, TechApp 
Switzerland). The particle size was expressed as Waddle disk diameter, which is the 
diameter of a disk with the same area as the detected particle. The particle size and 
shape of precipitated formulation 2 (PEG solution with FLP) and of formulation 3 
(MC-suspension with FLP) in biorelevant media were assessed by dynamic image 
analysis with an XPT-C particle analyzer (PS-Prozesstechnik GmbH, Basel, 
Switzerland) with a peristaltic pump (Ismatec SA, Glattbrugg, Switzerland) that 
transported the samples through a measuring cell equipped with a Flea 2, 1392 × 1032 
pixel CCD camera to analyze the size of precipitated samples (n=1000). Formulations 
were suspended in biorelevant media in 1:1 (v/v) ratio (FaSSGF) and 1:3.3 (v/v) ratio 
(FaSSIF). The number of crystals was detected in each sample by analyzing the 
pictures using the XenParTec software (Version 5.1, TechApp Switzerland). The 
particle size was expressed as Waddle disk diameter, which is the diameter of a disk 
with the same area as the detected particle. 
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8.2.6 In vivo pharmacokinetics after oral administration 
8.2.6.1 Animals and dosing protocol 
The non-clinical pharmacokinetic study was conducted at Absorption systems (Exton 
PA, USA) and the protocol followed established practice and operating procedures. In 
brief, male Sprague-Dawley rats of 280 g to 310 g were obtained from Hiltop Labs 
(Scotsdale, USA). The animal experiments were approved by the internal Absorptions 
Systems IACUC review board and were therefore in accordance with National 
Institutes of Health guide for the care and use of laboratory animals. 
198
 Food was 
withdrawn 12 h prior to the test article administration with water offered ad libitum. 
No food was allowed until four hours post dose. The animals were randomly divided 
into six groups each with six animals. FLP-formulations were administered at a dose 
of 4 mg/kg and TMX-formulations at a dose of 10 mg/kg. For group 2, water was 
immediately administered after administration of the FLP solution in PEG 400 to 
achieve a 1:10 dilution of the PEG 400 solution in vivo. Blood samples (~0.3 ml) 
were taken from the jugular vein pre-dose and at 15, 30 min and 1, 2, 4, 8 and 24 h 
following oral administration. Blood samples were collected into heparin. Plasma 
samples were obtained immediately by centrifuging blood samples at a temperature of 
2 to 8°C at 3000 x g for 5 min, after which plasma samples were transferred into 
polypropylene tubes and stored frozen until further analysis. 
8.2.6.2 Determination of felodipine and tamoxifen in plasma 
Plasma concentrations of the test articles were determined by LC-MS/MS. Plasma 
samples of the FLP-group were extracted by liquid-liquid extraction with methyl-t-
butyl whereas TMX-samples were extracted by protein precipitation with acetonitrile. 
Extracted samples were reconstituted in 75:25 acetonitrile: water mixture and 
chromatographic extraction was performed using a Waters Acquity UPLC system 
equipped with an Acquity UPLC BEH phenyl column (2.1x30 mm, 1.7 μm particle 
size) from Waters (Milford, USA).  
The column temperature was maintained at 40 °C with water containing 10% 
ammonium formate buffer (40 mM) (mobile phase A) and acetonitrile containing 
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10% ammonium formate buffer (40 mM) (mobile phase B) as the mobile phase at a 
flow rate of 0.8 ml/min. The following gradient program was used for sample 
separation: 0-0.75 min, 80% A; 0.75-0.80 min, 2% A; 0.8-1.0 min, 80% A. The PE 
Sciex API400 mass spectrometer (AB Sciex Pte. Ltd, Concord, Canada) was operated 
in a positive ion mode and the analytes were detected by multiple reactions 
monitoring (MRM). 
 
8.2.6.3 Pharmacokinetic data analysis 
Pharmacokinetic parameters were calculated from the time course of the plasma 
concentrations and were determined with Phoenix WinNonlin (V. 7.0) software 
(Certara USA, Inc., Princeton, USA) using a non-compartmental model. The 
maximum plasma concentration (Cmax) and the time to reach maximum plasma 
concentration (tmax) after oral dosing were observed from the data. The area under the 
time-concentration curve (AUC) was calculated using the linear trapezoidal rule with 
calculation to the last quantifiable data point. Plasma half-life (t1/2) was calculated 
from 0.693/slope of the terminal elimination phase. Mean residence time (MRT) was 
calculated by dividing the area under the moment curve (AUMC) by the AUC. Any 
sample below the limit of quantification was treated as zero for pharmacokinetic data 
analysis. 
The software package SigmaPlot V. 11.0 (Scystat Software Inc., San Jose, USA) was 
used for all statistical calculations. For each compound, an Analysis of the Variance 
(ANOVA) was comparing the three formulations with respect to the different 
pharmacokinetic responses. For those analyzes in which p < 0.05 was found, the 
Holm-Sidak-method for pairwise multiple comparison was conducted to study 
individual differences between groups. 
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8.3 Results 
8.3.1 Solubility and residual solid analysis 
A basic physico-chemical characterization of FLP and TMX is shown in Table 8.1. 
The solubility of FLP and TMX was determined at different polymer concentrations 
and values were compared to their aqueous solubility. Both compounds exhibited 
particularly low solubility in pure water; the solubility of FLP and TMX in water was 
0.0004 (± 0.0001) mg/ml and 0.008 (± 0.004) mg/ml, respectively. In comparison, 
presence of EPO increased the aqueous solubility of both compounds substantially. 
Even at very low polymer concentrations (0.1% (w/w)), the solubility of FLP was 66-
fold and of TMX 10-fold enhanced. At the highest tested polymer concentration (5% 
EPO (w/w)), solubility was 0.5 mg/ml for FLP (1250-fold) and 2.9 mg/ml for TMX 
(363-fold) (Figure 8.2). 
 
 
Figure 8.2: Solubility of FLP and TMX in EPO-solutions (pH 6.0) after 48 h equilibration at room 
temperature. 
 
8.3.2 Precipitation in vitro of EPO with and without API 
EPO exhibits pH-dependent solubility, dissolves rather fast at pH-values < 5.0 
(stomach) and is therefore used for taste masking and moisture protection of 
Interactions of dimethylaminoethyl methacrylate copolymer with non-acidic drugs demonstrated high 
solubilization in vitro and pronounced sustained release in vivo 133 
  
 
 
immediate-release solid dosage forms. The precipitation behavior of this polymer 
from a solution was tested in presence and absence of APIs. EPO precipitated 
between pH-values of 7.0 and 7.5 (Figure 8.3). Slight differences in precipitation 
behavior were observed when EPO-solutions with different concentrations were 
compared. At a higher polymer-concentration (5%) (Figure 8.4) small polymer flakes 
were visible even at a pH of 7.0. In contrast, at the same pH, the 3%-polymer solution 
was completely clear. 
 
 
Figure 8.3: Precipitation of EPO (3%-solution) in a pH-range between 6.0 and 9.0. Lines indicate the 
pH-range of rats’ intestine according to Kararli et al.199 
 
 
Figure 8.4: Precipitation of EPO (5%-solution) in a pH-range between 6.0 and 9.0. Lines indicate the 
pH-range of rats’ intestine according to Kararli et al.199 
 
Concentrations of the APIs in the supernatant were measured and used to calculate 
drug in the precipitated phase. For both drugs, the amount in the precipitated phase 
was close to 100% (100% (FLP), 99.6% (TMX)) and almost no drug could be 
detected in the aqueous phase.  
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8.3.3 Characterization of the in vitro formulations precipitates of FLP 
8.3.3.1 Dynamic image analysis 
The particle size of the precipitate of formulation 2 (PEG solution with FLP) and of 
the suspended particles in formulation 3 (MC-suspension with FLP) in biorelevant 
media was determined by dynamic particle analysis (Table 8.3). 
 
Table 8.3: Measured waddle disk diameter and Heywood circularity factor of FLP-precipitate of PEG 
400 solution and MC suspension in biorelevant media (mean values ± SD, n=1000). 
Formulation Medium 
Waddle disk diameter 
[µm] 
Heywood circularity 
factor 
PEG 400 solution FaSSGF 14.80 ± 0.58 0.97 ± 0.01 
FaSSIF 6.61 ± 0.91 0.92 ± 0.04 
MC suspension FaSSGF 5.94 ± 0.26 0.90 ± 0.01 
FaSSIF 6.10 ± 0.22 0.91 ± 0.01 
 
FLP particles of the precipitate from the PEG-solution in FaSSGF were 
approximately three times larger than those in the MC-suspension. Since FLP is only 
suspended in the MC-vehicle and not dissolved, it is likely that no precipitation takes 
place upon dilution in biorelevant media. The shape of the particles did not differ 
between media and formulations. For all, circularity factors close to one were 
obtained indicating that the particles’ shape in the two-dimensional projection was 
close to a disk. 
 
8.3.3.2 Solid state analysis of the in vitro precipitate 
The solid state of the EPO-drug-precipitate at pH 8.0 was analyzed by both XRPD 
(data not shown) and images obtained by polarized light microscopy (Figure 8.5). The 
XRPD results showed the absence of birefringent crystalline material in the 
coprecipitate of polymer and drugs. 
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Figure 8.5: Polarized light imaged of coprecipitate (pH 8.0) of EPO with FLP (left) and EPO with 
TMX (right). 
 
8.3.4 In vivo pharmacokinetics after oral administration 
8.3.4.1 Felodipine 
The plasma concentration-time profiles following a single oral administration of 4 
mg/kg FLP in different formulations are presented in Figure 8.6, and the 
corresponding pharmacokinetic parameters are summarized in Table 8.4. 
 
 
Figure 8.6: Average plasma drug-concentration versus time profiles after oral administration of FLP-
formulations in rats. Values are mean ± SD (n=6/group/time point). 
 
Interactions of dimethylaminoethyl methacrylate copolymer with non-acidic drugs demonstrated high 
solubilization in vitro and pronounced sustained release in vivo 136 
  
 
 
Table 8.4: Pharmacokinetic parameters of FLP-formulations after single oral administration of 4 
mg/kg body weight to rats. Values are mean ± SD (n=6/group/time point). 
Parameters EPO solution (1) PEG 400 solution (2) MC suspension (3) 
Cmax [ng/ml] 10.3 ± 1.4 48.0 ± 11.6 67.4 ± 12.7 
tmax [h] 2.1 ± 2.9 0.7 ± 0.7 0.8 ± 0.3 
AUClast [h ng/ml] 69.0 ± 38.0 195.0 ± 47.8 185.0 ± 31.0 
Dose-normalized 
AUClast [h kg ng/ml/mg] 
18.4 ± 10.1 51.5  ± 12.6 39.5 ± 6.6 
 t1/2 [h] 6.4 ± 2.7 2.0 ± 0.4 1.9 ± 0.3 
 
The main pharmacokinetic parameters, Cmax, tmax, and dose-normalized AUC were 
statistically analyzed regarding differences between the groups. In summary, the post-
hoc statistical test revealed differences in Cmax between formulations 1 and 2 (p< 
0.001), 1 and 3 (p< 0.001) as well as 2 and 3 (p= 0.004). There were also significant 
differences shown in the dose-normalized AUC between formulations 1 and 2 (p< 
0.001) as well as 1 and 3 (p= 0.002). 
FLP displayed an exposure peak post dosing between 30 minutes and five hours for 
group 1 (EPO solution), 15 minutes and two hours for group 2 (PEG 400 solution), 
and 30 minutes and one hour for group 3 (MC-suspension). However, these 
differences in tmax were statistically not significant, which was mainly attributed to 
high variability displayed by formulation 1. Oral bioavailability (dose-normalized 
AUClast) was comparable in groups 2 and 3, however bioavailability in group 1 was 
significantly lower (18.4 vs 51.5 vs 39.5 h·kg ng/ml/mg). Cmax differed significantly 
between formulations (10.3 vs 48.0 vs 67.4 ng/ml) and also the half-life was slightly 
increased in group 1 compared to group 2 and 3 (2.1 vs 0.8 vs 0.7 h). 
 
8.3.4.2 Tamoxifen 
The plasma concentration-time profiles of 10 mg/kg TMX following a single oral 
administration are presented in Figure 8.6. A summary of the average of the 
pharmacokinetic parameters of all TMX-formulations is shown in Table 8.5. The 
statistical post-hoc analysis revealed differences between the groups for all 
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pharmacokinetic parameters. In summary, Cmax values were different between 
formulations 4 and 5 (p< 0.001) and 4 compared with 6 (p< 0.001). Differences in tmax 
were significant between formulations 4 and 5 (p= 0.005) as well as 4 and 6 (p= 
0.018). Finally, the dose-normalized AUC showed differences 4 and 5 (p= 0.005) and 
between 4 and 6 (p< 0.001). 
 
 
 
Figure 8.6: Average plasma drug-concentration versus time profiles after oral administration of TMX-
formulations in rats. Values are mean ± SD (n=6/group/time point). 
 
Table 8.5: Pharmacokinetic parameters of TMX-formulations after single oral administration of 10 
mg/kg body weight to rats. Values are mean ± SD (n=6/group/time point). 
Parameters EPO solution (4) Acidic solution (5) MC suspension (6) 
Cmax [ng/ml] 86.2 ± 14.4 157.0 ± 23.4 185.0 ± 37.5 
tmax [h] 4.0 ± 2.2 1.5 ± 0.5 2.0 ± 0.0 
AUClast [h ng/ml] 1077.0 ± 95.8 1358.0 ± 143.0 1633.0 ± 239.0 
Dose-normalized 
AUClast [h kg ng/ml/mg] 
133.5 ± 11.9 172.8  ± 18.2 198.4 ± 29.0 
t1/2 [h] 6.5 ± ND 5.0 ± 0.6 5.5 ± 0.5 
ND: not determined 
 
Following oral dosing of 10 mg/kg TMX maximum plasma concentrations post 
dosing were observed between 2 and 8 hours for group 4 (3% EPO solution), between 
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1 and 2 hours for group 5 (acetic acid solution) and at 2 hours for group 6 (MC-
suspension). Oral bioavailability was significantly higher in groups 5 and 6 compared 
to group 4. The maximum plasma concentrations (Cmax) was significantly lower in 
group 4 compared to groups 5 and 6 (86.2 vs 157.0 vs 185.0 ng/ml). 
 
8.4 Discussion 
Pharmaceutical development of poorly soluble drugs needs potent solubilizers to cope 
with oral delivery challenges. A particularly interesting polymer is EPO and initial 
work on solubilization was focusing on acidic compounds and on stabilization of the 
amorphous state. 
170, 171
 Moreover, it was recently shown that EPO can also greatly 
enhance solubility of crystalline acids via a mixture of ionic and hydrophobic 
interactions in the bulk phase. 
187
 Deprotonated acids would interact to a relevant 
degree with the dimethylaminoethyl group of the polymer but there were also notable 
hydrophobic interactions with the polymeric side chains evidenced. NMR data 
suggested that this contribution was especially important in case of aromatic drugs. 
170, 187
 Additionally, Kojima et al. evaluated the oral absorption of mefenamic acid 
from a supersaturated solution obtained by dissolving a cryo-grinded mixture of EPO 
and mefenamic acid in acetate buffer. 
170
 This supersaturated solution was compared 
with a suspension consisting of mefenamic acid in 0.5% carboxymethylcellulose-
solution and a dispersion of a physical mixture of EPO and mefenamic acid in acetate 
buffer. The administration of the supersaturated solution resulted in enhanced oral 
bioavailability in vivo. 
For the present study, two compounds were selected that revealed a rather surprising 
solubility enhancement in combination with EPO. Both are not expected to interact 
via ionic interactions with the dimethylaminoethyl groups since FLP is apparent 
neutral and only charged at pH < 4 and TMX is positively charged up to a pH-value 
of around 9-10. The solubility enhancement is therefore likely caused only by the 
hydrophobic interactions of the lipophilic and aromatic moieties of the APIs and the 
side chains of the polymer. A previous study showed pronounced solubility 
enhancement with the tested bases, which was in line with the current findings of FLP 
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and TMX together with EPO. 
194
 Similar to the aforementioned in vivo results with 
mefenamic acid and EPO, the present work addresses the question to which extent the 
remarkable in vitro solubilization by EPO would translate into an enhanced in vivo 
drug exposure for non-acidic model drugs. 
 
In the case of FLP, the oral bioavailability in rats of an EPO-solution was compared 
with two other liquid formulations with the same dose. Surprisingly, the reference 
formulations, a cosolvent-solution and a suspension exhibited higher bioavailability 
than the EPO-solution. Moreover, other pharmacokinetic parameters were affected by 
the presence of EPO. While the AUC between the suspension and the cosolvent-
solution did not differ statistically significant, both Cmax and bioavailability of the 
EPO-solution were lower. The time to reach the maximum concentration appeared 
different, however was not statistically significant. In contrast to the suspension and 
the cosolvent-solution there was no sharp peak in the first three hours in the EPO-
solution group. 
In the case of TMX, the reference formulations were a suspension and a pH-adjusted 
solution. For TMX, the EPO solution also showed the lowest bioavailability. 
Additionally, the time needed to reach the maximum plasma concentration was 
significantly delayed in the EPO-solution group (Figure 7). 
Oral administration of cosolvents-solutions is followed by a dilution with aqueous 
media in vivo and precipitation is likely to occur during this dilution step. As shown in 
Table 3, particles originating from precipitation of cosolvent-solution with FLP in 
biorelevant media had a larger particle size compared to particles in the MC-
suspension. Since larger particles have a smaller surface area available for dissolution 
this may explain the lower Cmax of the cosolvent-solution compared to the suspension. 
In contrast, the AUC of both formulations was comparable. Several studies showed 
that the particle size influences the dissolution rate as well as the oral bioavailability 
of a compound. 
200-202
 Since the precipitation takes place as soon as the formulation 
enters the rats’ gastrointestinal tract, it seems that the precipitate can still dissolve and 
obtain a sufficient bioavailability. 
It is likely that the pH-dependent solubility of the polymer is of relevance for the 
obtained findings. Best solubility is obtained at low pH, which has been utilized, for 
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example, to enable fast disintegrating tablets. 
203, 204
 However, EPO was shown to 
precipitate at elevated pH values. We found that EPO precipitates mainly between pH 
7.0 and 7.5 which is in good agreement with literature reports.
205
 The pH-range in 
rats’ intestine (at fasted conditions) was reported between 7.1 and 8.0 199 but it should 
be added that no final consensus on this exact pH range is given in the literature. 
206
 
For relatively higher pH values, EPO is expected to precipitate in the intestinal 
passage. A concomitant precipitation of drug and polymer is a likely mechanism that 
would explain the observed decrease in the maximum plasma concentration as well as 
the delayed tmax for TMX and a decreased AUC for FLP and TMX (Figures 6 and 7). 
This is also supported by the in vitro precipitation results which showed that only a 
very low amount of API was in the supernatant and that most of the drug co-
precipitated with the polymer. Interestingly, previous co-precipitation experiments 
from EPO-drug solutions e.g. with ondansentron hydrochloride and metoclopramide 
hydrochloride resulted in drug-polymer-complexes. 
203, 204
 This complexation of 
polymer and drugs led to a taste-masked formulation which was releasing the drugs in 
gastric conditions immediately. Additionally, the authors showed that the drug was 
still in a crystalline solid state even after complexation with the polymer. 
Interestingly, our study detected no crystalline drug in vitro for FLP and TMX when 
co-precipitated with the polymer. A polymeric de-swelling and precipitation may 
have entrapped drug without occurrence of a crystalline drug precipitate. Strong 
molecular interactions and the drug entrapment in the generated co-precipitate of drug 
and polymer in situ could have caused reduced thermodynamic activity of the active 
compound thereby leading to a slower release rate. 
Even if no or only slight precipitation occurred in a lower pH-range than expected for 
the rat intestine, 
206
 strong interactions between the polymer and the drugs might still 
have affected the kinetics and extent of how the compounds were released and 
absorbed. 
No such pharmacokinetic effects were observed by Kojima et al. compared to the 
present work. 
170
 Potential reasons could be (1) the low EPO concentrations in the 
mefenamic acid study, (2) the high application volume of acetate buffer (for rodent 
experiments), and (3) that mefenamic acid is charged in the small intestine and will 
not precipitate. Moreover, the hydrophobic nature of the drug-polymer interactions 
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makes further a difference to the situation with acids despite of strong interactions of 
EPO and mefenamic acid. 
The finding of changed absorption kinetics is not only academically interesting but 
may be also technically harnessed. Especially when the exposure is not compromised, 
such a simple modified release principle could be of great merit in early formulations 
supply. This early development phase comes with practical limitations of any other 
sophisticated modified release technology. Furthermore, monolithic modified release 
systems are rather problematic for rodents. Once checked and validated, an in situ 
generated modified release formulation could provide here an alternative to avoid 
plasma concentration fluctuations regarding an excessively high Cmax followed by a 
possible fast decay to rather low concentration. Such a high peak-to-trough ratio is a 
typical concern for many drugs especially at the high doses used in preclinical studies. 
For such drug candidates, ordinary drug solutions with high peak-to-trough ratios may 
lead to adverse events that are later on the market often encountered by a modified 
release formulation in the therapeutic dose range. Especially in long term treatment 
with given adverse effects such as with antipsychotic and antihypertensive drugs or 
pain medication, there are often modified release formulations employed to avoid 
large plasma fluctuation. 
207
 An in situ generated modified release formulation based 
on specific drug-polymer interactions is a very simple approach. A use for market 
formulations is rather discouraged because more established techniques exist for 
modified drug release, which, however, require sufficient development time. We see a 
possible application in preclinical formulations to avoid that drug candidates fail in 
toxicity studies due to avoidable issues of peak-to-trough toxic kinetics. Furthermore, 
a modified release technology may provide pharmacokinetic profiles in the preclinical 
studies similar to those obtained later for the clinical or market formulations. 
 
8.5 Conclusions 
The methacrylic copolymer EPO has been shown to effectively solubilize acidic 
drugs. More recent work demonstrated similar effects also for basic compounds. The 
present work confirmed these remarkable solubilization effects for FLP and TMX. 
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This study aimed to show in vivo effects of the in vitro enhancement of drug 
solubility. Interestingly, oral exposure was not increased by the presence of the 
polymer. However, EPO-drug solutions were shown to change pharmacokinetic 
parameters compared to pH-adjusted solution, cosolvent-solution or simple 
microsuspension. Delayed and decreased absorption of the drugs were observed and 
are most likely due to hydrophobic drug polymer interactions and co-precipitation of 
the compound with polymer in the gastrointestinal tract of the rats. The present results 
are of interest for several reasons. First, in vitro solubilization results due to strong 
hydrophobic drug-excipient interactions may not translate necessarily into increased 
in vivo absorption, which is of general relevance for in vitro characterization. Second, 
the findings bear a potential technical exploitation of such specific drug-excipient 
interactions and entrapment by the polymer. The polymeric co-precipitation effect in 
vivo might be used for high-dose animal studies in the early phases of pharmaceutical 
development like toxicology or pharmacokinetic studies. Thus, high peak-to-trough 
ratios can be avoided in the preclinical program long before much more resource-
intensive modified release formulations can be developed. 
  
 
 
 
Chapter 9 
Final remarks and outlook 
A successful formulation design is a key process during drug development. However, 
finding a suitable formulation is challenging, especially during early phases since only 
a limited amount of compound is available. A more rational excipient selection would 
help to reduce the number of experiments. Therefore, a better mechanistic 
understanding of drug-excipient interactions is needed. Even though such molecular 
interactions have been studied intensively in the pharmaceutical literature, there is a 
lack of comparatively big datasets about solubility enhancement at a rather low 
additive concentration. Such rather low excipient concentrations are relevant as model 
for a diluted oral dosage form and/or have relevance for preclinical formulation 
vehicles. Moreover, potential solid state changes of the drug have in the past mostly 
not been considered. The present thesis aimed to improve the mechanistic 
understanding of such drug-excipient interactions to ultimately provide some 
guidance in formulation development. 
Due to the limited amount of compound that is available in early phases of 
pharmaceutical development, miniaturized assays are desirable for in vitro tests at this 
stage. We developed a miniaturized X-ray assay for parallel determination of kinetic 
solubility and solid state transformations. The correction of X-ray pattern with 
measured background pattern led to detection of much smaller quantities of 
polymorphic forms in binary mixtures than in previous studies. The parallel study of 
solvent-mediated phase transformations and drug concentrations provided insights 
into influences of excipients on the drug in the liquid and the solid phase of the 
pharmaceutical system. For a more mechanistic study of the solvent-mediated phase 
changes, dynamic imaging was applied to kinetic measurements. To this end, image 
analysis was combined with a fractal analysis to gain insights into hydrate crystal 
growth. Both methods provide time-resolved data on excipient effects on solvent-
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mediated phase transformation and drug concentration. An important finding was the 
differentiation of excipient effects in the solid phase and in the liquid phase of a 
pharmaceutical system. Knowledge of these kinetic effects can be applied to liquid 
dosage forms but also to other development of aqueous drug mixtures. Additionally, it 
is relevant for oral administration of solid dosage forms as they are exposed to 
aqueous environment after administration and dispersion. 
Key excipients for solubilization are surfactants that are commonly used in dosage 
forms and therefore their influence was studied at low concentrations on solubility 
and solid state changes of 13 model compounds. The obtained dataset demonstrated 
high solubilization correlations among pegylated surfactants of similar type but also 
exceptional solubilization of anionic surfactants. Our results demonstrated further the 
importance of a solid state characterization of residual drug because surfactants were 
shown to affect solvent-mediated phase transformation in some cases. Current 
findings may serve as basis to guide a surfactant screening in preformulation 
regarding the choice of tested surfactants. 
Additionally to surfactants, polymers are widely used in suspensions formulations and 
are known to influence polymorphic transformations. We showed that EPO is a potent 
polymer to obtain solubility enhancement of seven crystalline acidic drugs in solution.
 
1
H NMR spectroscopy (including DOSY application) proved to be a suitable tool to 
study specific molecular interactions of drug and polymer. Additionally to expected 
ionic interactions, also hydrophobic interactions between the polymer side chains and 
the aromatic system were identified as crucial. Due to the molecular understanding of 
drug-polymer interactions, the application of EPO as a solubility enhancer was also 
tested for six basic compounds that were mostly protonated at physiological pH. 
Although some hydrophobic interactions were expected to occur, the high extent of 
solubility enhancement was surprising given the same positive charge type of 
aminoalkyl groups that abundantly exist in EPO. These findings broaden the 
application area of EPO, especially for simple formulations like suspensions and 
solutions that can be used in early phases of the drug development process.  
These molecular studies of EPO-drug interactions improved the understanding of in 
vitro results; however, the in vivo performance is finally important from a 
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biopharmaceutical perspective especially, when formulating poorly water-soluble 
compounds. Therefore, an in vivo study in rats with formulations with EPO and a 
basic (tamoxifen) and a neutral compound (felodipine) was performed. Interestingly, 
bioavailability could not be improved in presence of the polymer despite of the 
promising in vitro solubilization results. However, kinetic plasma profiles were 
significantly changed in EPO containing drug solutions and resulted in delayed and 
decreased absorption of the drugs compared to pH-adjusted solution, cosolvent-
solution or simple microsuspension. This result was most likely due to hydrophobic 
drug polymer interactions and co-precipitation of the compound with polymer in the 
gastrointestinal tract of the rats and can be used for high-dose in vivo studies in the 
early phases of pharmaceutical development like toxicology or pharmacokinetic 
studies. Thus, high peak-to-trough ratios can be avoided in the preclinical program 
long before much more resource-intensive modified release formulations can be 
developed. 
This work provides an improved mechanistic understanding of drug-excipient 
interactions in vitro as well as in vivo at low excipient concentrations. However, it 
was seen that excipient effects especially on the solid state are highly specific 
between drug and excipient. The findings were still encouraging that with an 
improved understanding, a more rational excipient selection is possible. 
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